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ABSTRACT 
 
There is an expanding catalogue of immune deficiency diseases with 
inflammatory and autoimmune manifestations. Understanding the genetic 
basis of this paradoxical association could enhance our understanding of 
the pathophysiology of not only rare immune deficiency syndromes, but 
also more common inflammatory or autoimmune diseases.  
 
We aimed to elucidate mechanism of such diseases using two approaches. 
First, a discovery project in which we identified a proband who presented 
with both inflammation and recurrent infections, including bronchiectasis 
by the age of 4 years, which was associated with 
hypergammaglobulinaemia. Whole exome sequencing revealed novel 
mutations in STAT4 and MTOR. Until now, there has been no human genetic 
analysis supported by functional studies to determine the role of STAT4 or 
MTOR in Th1 effector differentiation. 
 
The STAT4 mutation (affecting the DNA binding domain) results in 
prolonged STAT4 phosphorylation and nuclear retention, thus conferring a 
gain-of-function phenotype. We show that this promotes excessive Th1 and 
follicular helper T cell (TFH) formation. The MTOR mutation affects the 
negative regulatory domain, and is therefore also gain-of-function. We 
found biochemical evidence for cross-regulation between STAT4 and mTOR 
that explained accentuated TFH and Th1 formation. In this case, enhanced 
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TFH formation might help explain the aberrant antibody response 
observed in the proband.  
 
The second approach examined T cell differentiation in patients with 
known defects in STAT3. Loss-of-function (LoF) mutations in STAT3 result 
in autosomal dominant hyper IgE syndrome (ADHIES), and these patients 
present with unexplained atopic manifestations. Mouse studies have 
revealed that cytokine signalling via STAT3 promotes IL10 production by 
Th2 cells that have regulatory role. We found that suboptimal STAT3 
signalling in humans also compromises formation of inducible IL10 
production by human Th2 cells, which might explain this accentuated 
atopic phenotype in ADHIES.  
 
More recently, patients with STAT3 gain-of-function (GoF) mutations have 
been reported in which antibody deficiency occurs concurrently with 
organ-specific autoimmunity. We observed that suboptimal STAT3 
signalling promotes CD4+ T cell exhaustion marked by PD1 and CD57 
expression. Since CD57+ PD1high cells constitute a significant subset of 
human TFH cells, we proceeded to characterize this population in detail. 
Interestingly, we show that this subset contains CD4+ T cells with cytotoxic 
gene expression signature and activity. Interestingly, cytotoxicity is 
attenuated in CD57+ TFH cells when compared with their circulating 
counterparts. STAT3 LoF results in expansion of circulating CD57+ cells, 
but does not increase the cytotoxic fraction above the proportion normally 
observed in tonsil. By contrast, STAT3 GoF enhances the cytotoxic fraction 
in CD57+ CD4+ T cells in blood, with cytotoxic action against autologous B 
cells.  
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Since STAT3 is known to promote CXCR5 expression and abundance of 
TFH cells, concurrent promotion of cytotoxicity within TFH cells might 
provide an additional mechanism for defects in antibody production within 
germinal centres of patients with enhanced STAT3 activity. These findings 
point to events in germinal centres that can explain the paradoxical 
association between antibody deficiency and autoimmunity.   
 
Taken together, these approaches provide insight into new mechanisms to 
explain concurrent immune deficiency and autoimmunity. 
 
 
 
PUBLICATIONS ARISING 
 
STAT3 regulates cytotoxicity of human CD57+ CD4+ T cells in blood and 
lymphoid follicles (Alshekaili et al. 2018). 
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CHAPTER 1 : LITERATURE REVIEW 
1. General review  
1.1 Differentiation of a naïve T cellS into effector T cellS 
1.1.1 General introduction 
 
Most peripheral blood T cells express either CD4+ and CD8+. Both CD4+ and CD8+ 
T cells integrate many signals in a complex process to give rise to different effector 
and memory CD4+ and CD8+ T cell subsets. Different CD4+ T cell subsets can be 
recognized by their surface phenotype or commonly by their signature cytokine for 
each of these subsets. CD4+ T cell subsets include, T helper 1 [Th1] cells, with 
interferon –gamma (IFN-γ) as its signature cytokine, T helper 2 [Th2] cells, with 
interleukin -4 (IL-4) as its signature cytokine, T helper 17 [Th17] cells, with 
Interleukin-17 (IL-17) as its signature cytokine, T follicular [TFH] cells with 
interleukin- 21 (IL-21) as its signature cytokine.  Each of these subsets appears to be 
an adaptation for different types of immune responses. Therefore, T cell 
differentiation toward each of these subsets is crucial for mounting the appropriate 
immune response towards specific class of pathogen. T cell lymphocytes differentiate 
down one pathway or another as a result of a complex integration process of three 
main signals; T cell receptor (TCR), accessory molecules and cytokines that converge 
on signal transducer and activator of transcription (STAT) mediated signals(Santana 
and Rosenstein 2003). 
 
1.1.2 TCR signals 
 
Signalling through TCR is crucial for T cell survival. TCR signalling is initiated when 
the TCR is bound to a peptide on major histocompatibility complex (MHC) on the cell 
surface of an antigen presenting cell (APC). Therefore, factors affecting the TCR 
repertoire, strength and duration of binding to a given peptide (affinity) and type of 
MHC control the outcome of the TCR signalling in dictating the fate of the T cell. T 
cells that fail to express their TCR die gradually (Labrecque et al. 2001) in a similar 
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way to those present in environment that lack MHC (Labrecque et al. 2001). T cells 
engineered to express lower numbers of TCR continue to function, although these 
cells needed higher antigen dose to activate them (Labrecque et al. 2001) and support 
proliferation and interleukin -2 (IL-2 ) production. 
 
1.1.3 Accessory molecules 
 
Accessory molecules include both costimulatory and inhibitory molecules. They are 
surface receptors that are available at the surface of the T cell, the engagement of 
which modulates the outcome of the TCR signalling controlling further T cell 
activation and differentiation (reviewed by Chen, L et al (Chen and Flies 2013)). Co 
stimulatory molecules include CD28 and inducible T cell co stimulatory molecule 
(ICOS). CD28 is a well-known co stimulatory molecule expressed on the surface of 
naïve T cells that supports T cell activation through production of IL-2 and T cell 
differentiation (reviewed by Sharpe, A.H et al (Sharpe and Freeman 2002)). ICOS 
shares structural and functional similarities (Hutloff et al. 1999) with CD28 but is only 
expressed on activated T cells upon activation via TCR and CD28 (Sharpe and 
Freeman 2002).   
 
Inhibitory molecules control the outcome of the TCR signalling. These include 
program death-1(PD-1) (Ishida et al. 1992) and cytotoxic T-lymphocyte-associated 
protein 4 (CTLA-4). PD-1 is up regulated rapidly after T cell activation and on 
engagement to its ligand, program death-1 ligand 1 and 2) (PD-L1 and PD-L2), it 
inhibits cell cycle progression, IL-2 production and production of other inflammatory 
cytokines. CTLA-4 is another negative regulator, which competes with CD28 for 
costimulatory ligands, and inhibits many CD4+ T cell functions, particularly 
proliferation (Chambers, Sullivan, and Allison 1997). 
 
1.1.4 Transcription factors 
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The progression from a naïve T cell to an effector or memory cell is a complex 
process in which an interplay between many external signals are conveyed to the T 
cell to switch on and switch off transcription regulations and genes expression. 
Activation of transcription factors is under the control of different cytokines. In 
general, ligation of cytokine receptors by their cytokines leads to tyrosine 
phosphorylation of cytokine receptor associated Janus kinases (JAK), which then 
phosphorylate and activate specific signal transducers and activators of transcription 
(STAT) molecules that dimerize and polymerize. Nuclear translocation of activated 
STATs causes up-regulation of specific transcription factors and cellular 
differentiation (reviewed by Shuai, K et al (Shuai and Liu 2003)).  
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FIGURE ‎1-1 STRUCTURE AND SIGNALLING OF STAT 
Binding of cytokines to their respective cytokine receptors leads to recruitment and 
activation of JAK molecules. These in turn recruit and activate specific STAT 
molecules through phosphorylation (P). Activated STAT dimerizes and migrates to 
the nucleus to bind specific consensus element to activate specific transcription 
factors.  
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1.2 Signals needed for differentiation of a naïve T cellS into effector Th1 CELLS 
 
1.2.1 General introduction 
 
T helper-1 (Th1) cells are a distinct effector T cell subset that is characterized by the 
production of its signature cytokine, interferon- gamma (IFN-γ). The main function of 
this effector subset is clearance of intracellular organisms through macrophage 
activation(Hsieh, Macatonia, Tripp, Wolf, Ogarra, et al. 1993). Deficiency of IFN-γ 
immunity in humans gives rise to a spectrum of diseases characterized by increased 
susceptibility to mycobacterial diseases (reviewed in (Bustamante et al. 2014)). By 
contrast, pathological activation of Th1 cells in humans has been iimplicated in organ 
specific inflammation and autoimmunity (Luckheeram et al. 2012).  
 
The decision of a naïve T cell to undergo Th1 differentiation is under the control of 
different interrelated signals including TCR, co-stimulation, and cytokines mainly 
interleukin-12 (IL-12) that activates STAT4 (Tao et al. 1997; Trinchieri 1994; Kaplan, 
Sun, et al. 1996). 
 
1.2.2 TCR and Th1 
 
Strong T cell signalling favours formation of Th1 measured by IFN-γ secretion (Tao 
et al. 1997). Moreover, the duration of the TCR activation also influences T cell 
differentiation in conjunction with strength of TCR signalling (Rogers and Croft 
1999). For-example, in short-term stimulation (~4 days), low-level TCR stimulation 
can support Th1 formation. In contrast, long-term stimulation (~12 days)  with strong 
TCR stimulation was needed to induce formation of IFN-γ producing cells (Rogers 
and Croft 1999).  
 
1.2.3 Accessory molecules and Th1 cell formation 
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Co-stimulation is needed to control excessive Th1 deviation and immunopathology 
associated with Th1 deviation. Deficiency in CD28 (Hunig et al. 2010; Shahinian et 
al. 1993; Lenschow et al. 1996) or in ICOS (Dong et al. 2001) in animal models was 
associated with Th1 deviation. However, in rare humans with ICOS deficiency, no 
specific defect in Th1 formation was observed (Grimbacher et al. 2003a). So far, no 
human CD28 deficiency has been described.  
 
Inhibitory molecules also regulate Th1 deviation (McAlees et al. 2015). PD-1 
deficient mice exhibit increased Th1 cell formation (McAlees et al. 2015), and both 
auto-inflammatory and autoimmune manifestations (Okazaki and Honjo 2007). So far, 
no human PD-1 deficiency has been reported, although PD-1 polymorphisms have 
been reported to segregate with certain autoimmune diseases (ie type I diabetes, and 
systemic lupus erythematosus) (Nielsen et al. 2003; Prokunina et al. 2002).  
CTLA-4 is another inhibitory molecule that is expressed on the surface of activated T 
cells, and on regulatory T cells (Tregs). CTLA-4 deficient mice exhibit defective 
regulation of effector T cell proliferation leading to a fatal lymphoproliferative disease 
associated with increased cytokine release of both Th1 and Th2(Tivol et al. 1995; 
Chambers, Sullivan, and Allison 1997). Interestingly, there is no haploinsufficiency 
phenotype in mice. On the other hand, human haploinsufficiency of CTLA-4 results in 
phenotype that is associated with lymphocyte hyper-proliferation and tissue 
infiltration (Schubert et al. 2014; Kuehn et al. 2014). This phenotype is similar to that 
observed in mice with complete CTLA4 deficiency.  
 
 
1.2.4 Transcription factors and Th1 
 
IL-12 is necessary for Th1 cell formation and cell-mediated immunity. IL-12 receptor 
ligation activates STAT4 (Hsieh, Macatonia, Tripp, Wolf, O'Garra, et al. 1993). 
STAT4 activation leads to IFN-γ production which subsequently leads to the up-
regulation of the master regulator of Th1 cells, T-box transcription factor (T-bet) and 
maintenance of the Th1 phenotype (Yang, Ochando, et al. 2007). Furthermore, IFN-γ 
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activates STAT1 in macrophages and cause further activation and IL-12 production. 
T-bet up regulation can also be induced via IFN-γ that activates STAT1 in T cells 
(Yang, Ochando, et al. 2007). Therefore, IL-12(Magram et al. 1996), or 
STAT4(Kaplan, Sun, et al. 1996)or  T-bet (Szabo et al. 2000) deficient mice  have 
deficiency in Th1(IFN-γ production)  and have a higher propensity to form Th2 
deviated cells (Magram et al. 1996) emphasizing the role of IL-12 STAT4 in initiating 
and maintaining Th1 differentiation. 
 
 
In humans, 18 reported inborn errors of Th1 differentiation have been reported so far, 
summarised in Figure ‎1-2 (Bustamante et al. 2014), and reviewed by Rosenzweig, 
S.D. st al(Rosenzweig and Holland 2005)). Defects impeding IFN-γ production 
include mutations in IL-12B, IL-12RB1, ISG15, IRF8 and NEMO (Bustamante et al. 
2014). On the other hand, defects interfering with the function of IFN-γ include 
mutations in IFNGR1, IFNGR2, STAT1, IRF8 and CYBB (Bustamante et al. 2014). 
Most of these patients present with increased susceptibility to infections with low-
virulence mycobacteria (Rosenzweig and Holland 2005; Doffinger et al. 2002; 
Bustamante et al. 2014). Interestingly, in contrast to what has been reported in mice 
(Magram et al. 1996), patients with Th1 defects do not appear to have heightened 
susceptibility to Th2 associated diseases such as atopy (Wood et al. 2005). Of note, 
there are few reported mutations in the IL-12/ IFN- γ production pathway in humans 
similar to the one in mice. However, no STAT4 or TBX21 mutations have been 
reported in humans so far to support or prove their importance for development of Th1 
cells in humans.  
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Figure ‎1-2 Different known mutated proteins causing human inborn error of Th1 
differentiation 
Outline of the proteins involved in IFN-γ production or action. Mutations in proteins 
(filled blue colour) have been reported to cause Mendelian susceptibility to 
mycobacterial disease (MSMD).  Mutation of IL-12B, IL-12RB1, ISG15, IRF18 and 
NEMO interfere with normal IFN-γ production. On the other hand, mutations 
interfering with action of IFN-γ include IFN-GR1, IFNGR2, STAT1, IRF8 and CYBB. 
Adapted from (Bustamante et al. 2014).  
 
 
1.3 Signals needed for differentiation of a naïve T cellS into effector Th2 CELLS 
 
Pathological actions of STAT4, MTOR and STAT3 in human T cell 
differentiation 
  
29 
 
1.3.1 General introduction 
 
Th2 responses are important for providing help to B cells for class switching to IgG1 
and IgE (Le Gros et al. 1990). Th2 responses are important for immunity against 
extracellular pathogens.  
 
1.3.2 TCR signalling and Th2 cell formation 
 
The duration and the level of stimulation achieved through TCR activation is also 
crucial in determining Th2 differentiation (Rogers and Croft 1999). For example, after 
short-term (~4 days) stimulation of T cells, strong TCR signals gave rise equally to 
Th1 and Th2 formation (Rogers and Croft 1999). In contrast, after long-term (~12 
days) stimulation, a moderate dose of high affinity peptide (strong TCR) is needed to 
support Th2 formation(Rogers and Croft 1999). In addition, high level expression of 
major histocompatibility complex II (MHC II) supports Th2 differentiation in mice 
(Patel et al. 2005). 
 
1.3.3 Accessory molecules and Th2 cell formation 
 
Co-stimulation through CD28 (Hunig et al. 2010; Shahinian et al. 1993; Lenschow et 
al. 1996) and ICOS (Dong et al. 2001) is needed to support Th2 formation in animal 
models especially when the TCR signal is weak (Tao et al. 1997; Paul and Zhu 2010) 
(reviewed by Paul, W.E  (Paul and Zhu 2010)). In humans, however, co-stimulation is 
not mandatory for Th2 formation. Patients with ICOS deficiency have been described 
and they had normal proportions of Th2 cells compared to normal controls 
(Grimbacher et al. 2003a). On the other hand, co-inhibitory molecules influence Th2 
differentiation in humans. CTLA-4 is crucial in controlling Th2 differentiation in 
animal models (Oosterwegel et al. 1999). CTLA-4 deficient mice exhibit defective 
regulation of effector T cell proliferation leading to a fatal lymphoproliferative disease 
(Chambers, Sullivan, and Allison 1997).  
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1.3.4 Transcription factors and Th2 cell formation 
 
Cytokines play a major role in shaping Th2 formation as well. Naïve T cell exposure 
to IL-4 is crucial for inducing Th2 cells (Swain et al. 1990; Seder et al. 1992) through 
activation of STAT6 (Kotanides and Reich 1996; Schindler et al. 1994) and 
subsequent up-regulation of Trans-acting T-cell-specific transcription factor, GATA-3 
(GATA-3). STAT6 deficient cells failed to undergo Th2 differentiation downstream 
IL-4 stimulation (Kaplan, Schindler, et al. 1996) and so failed to mediate any of the 
known IL-4 responses, such as up-regulation of MHC II or IL-4 receptor expression 
(Kaplan, Schindler, et al. 1996). In contrast, constitutively active STAT6 resulted in 
induction GATA3 (Kurata et al. 1999) that led to up regulation of c–maf (Ouyang et 
al. 2000), and Th2 polarization (Kurata et al. 1999; Ouyang et al. 2000). Transgenic 
STAT6 mice had reduced numbers of CD3+ T cells, which exhibited an activated 
phenotype and increased propensity to cell death, as well as enhanced Th2 deviation 
(Bruns, Schindler, and Kaplan 2003; Wurster, Tanaka, and Grusby 2000). Recently, it 
was also shown that IL-2 acting through STAT-5 has as well a Th2 stimulating effect 
that is not simply explained by growth induction (Cote-Sierra et al. 2004; Yamane, 
Zhu, and Paul 2005). 
 
1.4 Signals needed for differentiation of a naïve T cellS into effector Th17 CELLS 
 
1.4.1 General introduction 
 
Th17 cells with their IL-17 as signature cytokine are important for host defences 
against extracellular organisms, including bacteria and fungi (Annunziato et al. 2007; 
Harrington, Mangan, and Weaver 2006).   
 
Deficiency of this subset has been described in patients with autosomal dominant 
hyper IgE syndrome (AD-HIES) (Minegishi et al. 2007; Ma et al. 2008), in which 
patients are more prone to recurrent bacterial (particularly S. aureus) and superficial 
fungal infections. On the other hand, excessive formation of Th17 cells has been 
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implicated in many inflammatory conditions. In fact, abnormal expansion of this 
subset is associated with autoimmunity and lymph proliferation (Milner et al. 2015).  
 
1.4.2 TCR and Th17 
 
High level antigenic stimulation supplemented by low level co-stimulation promotes 
Th17 differentiation in mice (Bouguermouh et al. 2009). In contrast, human Th17 
formation can be promoted in the context of low level of TCR signalling augmented 
by presence of CD28 (Purvis et al. 2010). Similarly, strong calcium influx 
compromises the formation of Th17 (Purvis et al. 2010). 
 
1.4.3 Accessory molecules and Th17 
 
Deficiency of ICOS in mouse models did not impede Th17 differentiation from naïve 
CD4+T cells (Bauquet et al. 2009). However, ICOS is required for the maintenance 
and expansion of Th17 (Bauquet et al. 2009). In contrast, formation of Th17 cells in 
humans is severely affected  in ICOS deficient patients (Warnatz et al. 2006). In 
humans, ligation of ICOS leads to induction of Th17 specific transcription factors 
such as c-MAF, RORC2 and T-bet (Paulos et al. 2010). ICOS is expressed on human 
naïve CD4+ T cells, but not on mouse naïve CD4+  T cells, which might explain this 
discrepancy (Paulos et al. 2010). 
 
1.4.4 Transcription factors and Th17 
 
In humans, Th17 formation can be achieved in vitro after stimulation of naïve CD4+ T 
cells in the presence of transforming growth factor beta (TGF-β) and IL-6. This 
combination activates STAT3 and promotes the up-regulation of transcription factor 
ROR-gamma (Yang, Panopoulos, et al. 2007) that leads to IL-17 production (Kimura 
and Kishimoto 2010; Hebel et al. 2011; Qin et al. 2009). IL-23 is then important for 
the maintenance of IL-17 production in T cells maintained in long term cultures 
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(Stritesky, Yeh, and Kaplan 2008) (Harrington, Mangan, and Weaver 2006; Langrish 
et al. 2005).  
 
1.5 Signals needed for differentiation of a naïve T cell into effector TFH 
 
1.5.1 General introduction 
 
T follicular helper cells (TFH) have emerged as a distinct Th subset that resides in the 
germinal centre (GC) and provides essential help for B cell maturation and 
differentiation (Kim et al. 2001; Breitfeld et al. 2000; Schaerli et al. 2000). TFH cells 
are characterized by high level surface expression of CXCR5, ICOS, and PD-1 
(Rasheed et al. 2006b) and production of IL-21 that is important for plasma cell 
formation and immunoglobulin production (Bryant et al. 2007). The formation of TFH 
is associated with up-regulation of its transcription factor, B-cell lymphoma 6(BCL-6) 
(Choi et al. 2013). 
 
Cells with a similar but non-identical phenotype are present in the blood, and are 
sometimes referred to as circulating TFH (cTFH)(Morita et al. 2011). cTFH are 
memory cells that express intermediate levels of CXCR5 and PD-1 and do not express 
BCL-6 at levels of GC TFH. Evidence that cTFH are the circulating counterparts of 
bona fide TFH cells is derived from patients with genetically specified defects in GC 
formation (Schmitt, Bustamante, and Bourdery 2013; Bossaller et al. 2006). Alteration 
in cTFH has been shown to be associated with many autoimmune and inflammatory 
conditions (Choi et al. 2015; Wang et al. 2013). 
 
1.5.2 TCR and TFH 
 
All T cell subsets require TCR signalling for differentiation. The degree or strength of 
TCR signalling necessary is variable among different T cell subsets. Strong TCR 
signalling is needed for TFH formation (Tubo and Jenkins 2014; Deenick and Ma 
2011)  
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1.5.3 Accessory molecules and TFH 
 
ICOS is also required for formation of TFH in mice (Bauquet et al. 2009). Similarly in 
humans, ICOS appears to be important for TFH formation (Grimbacher et al. 2003b) 
(Warnatz et al. 2006; Bossaller et al. 2006), as patients with ICOS deficiency exhibit 
deficiency of circulating blood TFH( cTFH) that can be identified by some surface 
markers such as CD45RO+ CXCR5+. ICOS deficiency also conferred failure of 
proper GC formation in lymph nodes (Bossaller et al. 2006), further contributing to 
loss of and defect in TFH formation in these patients. 
 
1.5.4 Transcription factors and TFH 
 
The formation of TFH is associated with up-regulation of its transcription factor, 
BCL-6 (Choi et al. 2013). However, which signal transducer is involved in this 
upregulation and therefore formation of TFH subset is still controversial in humans.  
In mice, IL-21 signalling through STAT3 appears to be crucial for TFH formation 
(Nurieva et al. 2008). Similarly, in humans, STAT3 appears to be important for cTFH 
formation (Ma et al. 2012) and therefore possibly TFH formation as well, However, it 
is interesting to note that in rare IL-21 and IL-21 receptor deficient patients, numbers 
of cTFH were reported to be normal (Jandl et al. 2017; Stepensky et al. 2015).This 
might implicated that IL-21 is not crucial for TFH formation. Moreover, in vitro 
studies, suggest that IL-12 is necessary for differentiation of TFH & cTFH from naïve 
human CD4+ T cells possibly through STAT3 (Ma et al. 2012) (Ma et al. 2009; 
Schmitt et al. 2009). In addition, patients with IL-12Rβ1 deficiency exhibit abnormal 
germinal centre formation, although it remains unclear whether TFH function is 
perturbed (Schmitt, Bustamante, and Bourdery 2013). On the other hand, it has been 
shown that STAT4 is expressed by human GC TfH cells (Schmitt, Bustamante, and 
Bourdery 2013), but there is no clear evidence of the role of STAT4 in TFH 
formation. 
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2. STAT4 
 
2.1 General introduction 
 
STAT4 protein was discovered based on its homology of the SH2 domain with other 
STAT SH2 domains (Zhong, Wen, and Darnell 1994; Yamamoto et al. 1994).  
 
Figure ‎1-3 Structure of STAT4 and its two isoforms 
Different STAT molecules share similar domains; N-domain (N), coiled-coil domain 
(C-C domain), DNA-binding domain (DNA-BD), linker domain (LK), Src homology 
2(SH2) domain and transactivation domain (TA) which contains a critical tyrosine 
residue (Y) and serine(S) in some STAT molecules. The phosphorylation of the Y as 
in Y693 in STAT4 is crucial for the STAT4 activation and dimerization through the 
reciprocal phosphor-Tyr-SH2 domain interaction. There are two isoforms of STAT4; 
STAT4α and a shorter form, STAT4 β.  
 
2.2 Expression and structure of STAT4 
 
STAT4 expression is restricted to early myeloid precursors (Yamamoto et al. 1994) 
thymus, testis and spleen (Zhong, Wen, and Darnell 1994). Human T cells express 
very little STAT4 protein in the resting state. Overall, STAT4 has a similar domain 
structure to other STAT molecules (reviewed by Levy, D.E. et al (Levy and Darnell 
2002)) (Figure 1.3). It is made up of the N-domain which facilitates dimerization of 
two STAT4 molecules, (Vinkemeier et al. 1998) even when non-phosphorylated (Ota 
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et al. 2004), and mediates phosphorylation of STAT4 dimers in its anti-parallel 
conformation (Murphy et al. 2000; Ota et al. 2004). The coiled-coil domain (C-C 
domain) is necessary for interaction with other proteins. STAT4 forms parallel dimers 
after phosphorylation, and these bind nuclear DNA regulatory elements via the DNA 
binding domains (DBD) (Horvath, Wen, and Darnell 1995; Meyer et al. 2003). The 
SH2 domain is the most structurally conserved domain among STAT proteins. STAT4 
docking on cytokine receptors occurs via interaction between the SH2 domain and 
phosphorylated tyrosine residues on the activated receptor. 
 
2.3 Activation of STAT4 
 
IL-12 is the principal inducer and activator of STAT4. IL-12 receptor is made up of a 
constitutively expressed IL-12Rβ1 subunit and a IL-12Rβ2 subunit that is upregulated 
on cell activation. IL-12 itself is the principal cytokine for induction and maintenance 
of IL-12Rβ2 expression (Wang 2001; Nishikomori et al. 2002; Ramos et al. 2007). As 
noted earlier (Bacon, Petricoin, et al. 1995), in the resting state, human T cell express 
very little STAT4 protein. Mitogens such as phytohaemagglutinin (PHA) or T cell 
activation via TCR and accessory moelcules (e.g. CD2/3/28) up-regulates expression 
of STAT4 as well as IL-12Rβ2 (Usui et al. 2003; Bacon, Petricoin, et al. 1995; Wang 
2001; Nishikomori et al. 2002). STAT4 expression is up regulated 24hrs after 
stimulation and reaches maximal expression 72 hours after stimulation. T cell 
activation with IL-12 results in phosphorylation of tyrosine 800 on the IL-12Rβ2, and 
this forms a docking site for the SH2 domain of STAT4 (Naeger et al. 1999). This 
interactions leads to STAT4 phosphorylation at tyrosine 693 (Figure 1.1 and Figure 
1.3) by JAK2 and Tyk2 (Bacon, Petricoin, et al. 1995; Naeger et al. 1999; Bacon, 
Mcvicar, et al. 1995). Stimulation with IL-12 phosphorylates STAT4 at tyrosine (693) 
as early as 5 minutes after stimulation, and this activation can last for more than 30 
minutes and perhaps up to 48 hours (Bacon, Petricoin, et al. 1995).  
 
IFN-α can also activate and phosphorylate STAT4 (Cho et al. 1996), although in 
human T cells, this occurs indirectly though through recruitment of STAT2 (Farrar, 
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Smith, Murphy, Leung, et al. 2000; Farrar, Smith, Murphy, and Murphy 2000). In 
contrast, in mice, IFN-α has the ability to activate STAT4 directly (Nguyen et al. 
2002). Mutational analysis indicates that the STAT4 N-domain seems to be crucial for 
its activation by both cytokines (Murphy et al. 2000; Chang et al. 2003). In addition, 
both IL-12 and IFN-α have the ability to induce IL-12Rβ2 expression  and both can 
phosphorylate STAT4 at both tyrosine 693 and serine 720 (Ramos et al. 2007).  It is 
mainly STAT4 phosphorylated on tyrosine 693 in response to IL-12 or IFN-α that has 
the ability to bind DNA segments (Cho et al. 1996), including interferon regulatory 
factor gene (IRF1), which results in IFN-γ production (Yamamoto et al. 1994). 
Phosphorylated parallel dimers of STAT4 bound to DNA are relatively protected from 
dephosphorylation (Meyer et al. 2003). This is crucial, since sustained STAT4 
activation is necessary for T-box transcription factor (T-bet) up-regulation, which is in 
turn important for Th1 deviation. T-bet up-regulation appears to be achieved more 
readily after stimulation with IL-12 than IFN-α (Jacobson et al. 1995; Kaplan, Sun, et 
al. 1996; White et al. 2001) (Thieu et al. 2008). By contrast, in mice, there is evidence 
for a vital role for serine phosphorylation for induction of IFN-γ production and Th1 
cell differentiation (Morinobu et al. 2002). 
 
2. 4 Isoforms of STAT4 
 
In humans, there are two isoforms of STAT4 protein (Figure 1.3). STAT4β is a 
protein of 704 amino acids, and lacks the 44 residues at the C terminus of STAT4α 
(748 amino acids) (Hoey et al. 2003). IL-12 induces tyrosine phosphorylation of both 
isoforms, which then mediate distinct STAT4 responses. After stimulation with IL-12, 
STAT4 β maintains its phosphorylation state for longer (>2 hours) and mediates IL-
12-dependent cellular proliferation. By contrast, STAT4 α is essential for the 
formation of Th1 cytokine signature (IFN-) in response to IL-12 (Hoey et al. 2003). 
Over-expression of STAT4β was found to be important in mediating pathological 
inflammatory diseases (O'Malley et al. 2008; Mo et al. 2008).  
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2.5 Control of STAT4 activation 
 
Persistent STAT4 activation is important for T-bet up regulation and full Th1 
commitment (Thieu et al. 2008). There are many mechanisms that prevent excessive 
Th1 activation. For example, exposure to IL-12 induces degradation of the total 
STAT4 protein and phosphoSTAT4 via proteasomal degradation (Wang 2001). The 
STAT4β isoform is especially prone to proteasomal degradation (Hoey et al. 2003). 
Activation of proteasomal degradation appears to be specific to the IL-12 system, as 
IFN-α causes only transient activation of STAT4, and the signal is hardly detectable 
after 6 hours (Wang 2001).  Moreover, after STAT dimers detach from DNA binding 
sites, the N-domain permits the dimer to assume an antiparallel conformation, which 
in turn permits dephosphorylation (Mertens et al. 2006) by PTP basophil like (PTP-
BL) phosphatase (Nakahira et al. 2007).  
 
2.6 STAT4 and Follicular helper T (TFH) CELLS 
 
TFH cells are distinct CD4+ T cell subset that is terminally differentiated (Rasheed et 
al. 2006a) and has the  ability to support plasma cell formation and antibody 
production (reviewed by Crotty, S. (Crotty 2011)). Circulating TFH (cTFH) are 
sometimes used as surrogate markers of TFH in human studies (Gomez-Martin et al. 
2011; Ma and Deenick 2014). Recently, it has been shown that in addition to its 
ability to induce Th1 differentiation through T-bet, STAT4 also also regulates TFH 
differentiation by inducing expression of both IL-21 and BCL-6. While STAT4 
induces Th1 and TFH differentiation states, it appears that the extent of T-bet up-
regulation is decisive for CD4+ T cell differentiation, as T-bet act as a repressor for 
TFH cell differentiation (Nakayamada et al. 2011). Furthermore, it was shown that 
STAT4 is expressed by GC TFH (Schmitt, Bustamante, and Bourdery 2013) 
supporting other findings that STAT4 is also important for formation of human TFH 
(Nakayamada et al. 2011; Schmitt et al. 2009; Wei et al. 2010). Patients with IL-
12Rβ1 deficiency have impaired STAT4 signalling. These patients were also found to 
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have impaired GC TFH formation as well as reduced cTFH and B memory cells 
(Schmitt, Bustamante, and Bourdery 2013).  
 
2.7 Expression of T-bet 
The transcription factor T-bet (encoded by TBX21) controls and maintains expression 
of IFN-γ production, which is a hallmark of Th1 differentiation (Szabo et al. 2000). T-
bet is expressed at low levels by naïve T cells, and is up regulated slightly after TCR 
ligation, (Szabo et al. 2000; Szabo et al. 2002). IL-12, IFN-α and IFN-γ can both up-
regulate T- bet expression. Early up-regulation of T-bet is IFN-α and STAT1 
dependent during CD4+ T cell activation (Afkarian et al. 2002; Lighvani et al. 2001). 
The addition of IFN-α, or IL-12 to media containing TCR augments T- bet expression 
(Ylikoski et al. 2005) through STAT4 activation (Ylikoski et al. 2005; Ramos et al. 
2007). 
 
The hallmark of Th1 differentiation is induction of IFN- downstream stable T-bet up 
regulation, which is most efficient in the presence of IL-12  compared to IFN-α or 
IFN-γ (Ylikoski et al. 2005; Ramos et al. 2007). On the other hand, IFN-α gives rise to 
transient T-bet up-regulation that reaches its maximum at about 6 hours, and so is 
insufficient for stable Th1 differentiation in human CD4+ T cells (Thieu et al. 2008; 
Ramos et al. 2007). Therefore, IL-12/STAT4 act on T-bet to polarize and maintain 
Th1 differentiation in human CD4+ T cells (Ramos et al. 2007; Usui et al. 2003). In 
addition, the level of T-bet expression is high in human effector CD4+ T cells 
compared to the naïve and central memory cell populations(Knox et al. 2014) . 
 
2.8 Diseases associated with abnormal STAT4 
 
STAT4 deficiency in mice does not impede T cell development (Hoey et al. 2003) but 
renders T cells unresponsive to IL-12, which reduces their capacity to up- regulate 
IRF1, express T-bet, and proliferate (Kaplan, Sun, et al. 1996; Thierfelder et al. 1996; 
Hoey et al. 2003). As a consequence, STAT4 deficiency in mice results in impaired 
IFN- production and cytotoxicity (Kaplan, Sun, et al. 1996; Thierfelder et al. 1996; 
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Hoey et al. 2003) in response to IL-12. Moreover, STAT4 deficient CD4+ T cells in 
mice not only fail to form Th1 cells, but also exhibit a propensity to form Th2 cells 
(Kaplan, Sun, et al. 1996; Chang et al. 2009). A recent report of DBD variant has been 
described in association with patients with classic Kaposi sarcoma (Aavikko et al. 
2015). The STAT4
Thr446Ile
 variant was associated with lower IFN- production, 
although this difference between mutant and wild type was not statistically significant 
(Aavikko et al. 2015).  There have also been reports of acquired states of human 
STAT4 deficiency resulting from enhanced degradation of STAT4 protein after 
chemotherapy(Lupov et al. 2011). In this context, STAT4 deficiency has been 
reported to reduce Th1 cell formation (Lupov et al. 2011). Finally, a common 
polymorphism of STAT4 has been identified to confer increased risk of several 
autoimmune and inflammatory diseases, including systemic lupus erythematosus 
(SLE) and rheumatoid arthritis (RA) (Sigurdsson et al. 2008; Zervou et al. 2008; 
Remmers et al. 2007). This polymorphism was thought to flag an allele with gain-of-
function, as it was shown to confer increased sensitivity to IFN-α (Kariuki et al. 
2009). 
3. Mechanistic target of rapamycin (mTOR) 
 
3.1  General introduction 
 
Rapamycin, named after its discovery in the Easter Island (Rapanui) soil, was first 
identified as an antifungal that inhibited Saccharomyces cerevisiae. It was later found 
to inhibit cell cycle progression. This led to investigation of the use of the agent as 
both an antitumor and immunosuppressive drug. The biochemical target is 
mechanistic target of rapamycin (mTOR) which was initially named the mammalian 
target of rapamycin (mTOR) (Sehgal, Baker, and Vezina 1975; Vezina, Kudelski, and 
Sehgal 1975).  
 
3.2  Structure of mTOR 
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The target of rapamycin (TOR) is a conserved ~290 kDa protein that belongs to the 
phosphatidylinositol 3-kinase related kinase family (PIKK), yet acting as 
serine/threonine kinase (Brown et al. 1994). mTOR is expressed constitutively in 
many tissues (Murakami et al. 2004). mTOR has multiple defined protein domains. 
There are two clusters of huntingtin, elongation factor 3, a subunit of protein 
phosphatase 2A, and TOR1 (HEAT) repeats within its N-terminal half. Two blocks of 
HEAT motifs each made up of 40 amino acids, form a pair of antiparallel α helices.  
The HEAT domains are important in protein-protein interactions, and mediate the 
nutrient dependent dimerization of the mTOR (Takahara et al. 2006). The HEAT 
motifs are followed by FRAP, ATM, and TRRAP sharing domain (FAT). The FAT 
domain is made up of ~500 amino acids and forms a structural scaffold for other 
proteins (Bosotti, Isacchi, and Sonnhammer 2000). The FAT domain is followed by 
the FKBP12-rapamycin-binding (FRB). Moreover, the FRB domain is crucial for 
assembly of the FKBP12-rapamycin complex (Chen et al. 1995). Mutation of serine 
2035 to threonine in the FRB domain leads to rapamycin resistance (Dumont et al. 
1995). The FRB domain is followed up by serine-threonine protein kinas (kinase) 
domain which is followed by a negative regulatory domain (NRD). The NRD 
(residues 2430-2450) is crucial for controlling activity of mTOR. Blockade of this 
domain by either an inhibitory peptide (Brunn et al. 1997) or deletion of the whole 
domain (Sekulic et al. 2000b), results in an increased mTOR activity, as assessed by 
PS6 kinase phosphorylation. At the C-terminal is the FATC domain, which is made up 
of 31 amino acids and is important for cellular stability and the kinase activity, which 
appears to be crucial for mTOR activity, as deletion of any of its amino acids 
compromise the kinase activity of mTOR. FAT and FATC domains interact with each 
other and this interaction is important for protein kinase activity (Bosotti, Isacchi, and 
Sonnhammer 2000) (Figure 1.4). 
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Figure ‎1-4 Structure of mTOR  
The mechanistic target of rapamycin (mTOR) is made up of multiple domains, each 
serve a different function (detailed in the text). N-terminal domain is made up of 
huntingtin, elongation factor 3, a subunit of protein phosphatase 2A, and TOR1 
(HEAT) repeats. This is followed by FRAP, ATM, and TRRAP sharing domain 
(FAT). FAT domain is followed by FKBP12-rapamycin-binding (FRB) domain. A 
serine-threonine protein kinas (KIN) domain is located between FAT domain and a 
negative regulatory domain (NRD). The NRD (residue 2430-2450) which are 
followed by FAT domain and FRB domain. At the C terminal there is another FAT 
domain called FATC domain. 
 
3.3  Function of mTOR 
 
The main function of mTOR is to translate different environmental signals such as 
availability of nutrients, energy, cytokines, T cell receptor engagement (TCR) and 
others to control the rate and appropriateness of protein synthesis, cell cycle 
progression, cell survival and growth. mTOR can associate with other molecules to 
form two related complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 
(mTORC2), each with different substrates. Most of the known functions of mTOR are 
due to mTORC1. Extracellular nutrients and insulin stimulate mTORC1 through the 
phosphoinositide-3-OH kinase PI (3) kinase Akt pathway. Activated Akt 
phosphorylates the tuberous sclerosis complex (TSC2) on multiple sites, which 
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removes its inhibitory action on mTOR. Thus, TSC1 and TSC2 act as tumour 
suppressors. TSC1 and TSC2 are crucial to prevent inappropriate stimulation of 
mTOR in the face of absent extracellular stimuli, mTOR (Manning et al. 2002; Tee, 
Anjum, and Blenis 2003; Castro et al. 2003; Garami et al. 2003; Tee et al. 2002; Lee 
et al. 2007; Qin et al. 2010; Ma et al. 2005). The absence of this normal and basal 
inhibition of TSC1/TSC2 leads to abnormal growth and division of the cell, as 
exemplified by defects observed in tuberous sclerosis complex disease, caused by 
autosomal dominant (AD) mutations in TSC1 or TSC2(Napolioni and Curatolo 2008). 
 
mTORC1 can also be activated via an insulin/PI3K/Akt independent pathway that is 
mitogen-activated Ras/MEK (MAPK/ERK kinase)/MAPK dependent, causing 
phosphorylation of the TSC complex to alleviate the inhibitory effect on mTOR. 
Moreover, mTOR can be activated by TCR ligation, and ligation of the co stimulatory 
receptor CD28 (Hamilton et al. 2014; Gorentla, Wan, and Zhong 2011; Colombetti et 
al. 2006). Importantly, mTOR activation is maintained by other signals, including IL-
12/STAT4 (Rao et al. 2010).  Activation of mTOR leads to phosphorylation and 
activation of its substrate, S6 kinase (S6K), and phosphorylation and inactivation of 
the repressor of mRNA translation factor (4E-BP1). Both substrates are sensitive to 
rapamycin, and both are important for initiating the translational machinery leading up 
to protein synthesis and cell growth (Laplante and Sabatini 2009; Hay and Sonenberg 
2004). Overall, mTOR is activated by the presence of extracellular stimuli through 
PI3K/ Akt dependent and independent pathways and translates these environmental 
cues into protein synthesis and cell growth (Figure 1-5).  
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Figure ‎1-5 Signaling of mTOR   
Schematic representation of different stimulants and inhibitors of the mTOR 
complexes and the downstream effect of mTOR activation into different cellular 
functions.   (Showkat, Beigh, and Andrabi 2014)  
 
3.4 CD8+ T cell subsets 
 
CD45, also known as common leukocyte antigen, is expressed on all human T cells 
after thymic development (Serra et al. 1988). Two common CD45 isoforms are 
expressed on T cells. CD45RA is usually expressed on naïve T cells (Prince, York, 
and Jensen 1992), whereas the CD45RO isoform marks memory (antigen-
experienced) T cells (Prince, York, and Jensen 1992). However, there is also a T cell 
subset that is CD45RA+ despite being antigen experienced that is present among 
human CD4+ and CD8+ T cells and produces IFN-γ and expresses high levels of 
perforin (Hoflich et al. 1998). This subset has received the descriptive designation of 
T-effector memory, CD45RA positive (Temra), and expresses lymph node homing 
molecules such as CCR7 (CD45RA+CCR-) and CD62L (Sallusto et al. 1999). In 
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contrast, absence of both CD45RA and CCR7 (CD45RA-CCR7-) defines effector 
memory T cells (Tem). In summary, human CD8+ T cells can be divided into four 
subsets using a combination of these surface markers including CD45RA or CD45RO, 
CD27, CD62L or CCR7 (Hamann et al. 1997; Sallusto et al. 1999; Tomiyama et al. 
2004). The relative abundance of each subset in the blood is normally naïve 
(CD45RA+CCR7+) > Temra(CD45RA+CCR7-) > Tem (CD45RA-CCR7-) > Tcm 
(CD45RA-CCR7+) (Sathaliyawala et al. 2013). However, human aging is associated 
with accumulation of the CD8+ T cell Temra subset (Koch et al. 2008). Similarly, 
chronic viral antigenic stimulation causes accumulation of this subset in humans. 
Interestingly, mice have three subsets only and lack the  Temra subset.  
 
CD8+ T cell subsets defined by surface phenotype are also functionally different. 
Naïve CD8+ T cells are CD45RA+ and co-express CD27, CD62L and CCR7. They 
produce mainly IL-2 and lack any cytotoxic activity (Hamann et al. 1997; Sallusto et 
al. 1999; Romero et al. 2007). They express IL-7 receptor (CD127) which is important 
for their survival (Schluns et al. 2000; Tuma and Pamer 2002). Expression of (CD127) 
by naive CD8+ T cells is thought to be important for the expansion phase of the 
immune response, especially in the context of lymphopenia (Schluns et al. 2000; 
Goldrath et al. 2002).  
 
CD45RA- CCR7+ CD8+ T cells are defined as central memory cells by virtue of their 
tendency to home to lymph nodes. They are not cytotoxic ex vivo but exhibit recall 
responses after antigen re-exposure (Hamann et al. 1997; Sallusto et al. 1999). Similar 
to naïve CD8+ T cells, CD8+ Tcm cells express either IL-7 or IL-15 to maintain their 
homeostatic proliferation (Schluns et al. 2000; Tuma and Pamer 2002). 
 
Both CCR7 positive CD8+T cells (naïve and central memory) have the capacity to 
proliferate and divide (Champagne et al. 2001). Moreover, both exhibit high 
expression level of the pro-apoptotic Bcl-2 molecule (Geginat, Lanzavecchia, and 
Sallusto 2003) and have also been noted to possess longer telomeres (Sallusto et al. 
1999).  
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Tem and Temra cells are effector memory T cells that have ability to mount effector 
and cytotoxic responses in the periphery. They produce large amounts of IFN- and 
express perforin (Hamann et al. 1997; Sallusto et al. 1999). Effector CD8+ T cells 
lack the node homing receptors (CCR7 and CD62L)(Hamann et al. 1997; Sallusto et 
al. 1999), have shorter telomeres than their naïve counterparts (Sallusto et al. 1999), 
express only low levels of BCL-2, and exhibit lower proliferative ability and turnover 
than their memory counterparts (Geginat, Lanzavecchia, and Sallusto 2003). Both 
Tem and Temra CD8+ T cells express low levels of IL-7 receptor (CD127) (Tuma and 
Pamer 2002; Geginat, Lanzavecchia, and Sallusto 2003). 
 
The ontogeny of different CD8+ T cell subsets remains contentious, especially in 
humans. One model describes a linear progression from naïve to Tcm to Tem. Short 
term TCR stimulation of human naive CD8+ T cells lead them to acquire Tcm 
phenotype (CD45RA- CCR7+) with little IFN- production (Sallusto et al. 1999). 
Furthermore, short term TCR stimulation of Tcm results in loss of CCR7 and 
acquisition of inflammatory cytotoxic effector phenotype Tem (Sallusto et al. 1999; 
Geginat, Lanzavecchia, and Sallusto 2003). Both of these observations support a 
linear model of naïve to Tcm to Tem in response to short term TCR stimulation. Much 
less is known about formation of Temra, since mice lack an equivalent subset. Some 
evidence suggests that Temra can be generated in vitro from Tcm by activation in the 
context of IL-15, while the presence of TCR stimulation antagonises the formation of 
Temra (Geginat, Lanzavecchia, and Sallusto 2003).  
 
3.5 mTOR and peripheral CD8+ T cell subset differentiation 
 
Recent evidences indicate that mTOR not only inhibits immune system activation, but 
also also has a somewhat paradoxical action that fine tunes and enhances CD8 
immunity. mTOR signalling through the mTORC1 complex influences memory 
versus effector differentiation of naïve CD8+ T cells (Araki et al. 2009). Blocking 
mTOR with rapamycin early in the course of viral infection (proliferation phase), or in 
Pathological actions of STAT4, MTOR and STAT3 in human T cell 
differentiation 
  
46 
 
the T cell contraction phase, promotes formation of memory CD8+ T cells (Araki et 
al. 2009), that express high levels of CD127, CD62L and Bcl2 (Tcm, phenotype). 
These effects appear to be CD8+ T cell-intrinsic, since RNA interference of mTOR 
solely in CD8+ T cells replicates the effect of incubating PBMCs with rapamycin 
(Araki et al. 2009). Furthermore, the use of mutant CD8+ T cells, rendered 
specifically insensitive to rapamycin failed to replicate the phenotype of expanded 
memory CD8+ T cells when cells were treated with rapamycin (Araki et al. 2009). 
 
 
 
3.6 Effect of IL-12- STAT4 and mTOR on CD8+ T cell subset differentiation 
 
IL-12 is important for the differentiation of naïve CD8+T cells into effector and 
subsequent memory CD8+ T cells formation (Chang et al. 2004). In the presence of 
IL-12 and antigenic stimulation, naïve CD8+ T cells differentiate into effector cells, 
producing high amounts of interferon-, granzyme-B and acquire more potent 
cytotoxic activity (Chang et al. 2004; Rao et al. 2010; Chowdhury et al. 2011). 
Induction of T-bet is crucial in deciding the effector (Knox et al. 2014) over 
memory(Takemoto et al. 2006) fate of CD8+ T cell subsets after stimulation with IL-
12 (Li et al. 2006; Yang, Ochando, et al. 2007). In the absence of IL-12, developing 
CD8+ T cells exhibit lower expression of T-bet and acquire a memory phenotype 
(CD127+) (Takemoto et al. 2006). 
 
T-bet up-regulation by IL-12 appears to be STAT4 and mTOR dependent (Rao et al. 
2010). Furthermore, mTOR activation (as judged by S6K phosphorylation) was 
activated for longer in the presence of IL-12, suggesting that these signals are crucial 
for effector CD8+ T cell differentiation (Rao et al. 2010). Conversely, activation of 
STAT4 was found to be mTOR-dependent, as the presence of rapamycin reduced 
STAT4 phosphorylation (Rao et al. 2010) and the absence of active mTOR diminished 
the ability of IL-12 to phosphorylate STAT4 (Delgoffe et al. 2009). Active IL-12-
STAT4 and mTOR were both needed to up regulate T-bet (Li et al. 2006; Takemoto et 
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al. 2006; Rao et al. 2010) that favour effector fate of CD8+ cells. On the other hand, 
enhanced quality and increased quantity of Tcm CD8+ T cells was achieved by 
blocking mTOR leading to down-regulation of T-bet and up-regulation of 
eomesodermin (Eomes) (Rao et al. 2010). The resulting Tcm were competent to 
proliferate when restimulated with TCR, and adopted Tem phenotype, expressing high 
levels of perforin and granzyme-B (Ramos et al. 2009).   
 
3.7  Effect of mTOR on tissue resident CD8+ T cell differentiation 
 
CD8+ T cells are outnumbered by CD4+ T cells in all body compartments including 
blood and lymph nodes. The exception appears to be in the intestine, where there is an 
equal distribution of CD4+ and CD8+ T cells (Sathaliyawala et al. 2013). CD8+ T 
cells at the intestinal mucosa are predominantly tissue resident effector memory cells 
(Trm) that are recruited to the intestinal mucosa through up regulation of adhesion 
molecules. These adhesion molecules include CCR9 and α4β7 (Agace 2010), and the 
level of CD103 expression (Sowell et al. 2014). Temra subsets are not normally 
present in the intestinal mucosa (Sathaliyawala et al. 2013). 
 
Trm cells have a distinct phenotype that distinguishes them from classical Tem and 
Tcm. Trm cells were found to be more like effector cells in some aspects; they are 
CD62L
low
, granzyme-B 
high
, and CD69
high
, and mount vigorous IFN-γ responses 
(Sathaliyawala et al. 2013). On the other hand, Trm resemble central memory 
characteristics in that they have high replicative capacity and high BCL-2 expression 
(Masopust et al. 2006), which is different from classical effector Tem and Temra 
population. This phenotype of intestinal tissue resident memory CD8+ T cells is 
different from those resident in other tissues (Masopust et al. 2006). Once located in 
the intestine, Trm form long term memory cells that do not recirculate (Masopust et 
al. 2010).  
 
Up-regulation of tissue homing markers such as CCR9 and α4β7 (Agace 2010), and 
the level of CD103 expression on Trm CD8+ T cells (Sowell et al. 2014) is under the 
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control of mTOR (Sowell et al. 2014). While rapamycin enhances the quality and the 
quantity of CD8+ T central memory, especially at their reservoir in secondary 
lymphoid organs (SLO), rapamycin impairs the formation of Trm at mucosal sites 
(Sowell et al. 2014). While there is relatively little data available on the normal 
distribution of CD8+ T cell subsets in the oesophagus, biopsies from patients with 
erosive gastritis revealed that, CD8+ T cells as the dominant cell type (De Jonge et al. 
2008; Tantibhaedhyangkul et al. 2009). There are very few Temra in the intestine 
compared to the lung (Sathaliyawala et al. 2013) and the main CD8+ T subset in any 
tissue including intestine is Trm.  Excessive Trm are thought to contribute to the 
pathogenesis of various inflammatory diseases, including psoriasis (Suarez-Farinas et 
al. 2011) , allergic contact dermatitis (Gaide et al. 2015) and Crohn’s disease (Raine et 
al. 2015; Kleinschek et al. 2009).  
 
4. Interleukin- IL-10 (IL-10) 
 
4.1 Cellular sources, stimuli and signals required for IL-10 production 
 
IL-10 is produced by many hematopoietic cells including, monocytes, B cells and T 
cells (Yssel et al. 1992; Xu et al. 2009; Delprete et al. 1993). The importance of 
haemopoietin sources of IL-10 was demonstrated by the good clinical response to 
bone marrow transplantation in patients with IL-10 deficiency (Engelhardt et al. 2013; 
Engelhardt and Grimbacher 2014).  
 
4.1.1 Antigen presenting cells 
 
In mice, IL-10 is produced by monocytes and myeloid dendritic cells in response to 
different microbial products (Boonstra et al. 2006; Saraiva and O'Garra 2010). 
Stimulation of pattern recognition receptors such as TLR2 and TLR4 signal in 
macrophages and myeloid dendritic cells (DC) induces production of IL-10, mainly 
through MYD88 (Boonstra et al. 2006; Saraiva and O'Garra 2010) (reviewed by 
Saraiva, M.(Saraiva and O'Garra 2010)). Myeloid DC produce IL-10 in response to 
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Dectin 1 and TLR2 stimulation through Syk and NF-κB dependent pathways, 
respectively. On the other hand, plasmacytoid dendritic cells produce little IL-10.  
 
In humans, activation of STAT3 by lipopolysaccharide (LPS) stimulation , is an 
important but not the exclusive  regulator of IL-10 production by human monocytes 
and human B cells (Staples et al. 2007; Benkhart et al. 2000; Ziegler-Heitbrock et al. 
2003). Thus, STAT3 mutated on tyrosine or lacking DNA binding activity blocks the 
ability of STAT3 to induce IL-10 production (Benkhart et al. 2000). In addition, IL-10 
has the ability to induce its own production by human monocytes (Staples et al. 2007), 
and this autocrine pathway is entirely STAT3-dependent (Staples et al. 2007).  
 
4.1.2 IL-10 in T cells 
In humans, IL-10 can be detected in vivo mainly among effector memory (CD45RA- 
CD4+) T cells after stimulation with TCR co-stimulation with T cell activation and 
expansion beads (CD2/CD3/CD28)(Cohen et al. 1997; Yssel et al. 1992). Stimulation 
via common gamma chain cytokines (IL-2, IL-7, IL-4, IL-15, and IL-21) augments 
IL-10 production by mitogen activated T cells (Cohen et al. 1997). Investigation of 
rare cases of human deficiency of IL-2Rα (CD25) revealed failure to induce IL-10 by 
CD4+ T cells after stimulation with mitogen and IL-2 (Caudy et al. 2007). Similarly, 
IL-10 production by mitogen activated cells is inhibited by rapamycin through 
inhibition of IL-2 production (Cohen et al. 1997). Interestingly, IL-12 also induces IL-
10 from mitogen activated (CD2) human PBMCs and T cells (Meyaard et al. 1996). 
 
4.1.2.1 Th1 
 
In humans, IL-10 can be detected in Th1 clones (Yssel et al. 1992). In mice, memory 
Th1 cells require continuous exposure to IL-12 to induce IL-10 production and once 
IL-12 is eliminated from the system, there is a decline in the production of IL-10 
(Chang et al. 2007). IL-10 production by murine Th1 requires high concentrations of 
IL-12 and strong TCR stimulation, and is dependent on active STAT4 and ERK 
signalling (Saraiva et al. 2009). This appears to provide a regulatory feedback 
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mechanism that controls Th1 responses while not interfering with proper secondary 
immune responses. In addition, IL-21 has the ability to augment IL-10 production 
from murine Th1 cells through STAT3 dependent pathway (Spolski et al. 2009). 
 
IL-12 has also been shown to induce IL-10 from human Th1 clones (Meyaard et al. 
1996). Prolonged exposure to IL-12 and concurrent increased IL-10 production is 
associated with suppression of Th2 effector cytokines in human T cells (Meyaard et 
al. 1996). IL-10 is not considered to be a memory Th1 cytokine, because in committed 
Th1 cells, the IL10 gene is silenced (Kang and Im 2005). However, repeated allergen 
exposure in human has been associated with the in vivo switch of allergen Th1 from 
IFN-γ producing- to IL-10-producing CD4+ T cells (Meiler et al. 2008). More 
recently, it was shown that special rare in vivo human Th1 subset produces IL-10 
(Haringer et al. 2009). IL-10 expression was only observed after continuous and 
strong stimulation in the presence of IL-12 to maintain its expression. 
 
4.1.2.2 Th2 cells 
 
Human Th2 clones produce more IL-10 than Th1 clones (Delprete et al. 1993). IL-12 
has also the ability to induce IL-10 from human mitogen activated (CD2) Th2 clones 
(Meyaard et al. 1996). IL-4 is known to induce the signature transcription factor 
GATA3 in Th2 cells (Chang et al. 2007). Repeated exposure of Th2 clones to IL-4 
leads to IL-10 production as a stable phenotype of Th2 cells (Chang et al. 2007). In 
fact, chronic Th2 inflammation in mice results in skewing of Th2 differentiation to 
cells that make both IL-4 and IL-10. Active STAT3 signalling has a positive effect in 
inducing more IL-10 production in murine Th2 cells (Altin, Goodnow, and Cook 
2012). In mice, this regulatory subset has a gene expression profile that resembles that 
of regulatory T cells (Tregs), except that they are Foxp3-negative (Altin, Goodnow, 
and Cook 2012). The subset is characterised by production of both IL 10 and IL-4, 
and is dependent on STAT6 and GATA3.  
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4.1.2.3 Th17 cells 
 
Most of the available literatures on IL-10 in Th17 comes from animal models. In the 
murine system, polarisation to Th17 differentiation is supported by the use of IL-6 and 
TGF-β, both of which induce STAT3-dependent up-regulation of c-Maf, which in turn 
induces production of IL-10 (Xu et al. 2009). IL-10 is crucial in controlling Th17-
mediated inflammation (Xu et al. 2009). Moreover, IL-21 signalling through STAT3 
also augments production of IL-10 in committed Th17 cells in mice (Spolski et al. 
2009). The production of IL-10 by Th1, Th2 and Th17 subsets relies on the ERK1/2 
and c-maf expression (Saraiva et al. 2009). 
 
4.2 Action of IL-10 and molecules needed to exert its function. 
 
IL-10 is well known as a cytokine synthesis inhibitory factor (CSIF) (Vieira et al. 
1991). IL-10 binds to its dimeric receptor which is made up of IL10R1 and IL10R2. 
IL10R2 is ubiquitously expressed, while IL-10R1 is an inducible subunit. IL-10 binds 
primarily to IL-10R1 compared to IL-10R2 (von Lanzenauer et al. 2015; Liu et al. 
1994), (reviewed by Moore, K.W (Moore et al. 2001)). Differential expression of 
these two receptors, particularly IL-10R1, determines the extent of responsiveness to 
IL-10 (von Lanzenauer et al. 2015; Moore et al. 2001). In humans, IL-10R1 is mainly 
expressed on hematopoietic cells including monocytes, B and T cells (Liu et al. 1994). 
 
IL-10 has a direct suppressive effect on proliferation of naïve and memory T cells 
(Haringer et al. 2009) as well as directly inhibiting cytokine productions by Th1 cells 
(Delprete et al. 1993). IL-10 has also the same inhibitory effect on human Th2 clones 
(Delprete et al. 1993; Altin, Goodnow, and Cook 2012). Recently, it was shown that 
IL-10 has the ability to inhibit Th2 proliferation directly in a Foxp3 independent 
pathway (Altin, Goodnow, and Cook 2012) (reviewed by Hawrylowicz, C.M. 
(Hawrylowicz and O'Garra 2005)). Therefore, IL-10 is crucial in controlling ongoing 
Th1 immune response and excessive Th2 inflammatory response to prevent 
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immunopathology associated with exaggerated Th1 or Th2 immune response 
(Hawrylowicz and O'Garra 2005; Akdis et al. 1998; Altin, Goodnow, and Cook 2012). 
 
4.2.1 Monocytes and IL-10 
 
Much of the available information on effects of IL-10 is derived from studies on 
antigen presenting cells such as monocytes, macrophage and dendritic cells. Most of 
the known effects on IL-10 on monocytes are inhibitory. Macrophages activated in the 
presence of IFN-γ or LPS express high levels of activation markers such as MHC 
class I and II, as well as B7 co stimulatory molecules (Ding et al. 1993). One of the 
main actions of IL-10 on monocytes is down-regulation of antigen presentation by 
macrophages (Vieira et al. 1991) and dendritic cells. This is achieved through down-
regulation of MHC class II (de Waal Malefyt et al. 1991; Ding et al. 1993; Buelens et 
al. 1995), CD80 (Ding et al. 1993), and CD86 (Buelens et al. 1995)expression. IL-10 
also inhibits endogenous monocyte inflammatory cytokine production, including IL-
1β, IL-6 and TNF-α, which are usually produced early (4-8 hrs) after activation of 
monocytes (de Waal Malefyt et al. 1991; Fiorentino, Zlotnik, Mosmann, et al. 1991). 
 
IL-10 down regulation of activated antigen presenting cells(Delprete et al. 1993) 
causes eventually inhibition of T cell proliferation (Fiorentino, Zlotnik, Mosmann, et 
al. 1991; Fiorentino, Zlotnik, Vieira, et al. 1991; Meyaard et al. 1996) and cytokine 
production of Th1. In fact, treatment of dendritic cells with IL-10 also reduces their 
capacity to induce competent T cell responses. Therefore, one consequence of IL-10 
treated dendritic cells is induction of Foxp3 positive regulatory cells (induced Tregs) 
(Steinbrink et al. 2002). 
 
In macrophage and dendritic cells, IL-10 signals mainly through STAT3 (Finbloom 
and Winestock 1995). Thus, mice engineered to carry targeted STAT3 deficiency in 
their gastrointestinal macrophages and polymorph nuclear cells (PMN) develop early-
onset and severe colitis, a similar phenotype to those mice with IL-10 deficiency 
(Takeda et al. 1999). Disruption of STAT3 results in the generation of inflammatory 
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antigen presenting cells (Cheng et al. 2003; Giacomelli et al. 2011). This explain why 
monocytes obtained from patients with autosomal dominant hyper IgE syndrome 
(ADHIES), in which STAT3 signalling is impaired, generate enhanced inflammatory 
cytokine responses after exposure to LPS (Giacomelli et al. 2011). The main anti-
inflammatory action of IL-10 on monocytes and polymorphonuclear leukocytes 
(PMN) in the gastrointestinal tract is mediated by STAT3 (Takeda et al. 1999), and 
this appears to be crucial for protection against inflamed bowel. This IL-10 anti-
inflammatory response is inhibited by pro-inflammatory cytokines such as IL-1 and 
TNF-α (Ahmed and Ivashkiv 2000).  Inhibition is at the level of STAT3 
phosphorylation and subsequent DNA binding (Ahmed and Ivashkiv 2000).  
 
4.2.2 B cells and IL-10 
 
In contrast to the general inhibitory direct and indirect effect of IL-10 on monocytes 
and T cells, IL-10 signalling through STAT3 has stimulatory effect on B cell, and 
augments formation of plasma cells (Choe and Choi 1998; Yoon et al. 2009). IL-4, 
has proliferative effect on B cells but, do not support formation of plasma cells (Choe 
and Choi 1998). IL-4 supports class switching to IgE production (Punnonen et al. 
1993). On the other hand, IL-10 stimulates B cells toward formation of plasma cells in 
the germinal centres (Yoon et al. 2009). Moreover, IL-10 inhibits class switching to 
IgE (Punnonen et al. 1993) at the level of germ line transcripts. This effect was shown 
to be dependent on the presence of monocytes in the culture system and was 
independent of inhibition of other cytokines, including IL-6 and TNF-α (Punnonen et 
al. 1993). 
 
4.3 DiseaseS associated with deficiency of IL-10  
 
IL-10 deficiency in mice results in resistance to infection especially chronic viral 
infections (Ejrnaes et al. 2006; Brooks et al. 2006). IL-10 deficient mice exhibit 
efficient clearance of chronic virus infection, which results from enhanced action of 
effector Th1 cells and IFN-γ producing CD8+ T cells (Ejrnaes et al. 2006; Brooks et 
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al. 2006). On the other hand, IL-10 deficient mice are also more susceptible to 
immunopathology from exaggerated Th1 responses (IL-12, TNF-α and IFN-) after 
certain infections, including toxoplasmosis and plasmodium (Gazzinelli et al. 1996; 
Li, Corraliza, and Langhorne 1999). In fact, exaggerated and uncontrolled Th1 
responses can be triggered even by gut bacterial commensals (Kuhn et al. 1993; 
Takeda et al. 1999). In humans, genetically determined IL-10 or IL10R deficiency 
results in very early-onset and severe colitis (Kuhn et al. 1993; Berg et al. 1996; Sato 
et al. 2006; Engelhardt et al. 2013; Engelhardt and Grimbacher 2014) and (Glocker et 
al. 2010; Kotlarz et al. 2012; Glocker et al. 2009; Lee et al. 2014). Aside from these 
rare damaging mutations, certain more common IL10 polymorphisms confer an 
increased risk of IBD, especially ulcerative colitis (Franke et al. 2008). 
5. T cell exhaustion 
5.1 IL-10 and T cell exhaustion 
 
IL-10 deficiency renders humans more susceptible to inflammatory diseases. On the 
other hand, up regulation of IL-10 by APC or by CD4+ T cells (Ejrnaes et al. 2006; 
Brooks et al. 2006; Wherry 2011) during the course of viral infections is associated 
with the risk of chronic and persistent infection (Brooks et al. 2006). Conversely, IL-
10 inhibition has been shown to enhance control of virus replication through 
restoration of the effector T cell functions (Brooks et al. 2006; Porichis et al. 2014). 
This is mainly due to the inhibitory action of IL-10 on effector Th1 CD4+ and CD8+ 
T cells. These cells lose the ability to proliferate and produce their inflammatory 
cytokines such as (IL-2, IFN- and TNF-α) (Brooks et al. 2006; Zajac et al. 1998). 
This state is called T-cell exhaustion (Yi, Cox, and Zajac 2010; D'Souza et al. 2007; 
Wherry 2011).  
 
5.2  PD-1 and T cell exhaustion 
 
High level antigenic stimulation, as occurs during chronic viral infections, drives T 
cell exhaustion, a state associated with impaired effector T cell responses (Mueller 
and Ahmed 2009). T cell exhaustion is very well-described process in CD8+ T cells 
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(Yi, Cox, and Zajac 2010) (and reviewed by Akbar, A.N.(Akbar and Henson 2011) 
and Wherry, E.J.(Wherry and Kurachi 2015)). PD-1 is an established marker of clonal 
exhaustion on CD8+ T cells (Akbar and Henson 2011; Buggert et al. 2014; Wherry 
and Kurachi 2015) in chronic viral infections such as HIV (Day et al. 2006; Buggert et 
al. 2014), and chronic hepatitis virus infection (Ye et al. 2015). Expression of PD-1 by 
exhausted CD8+ T cells marks them as highly sensitive to spontaneous apoptosis and 
Fas-induced cell death, (Petrovas et al. 2009), which results in progressive loss of 
antigen specific T cells (Yi, Cox, and Zajac 2010). High expressing PD-1 (PD-1
hi
) 
exhausted cells are characterized by low levels of T-bet expression but high levels of 
Eomes (Buggert et al. 2014). Blockade of PD-1 has been shown to reverse aspects of 
the exhaustion phenotype in CD8+ T cells (Day et al. 2006). While better 
characterised in CD8+ T cells, clonal exhaustion of CD4+ T cells has been described, 
and is also characterised by up regulation of inhibitory molecules such as PD-1 
(Morou, Palmer, and Kaufmann 2014; Day et al. 2006). Furthermore, in CD4+ T cells, 
blocking PD-1 liberates them from their nonresponsive state and promotes production 
of inflammatory cytokines such as IFN- and IL-2, and restores capacity for cell 
proliferation (Rosignoli et al. 2009; Porichis et al. 2011; Porichis et al. 2014).  
 
5.3 T cell senescence 
 
Chronic antigenic stimulation of terminally differentiated effector CD8+ T cells can 
also induce cellular senescence, in which T cells can retain effector and cytotoxic 
capacity, but lose their replicative potential. This is in contrast to the exhausted cell, 
where cells have impaired proliferative capacity coupled with impaired functional 
abilities and reduced cytotoxicity (Akbar and Henson 2011). CD57 is thought to be a 
specific marker of senescence (Larbi and Fulop 2014). Senescent cells are 
characterized by short telomeres (Akbar and Henson 2011; Larbi and Fulop 2014; 
Moro-Garcia, Alonso-Arias, and Lopez-Larrea 2012). 
 
5.3.1 CD57 
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CD57 was initially thought to be a marker of natural killer (NK ) cells only (Abo and 
Balch 1981) but was later found to be expressed by other lymphocytes. As noted 
above, in general, CD57 marks senescent terminal effector cells with reduced 
proliferative capacity (Kared et al. 2016). CD57 is expressed by mature CD56 
dim
 
CD16 +NK cells (Abo, Cooper, and Balch 1982), and expression of CD57 by NK 
cells increases naturally with age (Lopez-Verges et al. 2010), but this process appears 
to be accelerated in the setting of chronic antigenic stimulation, such as autoimmune 
diseases, chronic viral infection, and cancer (Nielsen et al. 2013). In NK cells, CD57 
is a marker of cytolytic activity with enrichment for granzyme-A, granzyme-B and 
perforin (Chattopadhyay et al. 2009). Increased or enhanced cytolytic function of 
CD57+ NK cells was found to be associated with better outcome in different 
malignancies in support of their function in tumour surveillance (Nielsen et al. 2013).  
CD57+CD8+ T cells are also increased in setting of antigenic stimulation such as in 
HIV and CMV (Bandres et al. 2000; Brenchley et al. 2003; Akbar and Henson 2011; 
Petrovas et al. 2009; Strioga, Pasukoniene, and Characiejus 2011; Le Priol et al. 
2006). They are highly effector, cytotoxic and distended for homing to peripheral 
tissues (Le Priol et al. 2006). 
 
5.3.1.1 CD57+ CD4+ T cells 
 
CD57 is mainly expressed by peripheral terminal effector CD4+ T cells, both Temra 
and Tem subsets in humans (Palmer et al. 2005; Velardi, Grossi, and Cooper 1985; Di 
Mitri et al. 2011). The CD57 +CD4+ T cells subset has been found to be expanded in 
states of chronic immune activation (Fleischer 1984), including in patients with EBV 
or HIV infection (Palmer et al. 2005), autoimmune diseases such as rheumatoid 
arthritis (Maeda et al. 2002; Appay 2004), and IgG4 related disease (Mattoo et al. 
2016). CD57+ CD4+ T cells produce mainly IFN- (Palmer et al. 2005). Similar to 
CD8+ T cells, expression of CD57 by CD4+ T cells identifies cellular senescence  
characterised by proliferative incompetence (Palmer et al. 2005; Brenchley et al. 
2003; Di Mitri et al. 2011).  
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Recent reports have also shown that human peripheral blood CD57+ CD4+ are 
terminally differentiated effector but also possess cytolytic potential marked by 
expression of granzyme-A, granzyme-B , perforin and CD107a degranulation 
(Casazza et al. 2006; Chattopadhyay et al. 2009). In addition to circulating CD57+ 
CD4+ T cells, there is also a subpopulation of CD57+ CD4+ T cells that reside in the 
tonsil as TFH cells (Sattarzadeh et al. 2015; Gomez-Martin et al. 2011; Bouzahzah et 
al. 1995). It remains unclear whether this TFH subset is functionally distinct, with 
conflicting evidence regarding their capacity to help B cell differentiation, relative to 
their CD57- counterparts. CD57+ TFH cells are thought to lack cytolytic activity 
based on analysis of their ability to kill K562 cell lines. (Velardi, Grossi, and Cooper 
1985). . 
  
6. Summary of literature and points to be discussed 
6.1 Human T cell differentiation by STAT4 
The capacity of peripheral T cells to differentiate into different effctor subsets is a 
result of interplay between TCR ligation, cytokine stimulation, co-stimulation and or 
co-inhibition signals. The three stimuli converge on specific transcription factors that 
mediate the signal to switch on or switch off certain transcriptional regulators that 
result in adoption of specific T cell fate.  
 
In animal models, it has been shown very clearly that STAT4 is needed for Th1 T cell 
formation, and is associated with T-bet up-regulation and IFN- production. STAT4 
has also been implicated in the formation of TFH and cTFH based on association 
studies in patients with IL-12Rβ1 deficiency, together with  detection of STAT4 in 
normal germinal centres. Despite the suggestions from previous reports, there is as yet 
no conclusive genetic or functional evidence for STAT4 gain of function or loss of 
function mutations in humans. This has impeded any confirmation what has been 
suggested from the animal models and in-vitro assays in regard to contribution of 
human STAT4 toward formation of human Th1, cTFH and TFH. 
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6.2 MTOR in human T cell differentiation 
Different types of effector CD4+ and CD8+ T cells can also be classified according to 
expression of CCR7 and CD45RA. Of the many molecules important in guiding T cell 
differentiation from naïve to different effector and memory subsets, mTOR has been 
elegantly shown to be required for effector Tem development in animal models 
especially for the CD8+ T cell subset. The Temra subset is lacking in mice, and 
therefore can only be investigated in humans. Human mutations in PI3K have been 
shown to result in enhanced mTOR activity, and are associated with deviation toward 
terminally differentiated (Tem and Temra) effector CD4 and CD8+ T cells with a Th1 
phenotype (Angulo et al. 2013; Lucas et al. 2014). Finally, mouse studies have also 
shown that mTOR can enhance STAT4 signalling and Th1 deviation in the CD8+ T 
cell compartment. There are no human ‘models’ available to confirm the action of 
mTOR in the differentiation of CD8+ T cell subsets, especially Temra, and the cross 
regulation of STAT4 and mTOR.  
 
6.3 STAT regulation of IL-10 and T cell exhaustion 
STAT3 loss of function (LoF) mutations are now well-characterised syndrome that 
results in Th17 deficiency in humans. The pathophysiology of the high level of IgE in 
HIES, however, remains enigmatic. The level of IgE does not become high until 
patients reach 1 year of age(Kamei and Honig 1988). Interleukin- 4 (IL-4) response as 
a main Th2 cytokine is a well know inducer of class switching to IgE (Romagnani 
1994; Avery et al. 2008). Unopposed IL4 has been suggested to cause the high IgE in 
ADHIES. However, this simple Th2 bias is not a consistent finding in peripheral 
blood in patients with HIES. IL-10 produced by CD4+ Th2 cells has also been shown 
to control excessive Th2 and IL-4 immunopathology in animal models. Formation of 
this regulatory subset was shown to be enhanced by STAT3-dependent cytokines, 
pointing to the possibility that a defect in this IL-10 producing subset might contribute 
to Th2 immunopathology seen in STAT3 LoF.  
 
TFH are distinct subset of helper CD4+T cells that are efficient in supporting B cell 
differentiation, plasma cell formation and immunoglobulin class switching and 
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production. TFH and their blood counterpart cTFH cells are commonly identified by 
their surface markers such as high and intermediate level of CXCR5 respectively. In 
addition, TFH cells also express other markers such as PD-1(exhaustion marker) with 
or without CD57 (cytotoxic marker) among other markers. Formation and function of 
TFH and cTFH are comprised in patients with AD-HIES (STAT3 LoF) defined by the 
classical marker of CXCR5. However, it is not clear if there is a clear cytotoxic or 
exhaustion distinction between the two subsets based on expression of CD57 by TFH 
and cTFH. Moreover, there is no data to implicate STAT3 in the formation of these 
two subsets. 
 
In this thesis, we describe the results of experiments aimed at investigating the actions 
of STAT4 and STAT3 in controlling specific aspects of T cell differentiation. First, 
we describe analysis of immunity in a patient with a novel STAT4 gain of function 
(GoF) mutation. We confirm the importance of human STAT4 for Th1 differentiation 
namely, T-bet up regulation, IFN- production and we show that STAT4 is crucial for 
cTFH formation in vivo. We also report a gain of function mutation in MTOR and 
demonstrate the consequences for effector CD4+and CD8+ T cell differentiation, as 
well as cross regulation between STAT4 and mTOR during Th1 and TFH 
differentiation. 
 
Finally, using cells from patients with functional mutations in STAT3, we have 
characterised how STAT3 regulates IL-10 producing Th2 cells, T cell exhaustion, and 
acquisition of CD4+ T cell cytotoxicity by CD57+ CD4+ T cells. 
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CHAPTER 2 : MATERIALS AND METHODS  
1 Subjects 
 
Data and samples of patients and controls were collected as a part of the Australian 
and New Zealand Antibody deficiency allele study (ANZADA).  The collection of 
blood and saliva was according to a standard operating procedure. Tissue donated at 
time of diagnostic biopsy as part of patient's management plan after obtaining an 
informed consent. 
 
2.1.1 Ethical approval and informed consent 
 
All of the detailed work on samples of patients and controls (healthy volunteers) 
described and used in this thesis have been approved by local human research ethics 
committee at each institution. Patients and controls were given information sheets and 
verbal explanation prior to obtaining a signed consent form. All patients’ information 
with identifications were coded and kept securely. 
 
2.1.2 Subjects with STAT3, STAT4, MTOR mutations 
 
Subjects with STAT3 mutations were genotyped previously and the work has been 
published (Ma et al. 2008). Mutations in the initial subject with GoF-STAT4 and GoF-
MTOR were identified from the whole exome sequencing as part of this discovery 
project. These mutations were then confirmed in the same subjects and other available 
family members using Sanger sequencing.  
 
2 Statistical analysis 
 
The results were analysed with MedCalc software (Mariakerke, Belgium) and 
Microsoft Excel (Washington, USA). The differences between paired samples were 
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analysed using either independent student T test, Mann Whiteny or Wilcoxon rank test 
(for non-parametric paired samples).P<0.05 is considered statically significant.  
 
3 Materials and Methods 
2.3.1 Material and reagents 
All of the material used for the work of this thesis are listed in the below given tables 
from 2-1 to 2-11. 
Table‎2-1 Media and buffers for the cellular work .  
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Source Final 
concentration 
Ingredient  Media/ 
Buffer 
Sigma Aldrich  RPMI 1640 medium Culture Media 
(CM) Life 
Technologies 
10% Fetal calf serum(FCS) 
Sigma Aldrich 4mM L-glutamine200 mM 
Sigma Aldrich 100U/ml /100 
µg /ml 
Pencillin10000U/ 
10mg/ml) Streptomycin 
  CM as above Freezing 
Media(FM) Sigma Aldrich 10% Dimethyl sulfoxide 
(Hybri Max)(DMSO) 
Gibco  PBS FACS wash 
 Life 
technologies 
2% FCS 
Gibco  PBS Sterile FACS 
wash  Life 
technologies 
0.1-0.2% FCS 
BD 1X BD Perm wash buffer 
10X 
Perm wash 
buffer 1x 
(cytokine 
assays) 
 Distilled water,9 parts 
BD 1X FoxP3 Buffer A x 10, 1 
part 
Distilled water ,9 parts 
Fix buffer 
(FoxP3) 
BD 1X FoxP3 Buffer B (50X), 1 
part 
Perm buffer( 
Foxp3) 
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Table ‎2-2 Various cytokines and stimulants and their doses  
Name Source 
Final 
concentration 
Phytohemagglutinin(PHA)  Sigma 25 µg /ml 
T cell activation and expansion 
beads  Miltenyi Biotech 2:1 beads to cell 
Phorbol 12-myristate 13-acetate 
(PMA) Sigma 50nM 
IFN-α Schering-Plough 20IU/ml 
Recombinant human IL-1β Miltenyi Biotec 40ng/ml 
Recombinant human IL-2 
 Thermo-Fischer scientific 
80ng/ml 
 
Recombinant Human IL-4 R&D 50ng/ml 
Recombinant Human anti- IL-4 R&D 20 µg /ml 
Recombinant human IL-6 Miltenyi Biotec 200ng/ml 
Recombinant human IL-10 R&D 100ng/ml 
Recombinant Human IL-12 R&D 20 ng/ml 
Recombinant Human IL-21 
 
Mitenyi Biotec 
 
10ng/ml 
or100ng/ml 
Recombinant Human IFN-γ PeproTech  
Recombinant Human IFN-γ 
neutralizing BD 10 µg /ml 
Recombinant Human sCD40 
Ligand PeproTech 1 µg /ml 
Type B CpG oligonucleotide 
human 
TLR9 ligand(ODN2006) 
Invivogen 
 
1uM 
 
Rapamycin 
 
sigma Aldrich 
 
10ng/ml, or 100 
ng/ml 
Anti Igs [(Fab)2 (] Goat anti Jackson ImmunoResearch 5 µg /ml 
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human IgG,F(ab)2 fragment 
specific) 
 
Laboratories  
 
 
Table ‎2-3 Reagents for molecular and western blot work 
Catalogue 
number 
Company Reagent 
15596 Invitrogen Trizol 
 Sigma-Aldrich Chloroform 
  100 % Isopropyl alcohol 
  75% ethanol (in DEPC-treated water) 
218161 Qiagen miScript Reverse Transcriptase mix.  
miScript RT Buffer 5 x  
F-549S 
 
Thermo Scientific Phusion Hot Start II High-Fidelity 
DNA Polymerase2U/ul. 
5X Phusion HF Buffer. 
Phusion Hot StartII. 
  10mM dNTPs 
18265-017 Invitrogen Subcloning Efficiency™ DH5α™ 
Competent Cells 
V855-20 Invitrogen PcDNA™3.1/myc-His (-) A plasmid 
27106 QIAGEN QIAprep Spin Miniprep Kit 
41003 Biotium GelRed Nucleic Acid Stain10,000x 
 New England Biolabs Gel loading dye blue 6x 
10787-018 Invitrogen 1Kb Plus DNA ladder 
A9282 Promega Wizard® SV Gel and PCR Clean-Up 
System 
R0142 New England Biolabs KpnI restriction enzyme 10,000 unit/ml 
with 1X NEBuffer 3.1 
R0136 New England Biolabs  BamHI restriction enzyme 20,000 
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unit/ml with 1X NEBuffer 3.1 
M0202S New England Biolabs T4 DNA ligase 3 Weiss unit/ul 
  10x T4 DNA Ligase Reaction Buffer 
159910 Thermo Scientific Nunc EasYFlask 175cm2 
15092 Gibco 2.5% Trypsin 10x 
15338 Invitrogen lipofectamine LTX and PLUS reagent 
kit 
PAN LR0079 Millennium Science Pty 
Ltd    
STAT4 luciferase reporter vector 
3917 Corning Sterile 96 well solid white flat bottom 
polystyrene TC-treated microplates 
E2920 Promega Dual-Glo® Luciferase Assay System 
15338 Invitrogen lipofectamine LTX and PLUS reagent 
78420 Pierce Halt Phosphatase Inhibitor Cocktail, 
100X 
539134 Calbiochem Protease Inhibitor Cocktail Set III, 
EDTA-Free 
r0278-50ml Sigma RIPA 
BG-145  True Sep SDS sample buffer 
P2287 Sigma, Tween 20 
NB10-010& 
NB10-012 
nusep Tris glycine mini gel 10 and 12 % 
Lc2675 life technologies Tris -Glycin SDS Running Buffer 
(10x) 
NP00060 lifetechnologies Transfer Buffer 20X 
162-0177 BioRad Immun-Blot PVDF Membrane 
A7906-100g Sigma Albumin from bovine serum 
RPN2106 GE Healthcare A Amersham ECL Western Blotting 
Detection Reagents 
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Table‎2-4 The master mix for generation of cDNA 
Reagents volume 
5x miScript RT Buffer 4μL 
miScript Reverse Transcriptase mix 1μL 
Template RNA Volume making up 1μg 
RNase-free water To make up total of 20ul 
 
Table‎2-5 Amplification of STAT4 
Reagent volume 
5X Phusion HF Buffer 10 μL 
10mM dNTPs 1μL 
Primer forward 
ggctccaggatccaccatgtctcagtggaatcaag 
2.5ul(10pmol) 
Primer reversed 
gg ggt acc ttc agc aga ataaggagacttca  
2.5ul(10pmol) 
cDNA  1ul 
Phusion Hot StartII 0.5ul 
RNase-free water 32.5 ul 
 
Table‎2-6  Media and Buffers for the molecular and western blot work 
Name Reagent Volume Notes 
 10g of tryptane 1 L H2O PH of 7.0 sterilized 
in autoclave at 
121°C for 15 
minutes and left in 
4°C 
5g of yeast extract 
5 g of NaCl2 
LB –amp 
media 
LB-media  for short time use 
fresh ampicillin at a final of 
100 µg /ml 
LB-amp The LB media  Autoclaved at 
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agar plate 500 ml (pH adjusted to 7.5) 121°C, 15mns. Cool 
down to around 
50C. Plates poured. 
left overnight 
7.5 g of agar 
fresh ampicillin at a final 
concentration of 100 µg /ml 
TAE buffer 
50x 
 
242g Tris base 1 L  
57.1ml Glacial Acetic Acid 
18.6gEDTA 
900ml of distilled H2O 
1% agarose 
gel 
1 gram of agarose  boiled in a 
microwave for 1-2 
minutes till all 
components are 
well dissolved 
100 ml of (1x) TAE buffer 
10ul of GelRed Nucleic Acid 
Stain 
added to the cool 
mixture 
Cracking 
buffer 
5mM EDTA  
50mM NaOH 
0.5% SDS 
Full media 
of DMEM 
High glucose DMEM (Gibco)  
Transfectio
n media 
DMEM  
4mML-glutamine 
Plating 
media 
High glucose DMEM435 ml Gibco (11960-069) 
 
FCS 50 ml Invitrogen(16140-071) 
L-glutamine200mM(5ml) Sigma(59202c) 
Pencillin10000U/ 10mg/ml) 
Streptomycin(5ml) 
Sigma (p4333) 
Working 
RIPA buffer 
diluting the 10x in distilled 
water 
Prepared and used on the same day 
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1x Protease Inhibitor 
Cocktail, 
1x Halt Phosphatase Inhibitor 
Cocktail 
Working 
Cytobuster 
buffer 
Cytobuster buffer Prepared and used on the same day 
1x Protease Inhibitor Cocktail 
1x Protease Inhibitor Cocktail 
10X Tris 
Buffered 
Saline 
(TBS). 2L  
121 g Tris base  
15 g NaCl; adjust pH to 7.6 
with HCl ~70ml (use at 1X) 
Chilled 
transfer 
buffer2 L 
50ml of transfer buffer Mixed and left at -20 C ~2 hours 
before use 100 ml of methanol 
850 ml of water 
Wash buffer 
(TBS/T). 
1xTBS  
0.1%Tween-20 
Working 
SDS 
10% mercaptonethanol  
SDS buffer 
 
Table ‎2-7  Sequence analysis of STAT4 for Sanger sequencing 
 
STAT4 vector F1 CCAACATGCCTGTCCAGGGGC 
STAT4 vector F2 GGAAGCGGCGGCAGCAAATC 
STAT4 vector F3 GGGCTGTCACATGGTGACTGAAG 
STAT4 vector F4 GGTGGACCATTCTGAAAGTGGGG 
STAT4 vector R3 GCCAGCTCATCACCTCCAGT 
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Table‎2-8 Antibodies used for the western blot work 
 
2.3.2 Methods 
 
2.3.2.1 Separation and freezing of peripheral mononuclear cells (PBMCs) from 
blood 
 
Freshly drawn blood in anticoagulant tubes such as ACD tubes, were mixed by 
inverting the tube several times before diluting it 2:1 Blood: PBS in 50 ml falcon tube. 
After this, tubes were mixed by inverting the tube several times. The blood was poured 
directly into the leucosep tube (containing ficol under the filter) and centrifuged at 
1000g for 15 minutes, no break, at ~20°C. The buffy coat was then aspirated using a 
sterile pipette and transferred into new falcon tubes and the sample was washed 2-3 
times with PBS or cold RPMI at 350g for ~5-8 minutes with breaks on. The cells were 
counted using trypan blue staining before the last wash. The supernatant of the last wash 
Antibody Clone Source Dilution 
Rabbit anti-Phospho-
p70 S6 Kinase; Thr389 
108D2 Cell Signaling 
Technology 1/100 
Rabbit anti- P-
MTOR(Ser2448) 
(D9C2) XP Cell Signaling 
Technology 1/500 
Mouse anti-
STAT4(PY693) 
38/p-Stat4 
BD 1/200 
Rabbit anti STAT4 polyclonal Invtrogen 1/100 
Goat anti-mouse IgG-
HRP 
polyclonal 
Santa Cruz 1/4000 
Sheep anti- rabbit IgG polyclonal Abcam 1/4000 
Mouse anti GAPDH-
100 µg 
6C5 
Abcam 1/5000 
Mouse anti -TATA 
binding 
1TBP18] 
Abcam 1/5000 
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was discarded and the cell pellet was dislodged using gentle quick vortex and a freshly 
thawed freezing media was added to the dispersed cell pellet to make a final 
concentration of ~2millions of cells /1 ml of the freezing media. The sample was 
aliquoted into pre-labelled Nunc freezing vials which were then placed into Isopropanol 
container and then into -80°C freezer overnight. The samples were then moved into 
liquid nitrogen for long term storage.  
 
2.3.2.2 Separation and freezing of peripheral mononuclear cells (PBMCs) from 
tonsil 
 
Fresh extracted tonsils from individuals undergoing routine tonsillectomy was kept in 
culture media (CM) till processing, which was usually performed within 1-2 hours 
post-tonsillectomy. The tissue was put inside large plastic Petri dish containing either 
cold Roswell Park Memorial Institute medium (RPMI) or CM. The tissue was then cut 
into 3- to 10-mm fragments with scissors or scalpels. The cell suspension was then 
subjected to separation by Ficoll as described above. The cells were washed twice and 
before the last wash, counted by tryptan blue. The tonsil cells were frozen at ~10 
million/ml (Johnston, Sigurdardottir, and Ryon 2009).  
 
2.3.2.3 Cell Thawing 
 
The desired number of the vials were taken out of the freezer and placed on ice. 
Thawing of the samples was done by thawing individual vial at 37°C for1-2 minutes, 
wiping the vial with ethanol to prevent contamination, adding the sample into a pre-
labelled falcon tube half filled with warm CM. The sample was then centrifuged at 
350g for ~5-8 minutes with breaks on. Next, the supernatant was decanted, the pellet 
dislodged by gentle flicking and fresh media was added for another wash. The sample 
was counted just before the third wash and re-suspended as desired for the assay. 
Proceed with the required assay as per protocol. 
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2.3.2.4 Ribonucleic acid (RNA) isolation and purification 
 
In a biological safety cabinet dedicated to ribonucleic acid (RNA) work, RNA 
extraction was done on PBMCs following the company protocol. Briefly, to 
homogenise the sample, 0.5ml Trizol was added to a pelleted lymphocytes (~<1 x 10
6
 
cells) in a 15 ml flacon tube, mixed by pipetting up and down several times and 
incubated for 5 minutes at room temperature(RT). The cells were then transferred into 
1.5 ml microcentrifuge tube. The homogenised sample was separated by adding 0.1ml 
of chloroform after which the tube was capped and subjected to vigorous shaking for 
15 seconds and incubation at RT for ~3 minutes. The sample was then centrifuged at 
12,000g for 15 minutes at 4°C. The result of this was 3 phases in the tube. The 
colourless upper aqueous phase contained RNA which was transferred carefully into a 
new microcentrifuge tube. 250ul of 100% isopropranolol was added, followed by 
incubation at RT for 10 minutes for RNA precipitation. The RNA was pelleted at 
12,000g for 10 minutes at 4
 
°C. The supernatant was removed carefully by pipetting. 
The RNA pellet was washed using 500 ul of 75% ethanol (in DEPC treated water), this 
was followed by a brief vortex followed by centrifugation at 7500 x g, 4°C, 5 minutes. 
The ethanol was decanted and the RNA pellet was left to air dry for 5-10 minutes to 
avoid over drying and compromising the quality of the pellet. The pellet was 
rehydrated in ~20-30ul of RNase–free water via gentle pipetting. The resultant RNA 
was incubated in a heat block at 55-60°C for 10-15 minutes. The yield of the RNA 
sample was determined at absorbance of 260/280nm, left on ice till preparing the 
reaction for the cDNA conversion. 
 
2.3.2.5 Reverse transcription 
 
The template RNA was either frozen at -20°C or used immediately, in which case was 
left on ice while preparing the rest of the reaction. miScript RT buffer,5x and RNase-
free water were removed from the kit and left to thaw at RT (15-25°C), the tubes were 
flicked and centrifuged briefly to mix their content. The miScript Reverse Transcriptase 
mix was removed from the freezer and left on ice just when everything was ready to be 
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added into the master mix. The master mix was prepared following the company 
protocol for RNA (10pg-1 µg) as below in a total volume of 20ul.  
The template RNA was added last and mixed. The tube containing the mixture was 
incubated for 60 min at 37°C followed by 95°C, 5 minutes and last was left on ice for 
~5-10 minutes. The newly synthesized cDNA was placed in a -20°C freezer till further 
use for STAT4 amplification.  
 
2.3.2.6 Amplification of STAT4 gene 
 
Primer forward ggctccaggatccaccatgtctcagtggaatcaag, 
Primer reversed gg ggt acc ttc agc aga ataaggagacttca 
A master mix was prepared for the reaction in a total volume of 50 ul in a 0.2ml thin-
walled polypropylene PCR tubes as follows: 
The reaction mix was mixed by pipetting and subjected to quick spin and placed in a 
thermo cycler under the following conditions.  
Table ‎2-9 Conditions for STAT4 amplification 
 
Step Temperature Duration Cycle 
Initial 
denaturation 
98°C 30second 1 
Denaturation 98°C 10second 2-30 
Annealing 55°C 30second 2-30 
Extension 72°C 2.5minutes  2-30 
 
The PCR product was stored at -20°C till subsequent use for electrophoresis. 
 
2.3.2.7 Transformation to be cloned into pcDNA™3.1/myc-His (-) A vector, 
growing pcDNA™3.1/myc-His (-) A plasmid 
 
25 ul of aliquoted Sub cloning Efficiency™ DH5α competent cells in a 
microcentrifuge tube was removed from -80°C and placed directly on ice for 5 
minutes to thaw, the cells were gently mixed by tapping the tube, and 0.5 ul (25ng)of 
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pcDNA™3.1/myc-His (-) A plasmid was added aseptically. The tube was flicked 
gently and placed then on ice for 30 minutes.  The tube was then put in a 42°C heat 
block for 45 second after which the tube was placed on ice immediately. 225ul of RT 
LB media was added to the tube, which was then incubated for ~1hour at 37°C with 
shaking at 225 rpm. 100 ul of the reaction was plated onto LB-amp agar plates using 
inoculation loop. 2 plates were prepared. The plates were then incubated overnight 
(~16) hours at 37°C. The next day, single colonies were picked up aseptically and 
inoculated into a 10 ml LB/amp media and left to grow at 37°C on a shaker overnight 
(~16).  
 
QIA spin Miniprep Kit was used to isolate the vectors following the manufacture 
protocol. Briefly, the culture was pelleted by centrifugation at maximum speed of 
13000rpm for ~5 minutes, the supernatant was decanted, and the manufacture lysing 
buffer was added to the pellet which was then transferred into a new microcentrifuge 
tube pellet. The lysate was cleared by centrifugation. This clear lysate was then 
applied to a column to bind, followed by a washing step to purify the plasmid DNA. 
The pure DNA was eluted in small volume (~50ul/tube) of water after which the 
concentration was measured and the sample was stored at -20°C till further use.  
 
2.3.2.8 Nucleic acid electrophoresis 
 
Gels were run in TAE buffer. 10 ul of working loading ladder (5μL of 1Kb plus DNA 
ladder mixed with 1μL loading dye) was added to the first well. The rest of the 
samples were loaded to the remaining wells and electrophoresis was performed at 
100V of ~1.5hour. The gel was then visualised under UV light. For isolation of 
amplicons, band were excised in a minimum volume of agarose using disposable 
sterile scalpels, weighed and purified using membrane based system following the 
company protocol to eliminate the residual nucleotides and primers. Briefly the gel 
slice was dissolved using the buffer provided, applied to the provided column and the 
DNA recovered using a centrifugation system. Then, the recovered DNA was washed 
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using the provided wash solution and then eluted in water. Finally the concentration 
was determined and stored at -20°C till further use.   
 
2.3.2.9  Digestion and of the STAT4 product and the pcDNA™3.1/myc-His(-) A 
vector 
 
A sequential digest was performed on the STAT4 product as well as the 
pcDNA™3.1/myc-His (-) A, following the below tables. The sequential digest was 
done due to incompatibility of the two chosen enzymes and their optimal buffers.  
Table ‎2-10 Conditions for STAT4 digestionI 
 
Reagents volume 
DNA volume making up 1 µg ~ 
Buffer I 2.5ul 
KpnI 1ul 
BSA 0.25ul 
RNase-free water To make up total of 25ul 
 
The reaction was mixed by pipetting, followed by a quick (touch) spin-down and NO 
Vortex. The reaction mix was then incubated in a heat block 37°C for 2-3 hours. 
After which the following was added to the same mix. 
 
Table ‎2 Conditions for STAT4 digestion II 
 
 
 
 
 
 
Once again, the reaction was mixed by pipetting, followed by a quick (touch) spin-
down and NO Vortex. The reaction mix was then incubated in a heat block 37°C for 
Reagents volume 
BufferIII 2.5ul 
BamHI 0.5ul 
BSA 0.25ul 
RNase-free water To make a total of 50 ul 
Pathological actions of STAT4, MTOR and STAT3 in human T cell 
differentiation 
  
75 
 
another 2-3 hours. The reaction mix was then stored at -20°C for further use such as 
DNA electrophoreses (especially for the vector to make sure of the efficiency of the 
digestion step). 
 
2.3.2.10  Ligation of the STAT4 product and the pcDNA™3.1/myc-His(-) A vector 
 
The appropriate amount of the PCR, vector to be added was determined using the 
below formula to give the optimal molar ratio of PCR product: vector (6:1).  
Digested pcDNA™3.1/myc-His (-) A= 45ng/ul 
PcDNA™3.1/myc-His (-) A=5.5kbp 
Digested STAT4 PCR product= 21.6 ng/ul  
STAT4 is 2.2kbp  
Insert mass (ng) =6x insert length (bp)   x vector mass (ng)   
   Vector length (bp) 
 
 
Table ‎2-11 Ligation of STAT4 with its vector 
 
 
 
 
 
 
 
 
 
 
The reaction was set up at the end of the day left to continue over night at RT on the 
bench. 
 
Reagents volume 
Digested pcDNA™3.1/myc-His (-) A 1 ul 
Digested STAT4 PCR product 5ul 
10x T4 DNA Ligase Reaction Buffer 2ul 
T4 DNA ligase  1ul 
RNase-free water 11ul 
(a total of 20ul) 
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2.3.2.11 Transformation 
 
The next day a transformation reaction was performed using 50 ul of aliquoted MAX 
Efficiency® DH5α™ Competent Cells in a microcentrifuge tube.  The MAX 
Efficiency® DH5α™ Competent Cells were removed from -80°C and placed directly 
on ice for 5 minutes to thaw, the cells were gently mixed by tapping the tube, and 10 
ul of the ligation product was added aseptically. The tubes were flicked gently and 
placed then on ice for 30 minutes.  The tube was then put in a 42°C heat block for 45 
second after which the tube was placed on ice immediately. 450ul of RT LB media 
was added to the tube, which was then incubated for ~1hour at 37°C with shaking at 
225 rpm. 100 ul of the reaction was plated onto LB-amp agar plates using inoculation 
loop. The plate was then incubated overnight (~16) hours at 37°C.  By the next day 
the cultures have turned very cloudy. Single colonies were picked up and inoculated 
into a 2 ml LB/ampicllin media and incubated at 37°C overnight with a shake. The 
next day QIA spin Miniprep Kit was used to isolate the vectors following the 
manufacture protocol as briefed above.  
 
2.3.2.12 Isolating colonies with STAT4 insert 
 
The cracking method was used to identify the colonies with STAT4 insert. ~250 ul of 
the bacterial cultures were aliquoted into microcentrifuge tube which was then 
centrifuged using maximum speed for 1 -2 minutes to pellet the bacteria. The 
supernatant was decanted. 20-30 ul of the cracking buffer was added to the bacterial 
pellet, vortexed and incubated at 65°C for 15 minutes to lyse the bacteria and release 
both the genomic as well as the plasmid DNA. After which the samples exhibited 
high viscosity,  vigorously vortexed for 1 minute, followed by quick centrifuge to 
pellet the sample  and carefully loaded using a wide tip pipette into 1% agarose gel 
(with wider lane to accommodate larger volume) and electrophoresed for 2-3 hours at 
100V. The time was judged by seeing maximum separation of the control dye. The 
gel was viewed under UV-illuminator and the colonies corresponding to ~6 kb (had 
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STAT4 insert) were grown in 10 ml culture, followed by plasmid extraction and DNA 
quantification which were done as described above. 
 
2.3.2.13  Sequence analysis 
Primers listed in table ‎2-12 
Plasmids extracted by the QIA spin Miniprep Kit and were sent for Sanger 
sequencing using the listed primers to identify the normal from the mutant allele. 
 
2.3.2.14 Maintenance of HEK293T 
 
HEK293T were maintained in DMEM until ~90-95% confluent, and then passaged by 
aspirating the old media gently, rinsing in PBS once and then adding 2 ml of (1x) 
trypsin, swirling the flask and putting it back into the 37°C incubator for 5 minutes, 
after which the cells had detached. This was followed by washing in fresh full warm 
media, centrifugation at 350g for 5 minutes and then re-suspended in growth media in 
1:10 ration for a maintenance purpose.   
 
2.3.2.15 Transfection for Luciferase 
 
HEK293T cells which were maintained in full media were harvested by trypsin 
treatment as described above. Cells were washed, re-suspended at concentration of ~2 
x 10
5/
 ml of plating media. 500 ul /well of 24 wells plate was plated aiming for ~ 80-
90 % at the time of transfection. Plasmid DNA; 0.2 μg per well of the either the wild 
or mutant STAT4 alleles, 0.2 µg of the Stat4 Luciferase Reporter Vector, 0.2 µg of 
pRL-CMV Vector and 0.2 µg  of PcDNA™3.1/myc-His (-) A making up a total of 
0.8 µg of plasmid DNA which was used for cell transfection with the lipofectamine 
LTX and PLUS reagent kit following the company protocol. Briefly, a master mix 
tube was prepared for both the wild type and the mutant according to how many 
transfections of 24 well were needed following the table below. In this experiment 
each transfection was done in triplicate. The transfection media was added to a 
labelled microcentrifuge tube, followed by adding the calculated volume of the 
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plasmid, the mixture was mixed by pipetting, and then the plus reagent was added. 
The mixture was then mixed gently by pipetting. The mixture was incubated for 5 
minutes RT. The lipofectamine LTX was added separately to tubes with transfection 
media which was then added to the mixture containing the DNA and plus reagent and 
then incubated for further 30 minutes at RT. The whole final mixture was then added 
to the plated HEK293T in a drop wise manner and the plate was rocked gently and 
put back again in 37°C CO2 humidified incubator. 
STAT4 Plasmid (0.2 µg)  volume making up   0.2 µg  x3 wells 
IRF1      volume making up   0.2 µg x3 wells  
pRL-CMV     volume making up   0.2 µg x3 wells 
PcDNA™3.1/myc-His (-) A   volume making up   0.2 µg x3 wells 
Plus      xul (=1* DNA µg)=0.8ul   x3 wells 
DMEM/L-glutamine     50ul      x3 wells 
The mixture was mixed and incubated for 5 minutes 
Lipo       xul= (2.5*DNA µg )=2ul  x3 wells 
DMEM/L-glutamine     50ul      x3 wells 
The latter mixture was mixed with the former mixture and incubated for 30 minutes. 
 
The cells were inspected for media consumption and old media was replaced at 16-18 
hours post transfection. Cells were then counted and ~ 6x10
4
 / well were transferred 
into 96 white flat bottom polystyrene plate and  then left for a total of ~36- 40 hours 
post transfection to express the protein before stimulation with IFN-α (20IU/ml vs 
3000IU/ml) for 6 hrs, vs 24 hours. The activation was terminated at the given time by 
washing the cells twice with RT, 1X PBS. The cells were subjected to the luciferase 
assay following the company protocol (Dual-Glo Luciferase Assay System). Briefly, 
the cells were resuspended in 50 ul of RT PBS /well. 50 ul of Dual-Glo luciferase 
reagent was added /well and mixed by pipetting. The plate was incubated for ~15 
minutes RT dark after which the firefly signal was read by a luminometer. 50 ul of 
Dual-Glo Stop & Glo Reagent /well was added immediately and the plate was then 
incubated RT dark for ~20 minutes and the renilla signal was read by luminometer. 
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The signal of the firefly of the sample was then normalized against the signal of the 
renilla of the same sample. 
 
2.3.2.16 Transfection for western blot 
 
HEK293T cells which were maintained in full media of were harvested at ~90% 
confluency by trypsin treatment as explained above. The cells were washed, re-
suspended at concentration of ~2 x 10
5/
 ml of plating media and 500 ul /well of 24 
wells plate  was plated aiming for in 70-90 % at the time of transfection . Plasmid 
DNA (0.8 μg per well) carrying either the wild or mutant STAT4 alleles was used for 
cell transfection with the lipofectamine LTX and PLUS reagent kit following the 
company protocol. Briefly a master mix tube was prepared for both the wild type and 
the mutant according to how many transfections of 24 well are needed following the 
table below. The plating media was added to a labelled micro-centrifuge tube, 
followed by adding the calculated volume of the plasmid, the mixture was mixed by 
pipetting, then the plus reagent was added and the mixture again was mixed gently by 
pipetting. The mixture was then incubated for 5 minutes RT. The lipofectamine was 
added last, the mixture was mixed gently by pipetting, and then incubated for further 
30 minutes at RT. 100ul of the mixture/well was then added to the plated HEK293T 
in a drop wise manner and the plate was rocked gently manually and put back again 
in 37
 
°C CO2 humidified incubator. 
STAT4 Plasmid (0.8 µg)  volume making up 0.8 µg  x #well 
Plus      0.8 ul      x #well 
Lipo      (2.5*0.8)=2 ul    x #well 
DMEM/L-glutamine   100ul    x #well 
The cells were inspected for media consumption and old media was replaced at 16-18 
hours post transfection using warm full media of DMEM and were then put back in 
the incubator for a total of ~40 hours. 
 
2.3.2.17 Western blot 
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Transfected HEK293T (as described above) was left to express the protein before 
stimulation with IFN-α (20IU/ml or 3000IU/ml) for 1 hr, 5 hours. One well was left 
without any stimulation for comparison purpose. The activation was terminated at 
given time by adding cold 1X PBS followed by pelleting the cells at 450g for 5 
minutes. The samples were lysed by adding ~60 ul working RIPA buffer / well of 24 
well plates incubated for 5 minutes on ice, frozen at -80°C, clarified on the day of the 
western blot by centrifugation at 8000g for 10minutes. 
 
PBMCs of normal controls and the mutation carrier were plated in ~10million/ml in 
24 wells plate and left to rest for 2 hours. This was followed by stimulation with 
PMA for 1 hour and another well of the same sample was left unstimulated. The 
stimulation was again terminated at the given time by adding cold PBS and lysing the 
sample in ~50-60 ul of working cytobuster buffer for ~10 minutes on ice and the 
supernatant was obtained after centrifugation and frozen at -20°C for future use for 
western blot.  
 
Protein denaturation of the PBMCs and transfected HEK293T was achieved by 
adding equal volume of working SDS buffer to the sample, mixing, incubating at 
100°C for ~5-7 minutes after which the samples were left to cool down on ice for 5 
minutes, finally they were ready to be loaded on SDS- acrylamide gels. 
 
The separation was achieved by running the sample for ~1 hour 100V in a tank filled 
with working running buffer. The proteins were then transferred to a PVDF 
membrane (which was briefly activated by soaking it for 1minutes in methanol, 2 
minutes in water, and 5 minutes in transfer buffer) and the transfer was done at 100 V 
for~ 2 hours in chamber filled with chilled transfer buffer. The membrane was then 
blocked in 3% BSA /TBST 1 hour at RT. The membrane was then stained for the 
primary antibody in a sealed plastic bag with a total volume of ~3 ml of the specified 
dilution, overnight at 4°C with very gentle shaking. The next day, the membrane was 
washed three times of ~20 minutes each on a shaker with TBST. The secondary 
antibody was then added to the membrane in a sealed plastic bag with a total volume 
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of ~3 ml of the specified dilution, incubated for 1 hour shaking at RT. The membrane 
washed again, three times with TBST each 20 minutes on a shaker at RT. The protein 
detection was done using ECL Western Blotting Detection Reagents, and the strength 
of the signal was measured by assessing the densitometry relative to the loading (by 
comparing either GAPDH or TATA box) and the results were expressed in arbitrary 
units (AU). 
 
2.3.2.18 Flow cytometry 
 
2.3.2.18.1 Surface staining 
  
Cells were resuspended in FACS wash at 1 million /ml and plated in 1-2x10
5
cells 
(200 ul) in 96 well, centrifuged (350g x5 minutes, breaks on) and decanted on ice in 
the sink to prevent splash. During this time the required antibodies cocktail was 
prepared by diluting the antibodies in FACS wash according to the optimized dilution 
for each antibody.  At the end of the centrifugation, the plate was then subjected to a 
quick vortex to dislodge the cells and then ~25 ul of the required pre-diluted surface 
antibodies was added to each well and incubated for 20 min on ice, washed with 
FACS wash by adding 150ul/ well, mixing by pipetting, centrifugation (350g x5 
minutes, breaks on), decant, vortex and then the wash step was repeated one more 
time. Single colour compensation tubes were prepared simultaneously. Finally the 
plate was vortexed, and cells in each well were resuspended with 100 ul /well and 
transferred into FACS tubes and acquired using FACSCalibure and FACSCantoII. 
The data were then analyzed with FlowJo, version (8.7) (Treestar). 
 
2.3.2.18.2 Cell sorting 
 
Freshly thawed cells in CM, washed twice in CM and once in sterile plain PBS. The 
desired cocktail of the antibodies were diluted in PBS supplemented with 0.1 % FCS 
and 0.5ml of the staining cocktail were added. This was done for cell number of ~50 
million and if more cells were needed then the concentration of the antibodies and 
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volume for staining were adjusted. Single colour compensation tubes were prepared 
simultaneously. The staining was carried out by incubating the sample for 20 minutes 
on ice, washed once with plain PBS and finally resuspended in PBS/0.1 % FCS prior 
to sorting on a FACS ARIA I and/or II cell sorter (BD) under the supervision of 
MCRF staff. 
 
2.3.2.18.3 Intracellular cytokines detection 
 
Perm wash (cytokine), working Perm wash x1 was prepared on the day  
Intracellular cytokines were detected by stimulating 1-2 × 10
6
/ ml cells with 
leukocyte activation cocktail for ~ 4 hours in 24 wells plate. Unstimulated control 
from the same sample was setup at the same time to control for any background. 
After 4 hours the cells were harvested, mixed well and dispensed as1- 2x10
5
cells 
(100-200 ul /well) into 96 well plates. Cells were first washed twice with FACS 
wash, (350g 5 minutes, breaks on), supernatant decanted, plate was vortexed to 
dislodge the pellet and new FACS wash was added and the process was done one 
more time. The cells were stained with the desired antibodies using ~25ul of the pre-
diluted antibody cocktail / well and left on ice for ~20 minutes. This was followed by 
washing twice with FACS wash, followed by vortexing before fixing and 
permabilizing the sample. This was achieved by adding 100ul Cytofix/ Cytoperm, 
mixing by pipetting, and then the plate was incubated for 30 minutes on ice. The cells 
were then washed twice with freshly prepared 1x Perm wash, followed by vortex to 
dislodged the cells before adding the pre-diluted antibodies of the cytokines (dilution 
was done using Perm wash). The cells were last re-suspended using 100ul/well FACS 
wash and transferred into FACS tube for acquisition.  
 
2.3.2.18.4 Enumerating Treg, Foxp3 positive/BCL-6 
 
Working Fix buffer (FoxP3 fix) and Working perm solution (FoxP3 perm). Fresh 
buffers were made on the day and left to reach room temperature. 
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The cells were surface stained for CD4, CD25 and CD127 as above (surface 
staining). The cells were fixed in 100 ul of the working  buffer A 10 minutes RT 
away from light , washed once with FACS wash,  permed using ~50ul of the working  
perm buffer ~30 minutes on ice away from light.  This was followed by washing the 
cell twice with FACS wash, staining the cells with pre-diluted Foxp3, 20 minutes on 
ice, another wash with FACS wash. Finally cells were suspended in fresh FACS wash 
and transferred into FACS tube for acquisition. 
 
Detecting BCL6 signal was done using the fix and perm conditions for the Foxp3 as 
outlined above. 
 
2.3.2.18.5 Staining for signalling and transcription factors (STAT1, STAT3, STAT4, 
T-bet and GATA-3) 
 
Cells were thawed, washed and maintained in sterile CM at a final concentration of 2 
× 10
6
/ ml. 1- x10
5 
cells were plated in 50 ul/ well in sterile 96 well U bottom plates 
and rested for 2 hours at 37°C, under an atmosphere containing 5% CO2, either 
stimulated with 50 ul of the indicated cytokine or nothing  (adding 50 ul of pre 
warmed plain CM) for 20 minutes at 37°C incubator, fixed with 100 ul warm fix for 
10-15 minutes at 37°C incubators. The plate was centrifuged at 350g for 5 minutes. 
The supernatant decanted. This was followed by vortex to dislodge the cell pellet at 
the bottom of the plate, 100 ul of chilled perm solution was added and mixed by 
pipetting, and the plate was then incubated on ice for ~30 -40 minutes, washed with 
FACS wash twice and then stained with 25ul/well of  pre-diluted antibodies. The 
samples were then washed one more time with FACS wash and resuspended in100 
ul/well and transferred into FACS tube for acquisition.  
 
2.3.2.18.6 Screening TCR signalling 
 
Whole PBMCs were resuspended as 1million/ml and cultured either with nothing or 
with anti-CD2/CD3/CD28 expansion beads at bead-to-cell ratio 1:2. The plate was 
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put back in 37
 
°C incubator for 24 hours. Then the cells were harvested in 96 well 
plates, washed with FACS wash twice. The cells were stained for surface activation 
markers using the above surface staining method. 
 
2.3.2.18.7 Detection of PS6(Ser 235/236) by flow cytometry 
 
PBMCS were activated for 3 days with CD3 beads and IL-2. Cells were then washed 
with CM containing IL-2, activated T cells were separated using beads (CD4 /CD8 
microbeads). T cells were either fixed unstimulated or fixed after stimulation with 
CD3 or CD3 and rapamycin for 10 and 20 minutes.  
 
2.3.2.18.8 T-bet Up- regulation 
 
PBMCs were resuspended in 1million/ml and cultured with anti-CD2/CD3/CD28 
expansion beads at bead-to-cell ratio 1:2 with IL-2, IL-12, and with or without 
rapamycin for 2 days. Then the cells were harvested in 96 well plates, washed with 
FACS wash twice. The cells were fixed and permeabilised according to the method 
for the signal transduction and finally stained for T-bet. 
 
2.3.2.18.9 T cell polarization 
 
Th1 [(CD2/3/28 beads at bead-to-cell ratio 1:2) + IL-12, 20 ng/ml+ IL-2, 80ng/ml]. 
 Th2 [(CD2/3/28 beads at bead-to-cell ratio 1:2) + IL-4, 20 µg /ml+ IL-2, 80ng/ml]. 
Th0 [(CD2/3/28 beads at bead-to-cell ratio 1:2) + IL-2, 80ng/ml].  
 
Naive CD4+ T cells were obtained via FACS sort following the methods outlined for 
the cell sort (FACS sorted on CD3+CD4+ CD45RO negative), cultured with anti-
CD2/CD3/CD28 (bead-to-cell ratio 1:2), ml and desired combination of the desired 
cytokine for 4 days after which the surface and or the intracellular staining was done 
following the methods described above. 
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2.3.2.18.10 Screening BCR signalling 
 
Whole PBMCs were cultured alone or with human CD40L in 24 well plates for 24 
hours, after which the sample was harvested, washed twice using FACS wash and 
surface stained for the given activation markers. 
 
2.3.2.18.11 Plasma cell induction  
 
PBMCS were cultured with IL-21, Type B CpG or CD40L, with and without IFN-γ 
or anti-IFN- for 4 days. After which the cells were harvested, washed twice with 
FACS wash and stained for the desired combination. Intracellular IgG subclass 
staining was performed after fixing and perming following the method for cytokine 
detection.  
 
2.3.2.18.12 Cytotoxicity assay 
 
Cytotoxicity was determined using the PanToxiLux kit according to manufacturer’s 
instructions. Indicated cell populations were incubated with targets cells (labelled 
TFL4) at various ratios and lethal hit determined   by flow cytometry. 
 
2.3.2.18.13 T cell proliferation assays 
 
Indicated cell populations were labelled with Cell Trace Violet (CTV) according to 
manufacturers. For T cell proliferation, cells were stimulated with T cell activation 
beads (CD2/3/28) +/- cytokines (as indicated) for 5 days and analysed by flow 
cytometry.  
 
2.3.2.18.14 Cytokine induction assays 
 
Naive CD4+ T cells (FACS sorted on CD3+CD4+ CD45RO negative) or FACS sorted 
tonsil CD4T cells according to PD-1 and CD57 were cultured were cultured with anti-
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CD2/CD3/CD28 (at a ratio of 2:1) with or with out  either recombinant human IL-6 
(100ng/ml, Miltenyi Biotec),  recombinant Human IL-21(100ng/ml, Miltenyi Biotec), 
for 2 days. Cells were then analysed by flow cytometry for induction of IL-4 and IL-10. 
The same experiment was done but the cells were stimulated for 5 days for the CTV 
experiment. Cells were then analysed by flow cytometry for induction of IL21 and 
IFN- and proliferation.  
 
2.3.2.18.15 Flow cytometry acquisition and analysis 
 
Data were acquired on FACSCaliber or FACSCanto II and data were then analysed 
with FlowJo, version (8.7) (Treestar).  
 
2.3.2.18.16 Lymph node histology 
 
Frozen sections of human tonsil (6mm) frozen were incubated with indicated 
fluorescent antibodies for 30 mins then washed and analysed by confocal microscopy.  
 
2.3.2.18.17 RNA-Seq 
 
mRNA libraries for 9 samples were prepared at the Ramaciotti Centre for Genomics 
UNSW following the standard Illumina protocols.  Sequencing was performed on the 
Illumina NextSeq 500 platform to produce 75 bp reads.  There were 3 biological 
replicates (Tonsil 1, Tonsil 2 and Tonsil 3) for each of the three conditions: (1) PD-
1
hi
CD57+, (2) PD-1
hi
CD57-, (3) PD-1
lo
CD57-. The generated reads were mapped to 
the Ensembl Homo sapiens genome (GRCh38) using Tophat2 (v 2.0.12) (D. Kim et 
al., 2013) calling Bowtie2 (v 2.2.3) (Li and Durbin, 2010). HTSeq-count (Python 
package HTSeq, python v 2.7.3) (Anders et al., 2015) was used to generate counts of 
reads uniquely mapped to annotated genes using the GRCm38 annotation gtf file. We 
performed differential expression analysis using edgeR (v 3.12.0) (Robinson et al., 
2010). An MDS plot indicated that samples from Tonsil 2 were outliers. Accordingly, 
we performed differential expression analysis without Tonsil 2 samples. Low count 
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transcripts were excluded and only those genes with at least 1 count per million (cpm) 
in at least 3 samples were used for analysis.  Differentially expressed genes were 
defined as those genes with a Benjamini-Hochberg corrected p value less than 0.1. 
We then mapped the results back onto the full data set using unsupervised clustering 
to produce heatmaps comparing expression levels of the genes of interest over all 9 
samples. 
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CHAPTER 3 : HUMAN STAT4
P450S
 IS A NOVEL GAIN 
OF FUNCTION ALLELE 
 
3.1 Introduction 
 
The overarching aim of the project was to combine clinical, biochemical and detailed 
cellular data with whole exome sequencing to identify disease pathways in patients 
with unexplained immune deficiency and inflammatory disease.   
 
3.2 Detailed clinical, biochemical and cellular phenotyping to assist interpretation of 
whole exome sequencing (WES) 
 
We identified a currently 41 year-old male proband (II.3) who had been diagnosed 
with bronchiectasis at age of 4 years.  
 
Case history 
 
The proband presented at age 15 months with upper lobe pneumonia. Before this, he 
had experienced poor feeding, recurrent purulent nasal discharge and failure to thrive. 
Investigations at this time revealed opacification of the maxillary antra bilaterally, and 
right upper lobe consolidation. Sputum culture yielded H. influenzae. Immunoglobulin 
studies revealed an elevated IgA (2.87 g/L, normal range: 0.6-0.8), IgG at the upper 
limit of normal (10.0g/L, normal range: 8.0-10.0) and normal IgM (1.07g/L, normal 
range: 0.6-0.85). He had a normal sweat chloride concentration. He had mild 
hypochromic microcytic anaemia and iron deficiency and one episode of hematemesis. 
 
He had several similar presentations over the next 18 months and was diagnosed with 
bronchiectasis at age 4ys. He had chronic nasal discharge. He developed a chronic 
macular eruption over his arms and legs.  
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He was treated with regular chest physiotherapy and postural drainage. He required 
frequent courses of antibiotics for H. influenzae chest infections. At the age of 2 his 
immunoglobulin studies were repeated and revealed IgA 1.2g/L (0.27-1.92), IgM 
1.1g/L (0.41-1.68) and IgG 17g/L (4.0-16.2). Ultra-structural studies of nasal cilia were 
normal.  
 
He suffered recurrent infections throughout adolescence. He was small for his age. He 
also suffered from symptoms thought to be consistent with reflux or achalasia in 
adolescence. At the age of 16 he experienced an oesophageal obstruction from a piece 
of meat that was retrieved at gastroscopy. This study also revealed inflamed and friable 
oesophageal mucosa. A radionuclide swallowing study showed a hold up of the tracer 
in the upper third of the oesophagus. Maximum tracer clearance was 76% and was 
delayed (>18 sec) consistent with mild-moderate oesophageal dysmotility disorder.  
 
At age 18, investigations revealed IgG 15.5g/L and IgA 7.8g/L. IgM and IgE were 
normal. He was deficient for IgG2 (0.35, normal range: 1.95-4.5) and IgG4 (0.06, 
normal range: 0.15-0.3) while IgG1 (10, normal range: 3.9-9.0) and IgG3 (4.69 normal 
range: 0.4-0.9) were elevated. His specific antibody titres to tetanus toxoid and 
diphtheria were low but detectable after vaccination.  
 
He was commenced on intravenous immunoglobulin replacement and this resulted in a 
reduced frequency of chest infections. He experienced ongoing symptoms of gastro-
oesophageal reflux and non-specific dermatitis. His only other inter current infection 
was Trichophyton mentagrophytes onychomycosis. 
 
We initiated our investigations by a detailed assessment of different T and B cells 
subsets. T cell analysis revealed a marked CD8+ T cell expansion, which placed him 
outside of the distribution of other patients with antibody deficiency (Figure 3.1 A, 
upper row and Figure3.1B). More detailed analysis showed that the CD8+ T cell 
expansion was mainly due to an increase in the CD45RA+ effector subset (Temra, 
Pathological actions of STAT4, MTOR and STAT3 in human T cell 
differentiation 
  
90 
 
CD45RA+ CCR7-) (Figure 3.1 C-D).We also found him to have a partial memory B 
cell deficiency (Figure 3.1 A, lower row).  
 
Next we tested for any abnormalities in proximal T and B cell signalling through 
examination of up regulation of early activation markers after short term stimulation. 
CD25 (Waldmann 1986; Robb, Munck, and Smith 1981) and CD69 were used as 
early activation markers in T cells(Testi, Phillips, and Lanier 1989) and CD69 and 
CD83 were used as readout for early B cell activation (Kretschmer et al. 2007).The 
difference between 24 hours post stimulation compared to the baseline of the 
activation markers after in vitro  stimulation of PBMCs with CD2/3/28 labelled beads 
for T cell activation or with anti-Ig and CD40L for B cell activation, was examined 
by flow cytometry. We found no evidence for a defect in proximal T or B cell 
activation (Figure 3.1 E-H) in the proband compared to the controls. 
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Figure ‎3-1 Detailed T and B cell phenotype 
A. Representative flow cytometry analysis of circulating CD4+, CD8+T cells , naïve 
B(CD19+CD27-) and memory B cells (CD19+CD27+) in controls and proband (II.3). 
B. Summary of absolute counts of circulating CD4+, CD8+ T cells and NK cell 
(CD16/56) obtained by flow cytometry in II.3(Red) and patients with antibody 
deficiency(n=50). C. Representative flow cytometry analysis of different subsets in 
CD8+ T cells; Temra (CD45RA +CCR7-), Naïve (CD45RA+CCR7+), Tcm 
(CD45RA-CCR7+), Tem (CD45RA-CCR7-) in control (con) and II.3. D. Summary of 
circulating CD8+ T subsets as a percentage of CD3+ T cells. II.3 (red filled circle) 
and controls, n =11 (unfilled circles). E-F Overlay histograms of T cell activation 
markers (CD25 and CD69).PBMCs were cultured with CD2/3/28 beads (1: 2 ratio) 
for 24 hours. T cells were analysed by flow cytometry for CD25 and CD69 up-
regulation among total CD4+(CD3+CD4+)T cells and naive gated CD4+ T cells 
(CD45RA+CCR7+) and among total CD8+ and naïve gated CD8+ (CD3+CD8+) T 
cells (CD45RA+CCR7+) at baseline (grey filled histogram) and 24hrs post 
stimulation (red unfilled histogram). G. Overlay histogram of B cell activation 
markers (CD69 and CD83).PBMCs were cultured with anti-IgM and CD40L for 
24hrs, then B cells were analysed for activation by flow-cytometry according to 
induction of CD69 and CD83 on CD19 gated B cells at baseline (grey filled 
histogram) and 24hrs post stimulation (red unfilled histogram). H. Summary of 
percentage of up-regulation of different activation markers in T and B cells in II.3 
(red filled circle) versus controls (unfilled circles, n=7). 
 
We showed in the previous section that the proband (II.3) exhibits a deviation toward 
effector differentiation mainly in CD8+ T cells as assessed by the surface phenotype 
(Figure 3.1 C-D). Next, we examined II.3 T cells for effector differentiation 
according to cytokine expression. The CD8+ T cell compartment exhibited marked 
deviation to IFN- production (Figure 3.2 A-B). In particular, we observed substantial 
IFN- production by the Temra subset in the CD8+ T cell compartment (Figure 3.2 
C).Despite the normal distribution of memory and naïve cells in the CD4+ T cell 
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compartment (Figure 3.1 C), II.3 also exhibited deviation to IFN- production with 
the CD4+ T cell compartment (ie Th1 deviation) evident by cytokine (IFN-) 
expression as well as level of chemokine receptor (CXCR3+CCR6-) (Figure 3.2 D-
F). By contrast, ex vivo enumeration of Th2 (IL-4, IL10) (Figure 3.2 E), Th17 (IL-17) 
(Figure 3.2 F) and T regulatory (Treg) (CD25
high
 CD127
 lo
, Foxp3+) (Figure 3.2 G) 
revealed similar results r to those from normal controls. 
 
The observed Th1 deviation expressed by CD4+ and CD8+ T cells in II.3 might 
indicate an intrinsic propensity of T cells to adopt Th1 phenotype. To investigate this 
possibility further, we examined the ability of naïve CD4+ T cells (from II.3) to adopt 
this extreme Th1 differentiation under Th1 enriching environment. Naïve CD4+ T 
cells were sorted using fluorescence activated cell sorting (FACS) sorting from the 
proband (II.3) and a control. FACS sorted naïve CD4+ T cells were then cultured for 
four days under Th1 (CD2/3/28+IL-12) or Th2 (CD2/3/28+IL-4) polarizing 
conditions. Naïve CD4+ T cells from the proband (II.3) cultured under Th2 did not 
express excess IFN- relative to control cells from a healthy donor(Figure 3.2 H, 
lower row). By contrast, when naïve CD4+ T cells from II.3 cultured under Th1 
conditions, they exhibited marked Th1 deviation (Figure 3.2 H, upper row) compared 
to the normal control cultured under the same Th1 conditions. 
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Figure ‎3-2 Expanded IFN- γ production by CD4+ and CD8+ T cells 
A. Representative flow cytometry analysis of intracellular IFN-γ expression by CD8+ 
T and CD4 +T cells in II.3 and a normal control after 4 hours stimulation with PMA 
and ionomycin and brefeldin-A. B. Summary of IFN-γ producing cells as a 
percentage of total CD4+ and CD8 + T cells. II.3 (red filled circle) and controls, n=17 
(unfilled circles). C. Flow cytometry analysis of intracellular IFN-γ expression by 
sorted CD8+ T cell subsets and stimulated for 4 four days with + CD2/3/28 beads (1: 
2 ratio) + IL-12(0.2ng/ml). D. Representative flow cytometry analysis of Th1 by 
chemokines expression (CXCR3+ CCR6-) in CD4+ T cells in II.3 and normal 
controls (n=4). E. Representative flow cytometry analysis of intracellular IL10 and 
IL-4 expression by CD4+ T cells in II.3 and a normal control after 4 hours 
stimulation with PMA and ionomycin and brefeldin-A. F. Representative flow 
cytometric analysis of intracellular IL-17 and IFN-γ expression by CD4+ T in II. 3 
and a normal control after 4 hours stimulation with PMA and ionomycin and 
brefeldin-A. G. Representative flow cytometric analysis of T regulatory cells using 
surface phenotype of (CD127
low
, CD25
high
) then gating on intracellular Foxp3+( 
histogram; black unfilled gated on effector CD127 positive and blue unfilled gated on 
CD127
low
, CD25
high
 in II.3 and a normal control. H. Flow cytometry analysis of 
intracellular IFN-γ expression by induced Th1 in the upper row [(CD2/3/28 beads at 
bead-to-cell ratio 1:2) + IL-12, 20 ng/ml+ IL-2, 80ng/ml] and Th2 in the lower 
row[(CD2/3/28 beads at bead-to-cell ratio 1:2) + IL-4, 20 µg /ml+ IL-2, 80ng/ml] 
cells from naïve precursors FACS sorted on CD3+CD4+CDR5RO- after 4 days 
cultured under polarising conditions in II.3 and a normal control. 
 
This is an exaggeration of the normal response, since Th1 deviation was only 
observed when naïve cells were activated under Th1 conditions, with IL-12 (Figure. 
3.2H, upper row), but not when stimulated with IL-4 (Figure. 3.2H, lower row). 
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In summary, the most remarkable cellular phenotype identified in the proband (II.3) 
is deviation to IFN- production by both CD4+ and CD8+ T cells. This deviation 
appears to be cytokine-dependent, and not spontaneous.  
 
3.3 Analysis of whole exome sequence 
 
The proband (II.3) underwent a whole exome sequencing (WES) as part of our 
primary antibody deficiency discovery program (ANZADA project). We obtained 
>30X coverage for >96% of the coding genome. Our data analysis pipeline 
incorporates information obtained from dbSNP, OMIM, Gene ontology, and ExAC 
databases and the ImmGen expression database. This provided an initial filter, based 
on prevalence of the identified variants, known associated phenotypes, and relevance 
to immunity. In addition, we obtained PolyPhen-2 and SIFT scores for each 
nonsynonymous variant. 
  
Whole exome sequencing of the proband revealed 8511 non-synonymous single 
nucleotide variants, of which 116 were novel at the time of writing (Figure 3.3A). We 
typically assign scores to each variant that takes into account frequency, expression, 
in silico estimates of likelihood of damage and known disease associations, and by 
this tentative approach, a novel heterozygous variant in STAT4 yielded the highest 
score (Figure. 3.3A-B).  
 
This single nucleotide STAT4 variant encodes a proline to serine substitution at 
position 450 (P450S; chr2:191904011G>A; g.112312C>T; c.1348 C>T), and has not 
been reported in TGP, dbSNP, ExAC, ClinVar or HGMD and has not been detected 
in >300 in-house exome sequences from unrelated individuals. Proline-450 is a 
highly conserved residue (Figure. 3.3C) located in the DNA binding domain and the 
substitution with serine is predicted to be damaging by polyphen2, SIFT and mutation 
taster (Figure. 3.3A-B).  
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Figure ‎3-3 STAT4 P450S score 
A .Summary of whole exome sequence of proband and the filter score obtained for 
novel missense mutations (STAT4 score circled). B. Characteristics of STAT4
P450>S
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mutation and some of the used scores. C Conservation of mutated base and amino 
acid in STAT4 across different species (from Mutation taster). 
 
STAT4
P450>S
 was confirmed by Sanger sequencing (Figure. 3.4 A-B). The rest of the 
available family members were also genotyped for this mutation and we identified 
one sibling and one of her offspring with the same mutation (Figure. 3.4 C-D). 
 
 
 
 
Figure ‎3-4 Confirmation of STAT4P450>S  on available family members 
A. Electropherogram of STAT4 
P450>S  
in the proband (II.3). B. Cartoon of different 
domains of STAT4. The location of P450 is shown (*) in the DNA binding domain 
(DBD). C-C, coil- coil domain, SH-2 domain C. Electropherogram of STAT4 in the 
available family members and D. family pedigree of the available family members 
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indicating the one with STAT4 
P450>S
;
 
wild type family members (unfilled), un 
genotyped dead father (unfilled with crossing line), members carrying heterozygous 
STAT4 
P450>S
 (half- filled circle) and the proband carrying heterozygous STAT4 
P450>S
 
(half-filled square and an arrow).  
 
As noted in the introduction (Chapter 2.2- 2.4), the DNA binding domain of STAT4 
is crucial for recognition and binding to the DNA responsive element in the nucleus, 
including IFN-γ and IRF1 (Horvath, Wen, and Darnell 1995; Xu, Sun, and Hoey 
1996). The DNA binding domain of STAT4 is similar to that of STAT1 (Xu, Sun, 
and Hoey 1996). Mutation within this domain does not alter the ability to activate and 
phosphorylate the STAT1 molecules (Horvath, Wen, and Darnell 1995; Meyer et al. 
2003). Moreover, binding of pSTAT1 dimers to the DNA domain protects it from 
dephosphorylation (Takezaki et al. 2012; Meyer et al. 2003). Based on this, we 
predicted that STAT4 
P450>S
 would confer a gain-of- function. 
 
3.4 IL-12 STAT4 activation is necessary for Th1 deviation 
 
Phosphorylation after activation induces a conformational change in the STAT4 
homodimer (Meyer et al. 2003), which enhances recruitment to its nuclear binding 
elements, including regulatory elements of IRF-1 and IFN-G genes (Xu, Sun, and 
Hoey 1996). Binding of the STAT4 dimer to its nuclear element, results in relative 
protection from de-phosphorylation (Meyer et al. 2003). We noted in the previous 
section that CD4+ T cells from II.3 exhibited cytokine (IL-12) dependent Th1 
deviation (Figure 3.2H). IL-12 is crucial for naïve CD4+ T cells to adopt a Th1 
phenotype through recruitment and activation of STAT4 (Yamamoto et al. 1994; 
Zhong, Wen, and Darnell 1994; Kaplan, Sun, et al. 1996) and Th1 induction by IL-12 
is abrogated by STAT4 deficiency in mice (Kaplan, Sun, et al. 1996; Carter and 
Murphy 1999) (Chapter 2.3 and 2.8).  
 
IFN-γ is only induced at low levels in naïve CD4+ and CD8+ T cells after stimulation 
by TCR (Kaplan, Wurster, and Grusby 1998) (Figure 3.5 A). Optimal induction in 
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both naïve CD4+ and CD8+T cells of IFN- γ requires addition of IL-12 (Figure 3.5 
B). Moreover, stimulation of resting PBMCs cells with IL-12 does not activate 
STAT4 (Figure 3.5 C) due to the lack of expression of inducible IL12Rβ2 subunit of 
the IL-12 receptor on resting T cells (Igarashi et al. 1998; Ahlers et al. 2001) as well 
as low level of STAT4 expression by resting lymphocytes. Up-regulation of the 
expression of both IL12Rβ2 and STAT4 is induced by T cell activation with either 
TCR and co stimulation (CD2/3/28) or mitogen (PHA). After this, cells respond to 
IL-12 with phosphorylation of STAT4 (pSTAT4). Thus, activation of PBMCs from 
normal controls with either PHA or CD2/3/28 followed by stimulation with IL-12 or 
IFN-α, resulted in activation and phosphorylation of STAT4(pSTAT4) (Figure 3.5 D-
E). Of note, stimulation of IL-12 can maintain a longer phosphorylation of STAT4 
compared to IFN- α (Figure 3.5D-E). Activation of STAT4 by IL-12 also resulted in 
up-regulation of T-bet (Figure 3.5 F) which is crucial to maintain Th1 differentiation 
(IFN- γ) (Figure 3.5 B)(Cho et al. 1996; Yamamoto et al. 1994; White et al. 2001; 
Jacobson et al. 1995; Kaplan, Sun, et al. 1996; Testi, Phillips, and Lanier 1989) 
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Figure ‎3-5 IL-12 STAT4 dependent Th1 formation 
A-B. FACS sorted naïve CD4+ T cells (CD3+CD4+CD45RO-) and CD8+ T cells 
(CD3+CD4+CD45RA+CCR7+) from a healthy donor were cultured for 4 days with 
CD2/CD3/28 + IL 2 (80ng/ml) as in A or CD2/CD3/CD28 +IL-2 (80ng/ml) + IL- 12 
(20ng/ml) as in B. Cells were then analysed by flow cytometry analysis for 
intracellular IFN-γ and IL-4 expression (CD4+ T cells) and granzyme-B and IFN- γ 
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(CD8+ T cells). C. Overlay histogram of pSTAT4 expression in ex vivo PBMCs 
detected by flow cytometry in unstimulated (grey filled) versus stimulated for 20 
minutes with IL-12 (20ng/ml, unfilled red histogram). D. Overlay histogram of 
pSTAT4 expression detected by flow cytometry in blasted PBMCs with PHA (25 µg 
/ml) for 48 hours then either left unstimulated (grey filled) or re stimulated either for 
20 minutes(unfilled red) or for 2 hours ( unfilled blue) with IL-12(20ng/ml). E. 
Overlay histogram of pSTAT4 expression detected by flow cytometry in blasted 
PBMCs with PHA (25 µg /ml) for 48 hours then either left unstimulated (grey filled) 
or re stimulated for either for 20 minutes(unfilled red) or for 2 hours ( unfilled blue) 
with IFN-α(1000U/ml). PBMCs in both conditions were obtained from the same 
healthy donor. F. Overlay histogram of T-bet expression determined by flow 
cytometry. Naïve CD4+ T cells were stimulated for 4 days with either CD2/3/28 or 
IL-2 (80ng/ml, grey filled) or with CD2/3/28+IL-2 (80ng/ml) +IL-12 (20ng/ml, red 
unfilled). Naïve cells in both conditions were obtained from the same healthy donor. 
 
3.5 Novel STAT4 P450S is associated with cellular phenotype of deviated Th1 and 
IFN- γ expression 
 
We identified the mutation encoding STAT4
P450S
 in one out of three siblings of the 
proband (II.2) (Figure. 3.4C-D), and she remains clinically healthy with no evidence 
of bronchiectasis, oesophagitis or dermatitis. Nonetheless, we proceeded to 
characterize her lymphocyte phenotype. This revealed a normal distribution of CD4+ 
and CD8+ T cells and their subsets (Figure 3.6 A-B), and normal numbers of NK 
cells. She also exhibited normal B cells subsets (Figure 3.6C), normal serum 
immunoglobulin, and normal IgG subclass distribution. In vitro studies revealed 
normal plasma cell induction (Figure 3.11). We then examined T cells from all 
available siblings for deviation in effector cytokine production and differentiation.  
 
Ex vivo analysis of the circulating effector T cell subsets in the STAT4
P450S
 sibling 
revealed no abnormality of Th2, and Th17 or Treg differentiation. However, there 
was some heightened Th1 deviation as assessed by proportion of IFN- + CD4+ T 
Pathological actions of STAT4, MTOR and STAT3 in human T cell 
differentiation 
  
103 
 
cells (Figure 3.6D). Next, we examined the propensity of naïve CD4+ T cells to 
deviate toward Th1 cells after activation in vitro. In contrast with ex vivo analysis, 
naïve CD4+ T cells from the STAT4
P450S
 sibling exhibited very clearly an enhanced 
propensity to IFN-γ formation after stimulation under Th1 conditions (Figure 3.6E 
upper row). Similar to II.3, Th1 deviation was cytokine dependent as naïve CD4+T 
cells cultured with CD2/3/28 beads alone failed to adopt a Th1 phenotype (Figure 
3.6E, lower row). 
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Figure ‎3-6 Enhanced propensity toward Th1 deviation exhibited by carrier of 
STAT4
P450S
 
A. Flow cytometry analysis of circulating CD3+ T cell subsets in a control and (II.2). 
B. Flow cytometry analysis of circulating CD4+ and CD8 + T cells subsets according 
to CD45RA and CCR7 expression in a control and (II.2).C. Representative flow 
cytometry analysis of circulating B naïve(CD19+CD27-) and memory 
ells(CD19+CD27+) in a control and (II.2) and the surface IgM and IgD expression in 
each of these two subsets. D. Representative flow cytometry analysis of intracellular 
IL-17 and IFN- in CD4+T cells in a control and (II.2) after 4 hours stimulation with 
PMA and ionomycin and brefeldin-A. E. Flow cytometry analysis of intracellular 
IFN-γ expression in polarized CD4+ T cells after 4 days of culturing naïve CD4+T 
cells (CD3+CD4+CD45RO-) in a control and (II.2) with CD2/3/28 + IL-2 (80ng/ml) 
+IL-12 (20ng/ml ,upper row) or only with CD2/3/28+IL-2 (80ng/ml, lower row).The 
experiment has been done at least twice. 
 
3.6 Novel STAT4P450S missense mutation confers gain-of-function 
 
3.6.1 In-vitro analysis of PBMCs 
 
Mutations involving DNA binding domain in STAT1 protect it from 
dephosporylation and result in gain of function of STAT1 (Takezaki et al. 2012; 
Yamazaki et al. 2014; Frans et al. 2014; Faitelson et al. 2014; Uzel et al. 2013; Liu et 
al. 2011). We considered that a similar action might be conferred by the novel 
mutation in STAT4 discovered and described here. In order to test this postulate, we 
evaluated STAT4 phosphorylation (Y693) in naïve CD4+ T cells cultured under Th1 
conditions. FACS sorted naïve CD4+ T cells from II.2 (STAT4
P450S
) and cells from 
two healthy controls were cultured under Th1 inducing conditions (CD2/3/28 + IL-2+ 
IL-12) or under neutral conditions (CD2/3/28 +IL-2) for four days. We observed that 
only in cells bearing the STAT4
P450S
 variant, cytokine-dependent phosphorylation of 
STAT4 was maintained for a longer time (Figure 3.7 A).  
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3.6.2 In-vitro analysis of STAT4
P450S
 transfected HEK293T 
 
3.6.2.1 Cloning and expression of STAT4
P450S
 
 
In order to investigate the function of the STAT4
P450S
 allele in more detail and to 
eliminate any possibility of another mutation in II.3 or II.2 contributing to or 
modifying the prolonged pSTAT4, we set out to clone both normal and mutant 
alleles. Moreover, STAT4 is expressed as two isoforms, α and β. We were also 
interested in investigating whether the STAT4
P450
 mutation has led to alteration in 
relative expression of mutant or normal allele, or relative expression of either of the 
two isoforms.  
 
Since the II.3 is heterozygous for STAT4
P450S
, we aimed to clone both alleles from 
II.3 PBMCs. Detailed method is described earlier (Chapter 2.3.2.3- 2.3.2.13). Briefly, 
RNA was isolated from PBMCs of (II.3), and reverse transcribed. STAT4 cDNA was 
amplified from this template using high fidelity DNA polymerase (Phusion Hot Start 
II High-Fidelity DNA Polymerase). Amplified STAT4 was then transformed into 
MAX Efficiency® DH5α™ Competent Cells. Plasmids from positive colonies were 
extracted and sequenced. Colonies expressing mutant and wild type (WT) STAT4 
were found with similar frequency, indicating expression of both wild type and 
mutant alleles in similar proportion in patient's cell. We also identified that both 
common isoforms (splice variants) of STAT4 (Hoey et al. 2003) were found with 
either WT or g.112312C>T genotypes. 
  
Next, we tested the functional consequences of STAT4
P450S
 (Chapter 2.3.2.13-
2.3.2.16). Briefly, we transfected HEK293T cells with either normal or STAT4
P450S
 
alleles (HEK293T do not express endogenous STAT4).  Moreover, HEK293T do not 
express endogenous IL-12R and therefore, we used IFN-α to stimulate transfected 
cells to investigate the functional consequences of STAT4
P450S
 on inducing prolonged 
phosphorylation which was evaluated by flow cytometry, western blot, and 
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immunofluorescence. Furthermore, luciferase was used to assess the transcriptional 
consequences after stimulation of the mutant allele compared to the wild allele.  
 
3.6.2.2 STAT4
P450S
  is associated with prolonged phosphorylation and nuclear 
localization 
 
First, we attempted to replicate persistence of pSTAT4 seen on freshly polarised 
CD4+ Th1 cells using transfected HEK293T. Based on published findings (Hoey et 
al. 2003), isoform β (shorter) maintains a prolonged phosphorylation state compared 
to the α isoform. Therefore, we proceeded with our phosphorylation experiments by 
flow cytometry and western blot using the β isoforms of wild type and mutant alleles.  
Transfected HEK293T cells were stimulated with IFN-α for 2 days, and then rested in 
normal media for another 2 days with no further stimulus. Cells were then examined 
for phosphorylation of STAT4. Cells transfected with the STAT4
P450S
 showed 
sustained pSTAT4 compared to those transfected with wild STAT4 (Figure 3.7 B), 
replicating the findings from induced Th1 cells (Figure 3.7 A).  
 
Analysis of transfectants for abundance of pSTAT4 was performed by western blot. 
The signal obtained for pSTAT4 was normalized to the MYC (to control for the 
efficiency of the transfection) and TATA box (to control for the efficiency of protein 
loading) and then this signal was expressed relative to the unstimulated cells . The 
analysis revealed sustained phosphorylation after 1 and 5 hours in response to IFN-α 
stimulation which was most evident in response to low-dose stimulation. The 
differential response was evident at both time points, with a greater difference at the 
later time point (Figure 3.7 C-D).  
 
Next, we examined the distribution of STAT4 in transfected cells by direct 
immunofluorescence. This revealed a higher proportion of nuclear STAT4+ cells in 
mutant transfectants after overnight stimulation with IFN-α (Figure3.7E) . 
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Figure ‎3-7 STAT4 P450S is associated with prolonged phosphorylation and nuclear 
localization 
A. Overlay histogram of level of pSTAT4 in naïve CD4+ T cells 
(CD3+CD4+CD45RO-) cultured for 4 days with CD2/3/28+ IL-2 (80ng/ml) +IL-12 
(20ng/ml) in II.2 (red unfilled) versus normal control (filled grey) and sibling with 
wild type STAT4 genotype (unfilled blue). Cells were washed, fixed, permabilised and 
then stained for pSTAT4 staining. B. Overlay histogram of level of pSTAT4 in un 
transfected HEK293T (filled grey), transfected HEK293T with wild allele of STAT4 
(blue unfilled, β isoform) or transfected HEK293T with mutant allele of STAT4 (red 
unfilled, STAT4 β isoform). The three constructs were stimulated with IFN-α 
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(64IU/ml) for 2 days, washed and rested in culture media with no further stimulation 
for another 2 days. Then, cells were washed, fixed, permabilised and stained for 
pSTAT4. C. Western blots of pSTAT of HEK293T transfected with β isoform of wild 
(WT) or mutant type (P450S). The level of pSTAT4 by western blot was assessed at 
time 0, 1 and 5 hours of activation. Staining was done for pSTAT4, TAT Box as 
internal control and MYC as a control for the ratio of transfection. Cells were 
stimulated with low dose of IFN- α (20 IU /ml) versus high dose of (3000 IU /ml). D. 
Summary of level of pSTAT4 relative quantity after normalisation for the transfection 
efficiency using MYC and for the level of denaturation by TATA Box in wild type 
transfected HEK293T (unfilled columns) and mutant HEK293T (black filled 
columns). E. Transfected HEK293T with β isoform were stimulated with IFN- α 
overnight (64 IU/ml), washed, stained and subjected to examination by fluorescent 
microscope to assess the degree of nuclear localisation. Each experiment has been 
done once but under different conditions and using many different controls (minimum 
of two) to validate the given result.  
 
3.6.2.3 STAT4
P450S  
is associated with prolonged transcription 
 
STAT4 is activated after stimulation with IFN- α or IL-12. Moreover, expression of 
IRF1 is transcriptionally dependent on activation of STAT4. Mice deficient in either 
IRF1 (Coccia et al. 1999; Galon et al. 1999) or STAT4 (Kaplan, Sun, et al. 1996) 
have impaired Th1 development. Therefore, to assess the transcriptional consequence 
of STAT4
P450S  
, we co-transfected STAT4 luciferase reporter vector (IRF1) and pRL 
Renilla luciferace reporter vector (pRL-CMV vector) into HEK293T cells, together 
with either mutant or wild type and either alpha isoform or β isoform STAT4 cDNA 
plasmids. CMV pRL was co transfected as a control reporter (renilla signal). At ~36- 
40 hours after transfection (sufficient time for protein expression), HEK293T cells 
were stimulated with IFN-α (20IU/ml vs. 3000IU/ml) for 6 or 24h. Luciferase 
induction was terminated at 6 or 24 hours by washing the cells with phosphate 
buffered solution (PBS), and luciferase activity was assessed immediately by 
luminometry (Dual-Glo Luciferase Assay System). The signal obtained from the 
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experimental reporter (IRF1) was then normalised to the renilla (control reporter) and 
then this signal was expressed relative to the unstimulated cells. 
 
In cells transfected with β isoform of STAT4, we observed a statistically significant 
prolonged and increased IRF1 signal in the presence of the mutant STAT4 allele 
compared to the wild type. This was apparent in response to both the low-dose and 
the high dose stimulation with IFN- α, and it was cytokine-dependent (Figure 3.8.A-
B). Moreover, it was significant at 6 hours and remained significant 24 hours later. 
Interestingly, transfection with α isoform resulted in a high signal in cells transfected 
with the mutant allele compared with wild type allele, in response to stimulation to 
either low dose or high dose of IFN- α but only in the 6 hours duration(Figure 3.8.C-
D). At 24 hours, this difference was lost (Figure 3.8.C-D). These results are 
consistent with previous studies which have reported that the β isoform maintains 
phosphorylation and therefore transcription for a longer time (Hoey et al. 2003).  
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Figure ‎3-8 STAT4 P450S is associated with prolonged transcription 
HEK293T cells were transfected with IRF1 (firefly signal), Cmv-PRL (renilla signal) 
and either nothing extra (IRF+Cmv-PRL only, black), wild type (wt, blue) or mutant 
(mut) of STAT4 and subjected to luciferase assay according to the manufacture's 
recommendation (detailed in chapter 2.3.2.15). A β isoform of STAT4 was used and 
stimulation was done using IFN-α (20IU/ml) for 6 hours or 24 hours. B. β isoform of 
STAT4 was used and stimulation was done using IFN-α (3000IU/ml) for 6 hours or 24 
hours. C. α isoform of STAT4 was used and stimulation was done using IFN-α 
(20IU/ml) for 6 hours or 24 hours. D. α isoform of STAT4 was used and stimulation 
was done using IFN-α (3000IU/ml) for 6 hours or 24 hours. The obtained firefly 
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signal was first normalized according to the renilla signal and then expressed as 
relative change compared to the unstimulated isoform. Independent sample t-test was 
used, P<0.05 significant.  
 
Taken together, these results suggest a model of action in which STAT4
P450S
, affects 
the DNA binding domain of STAT4 and therefore protect STAT4 from the 
dephosphorylation by prolonged nuclear binding leading to enhanced transcription of 
IRF that leads to IFN-γ production.   
  
3.7 IL-12-STAT4 system is important for T-bet up-regulation but not the only 
determinant 
 
T-bet is the master transcriptional regulator of Th1 cells (Figure 3.5) (Szabo et al. 
2000), and therefore, the proportion of cells expressing T-bet expression can be used 
as a measure of the extent of Th1 deviation. Naïve T cell do not express measurable 
level of T-bet. T-bet up-regulation can be a direct result of IL-12/ STAT4 activation 
but can also be induced indirectly by IFN-γ and STAT1 activation (Lighvani et al. 
2001; Afkarian et al. 2002). FACS sorted naïve CD4+ T cells from a normal control 
were stimulated with TCR and co stimulation signals through the use of CD2/3/28 
with or without IL-2 have induced T-bet expression (Szabo et al. 2000; Szabo et al. 
2002), possibly through induction of IFN- that would in turn stimulate STAT1 
leading to T-bet up regulation. The addition of IL-12 to the same system of TCR and 
co stimulation (CD2/3/28+IL-2) was necessary for optimal T-bet up-regulation 
(Figure 3.5F and Figure 3.9A) (Ylikoski et al. 2005; Ramos et al. 2007; Thieu et al. 
2008).  
 
Examination of T-bet in PBMCs revealed that almost all CD3+ T cells were T-bet 
positive in II.3 (Figure 3.9B). PBMCs from II.2, the sibling with STAT4
P450S
 also 
exhibited much less impressive deviation to high level T-bet expression (Figure 
3.9B). We then examined naïve CD4+T cells, which normally express negligible 
levels of T-bet (Szabo et al. 2000). At baseline, the level of T-bet in FACS sorted 
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naïve CD4+T cells from II.3, a control and other member of his family was low 
(Figure 3.9C). Thus, T-bet over-expression is only observed after T cell activation 
and the high level of T-bet in STAT4
P450S
 is not due to simply abnormal high 
expression of T-bet that could be detected even in the naïve CD4+ T cells.  
 
Since the IFN-γ–STAT1 pathway is also important for T-bet up-regulation (Afkarian 
et al. 2002; Lighvani et al. 2001), we went on to examine the possibility that high T-
bet in the proband (II.3) is due to abnormal active STAT1. Therefore, we examined 
pSTAT1. Levels of STAT1 phosphorylation were similar in monocytes and 
lymphocytes from II.2 and II.3 and healthy donors (Figure 3.9 D-F). This finding 
argues against abnormal active STAT1 as the explanation for enhanced T- bet 
expression in II.3.  
 
Pathological actions of STAT4, MTOR and STAT3 in human T cell 
differentiation 
  
114 
 
 
 
Figure ‎3-9 Exceptional T-bet expression 
A. Overlay histogram of level of T- bet  on FACS sorted naïve CD4+T cells from a 
normal control ( filled grey), naïve CD4+T cells cultured for four days with TCR and 
co stimulation (CD2/3/28)(unfilled dotted blue), or with (CD2/3/28) and IL-2( 
unfilled blue long dashed, IL-2 (80ng/ml) or CD2/3/28 with +IL-2 (80ng/ml) +IL-12 
(20ng/ml, red ( unfilled red), fixed, permabilised and then stained for T-bet. B. 
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Overlay histogram of level of T-bet on CD3+. Control (filled grey), II.3 (red 
unfilled). II.2 (green unfilled) and II.4 (unfilled blue), PBMCs fixed, permabilised 
and then stained for T-bet. C. Overlay histogram of level of T-bet on FACS sorted 
naïve CD4+T cells. Control (filled grey), II.3 (red unfilled). II.2 (green unfilled) and 
II.4 (unfilled blue), fixed, permabilised and then stained for T-bet. D. Overlay 
histogram of level of pSTAT1 in PBMCS gated on monocytes and stimulated with 
different doses of IFN- (Filled grey is unstimulated versus stated dose of IFN- (red 
unfilled) for 20 minutes, fixed, permabilised and then stained for pSTAT1 in 
controls(n=2) and different members of the family. E. Overlay histogram of level of 
pSTAT1 in PBMCS gated on lymphocytes and stimulated with of IFN- (10U/ml), 
(Filled grey is unstimulated) versus IFN- stimulated (red unfilled) for 20 minutes, 
fixed, permabilised and then stained for pSTAT1. F. Overlay histogram of level of 
PSTAT1 in PBMCS gated on lymphocytes from the controls (n=2 filled, grey), II.3 
(red unfilled), II.2 (green unfilled), and II.4 and III.4 (blue unfilled), all unstimulated 
(upper histogram) and all stimulated with IFN-(10U/ml) lower histogram.  
 
3.8 STAT4 and TFH 
 
TFH and cTFH are characterized by expression of CXCR5 and IL-21 production. Our 
understanding of the signals necessary for TFH and cTFH formation remains 
incomplete. In humans, IL-12 and STAT4 signalling gives rise to Th1 (Kaplan, Sun, 
et al. 1996; Robertson et al. 2005) subset but recently, IL-12 has also been implicated 
in TFH differentiation (Schmitt et al. 2009). Consistent with this suggestion, patients 
with IL12Rβ1 deficiency have significantly reduced number of cTFH marked by low 
number of circulating CXCR5 (Schmitt, Bustamante, and Bourdery 2013). These 
patients are also deficient in memory B cells. 
  
In view of this evidence, we evaluated cTFH formation in the family members 
carrying STAT4 gain-of-function mutation. The number of CD4+ T cells that had 
adopted cTFH phenotype (CXCR5+CD45RA-) phenotype in II.3 was found to be 
significantly higher than the normal controls. By contrast, II.2 had a normal 
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proportion of CXCR5+ CD45RA- CD4+ T cells raising the possibility that CXCR5 
formation is not entirely dependent on STAT4 (Figure 3.10 A-B). Previously 
published results indicated that IL-12Rβ1 deficient patients had fewer CXCR5+ 
CD4+ T cells, and that the level of CXCR5 expression was lower compared to normal 
controls(Schmitt, Bustamante, and Bourdery 2013). We found no difference in 
median expression of CXCR5 in our two STAT4
P450S
 cases compared to normal 
controls. 
 
Next, we examined IL-21 and IFN- ex-vivo expression and induction. The 
percentage of ex vivo IFN- positive cells as shown previously was high for both II.2 
and II.3 (Figure 3.2), though higher for II.3 compared to normal controls. The 
percentage of cells which were IL-21 positive cells was also high in both STAT4
P450S
 
siblings (II.2 and II.3) (Figure 3.10 C-D) compared to normal controls.  
 
IL-12 signalling via STAT4 has also been implicated in the generation of TFH from 
naïve CD4+T cells. Therefore, we assessed induction of TFH (IL-21 production in 
cells co expressing TFH markers ) from FACS sorted naive CD4+T cells cultured 
under IL-12 containing conditions and co-stained for either PD-1 or ICOS. Both the 
II.2 and II.3 exhibited an increase in IL-21+ CD4+ T cells that co-expressed high PD-
1 or ICOS, compared to other controls (Figure 3.10 E-H). Of note, similar to the 
induction of Th1 in previous sections, induction of TFH from naïve CD4+ T cells in 
both II.2 and II.3 was cytokine-dependent, as there was no evidence of IL-21 
induction in conditions that had no IL-12 (Figure 3.10 E-H).   
 
BCL-6 is known as a master regulator for formation and maintenance TFH (Johnston 
et al. 2009; Nurieva et al. 2009). Previous work has suggested that BCL6 up-
regulation in humans is IL-12 and STAT4 dependent (Nakayamada et al. 2011). 
Analysis of cells immediately ex-vivo revealed that there was no difference in the 
level of BCL-6 expression which was similar in PBMCs from both II.2 and II.3 and 
healthy donors (Figure 3.10 I). In mice, it has been shown that IL-12 and STAT4 can 
lead to BCL-6 up-regulation, which then leads to up-regulation of IFN- and T-bet, 
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which in turn suppresses expression of BCL-6 (Nakayamada et al. 2011). Next, we 
stimulated naïve T cells with CD2/3/28 beads and IL-12.  This resulted in higher 
BCL-6 expression in naïve T cells from II.3 but not in II.2 (Figure 3.10 J).  
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Figure ‎3-10 STAT4P450S is associated with increase IL-21 producing TFH 
A. Representative flow cytometry analysis of circulating TFH in propand (II.3) and a 
normal control. B. Summary of the frequency (%) of CXCR5+CD45RA- cTFH out of 
CD4 +T cell compartment in the propand (II.3), II.2 and other family members and 
normal controls(n=10). C. Representative flow cytometry analysis of intracellular ex-
vivo IL -21 detection in CD4+T cells in II.3 and a normal control after 4 hours 
stimulation with PMA and ionomycin and brefeldin-A. D. Summary of the frequency 
(%) of IL-21 positive CD4+T cells in II.3, II.2 and normal controls (n=9). E. Flow 
cytometry analysis of frequency of intracellular IL-21 and PD-1 positive cells out of a 
system of FACS sorted naïve CD4+T cells cultured for 4 days with IL-12 (20ng/ml) 
+CD2/3/28 +IL-2(80ng/ml) in a control and II.3 .F. The same analysis was done on 
FACS sorted naïve CD4+ T cells of the same control and II.3 cultured for four days 
with CD2/3/28 and IL-4 (20 µg /ml). G. Flow cytometry analysis of frequency of 
intracellular  IL-21 and ICOS positive cells out of a system of FACS sorted naïve 
CD4+T cells cultured for 4 days with IL-12 (20ng/ml) +CD2/3/28 +IL-2(80ng/ml) in 
a control and II.2 H. The same analysis was done on cells obtained from FACS sorted 
naïve CD4+ T cells cultured in the presence of CD2/3/28 and IL-2 (80ng/ml) only. I. 
Histogram of the level of BCL-6 of freshly thawed PMCs, obtained from (II.2 (green 
unfilled), II.3 (red unfilled), II.4 (blue unfilled) and a normal control (grey filled).J. 
Histogram of the level of BCL-6 induction in FACS sorted naïve CD4+ T cells 
cultured with low dose of IL-12(1ng/ml) +CD2/3/28.(II.2(green unfilled),II.3(red 
unfilled),II.4(blue unfilled) and a normal control(grey filled). 
 
In summary, STAT4
P450S
 was associated with an enhanced TFH formation, assessed 
by ex-vivo IL-21 production. This was more evident in the in-vitro induced system 
with IL-21 production and co-expression of other TFH markers such as ICOS and 
PD-1. 
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3.9 B cell phenotype in the presence of Novel STAT4P450S and expanded Th1 and 
cTFH 
 
STAT4 is important for IFN- production by T lymphocytes but STAT4 has 
negligible expression in B cells. Assessment of ex-vivo IFN- production by B cells 
of the available family members did not yield any evidence of IFN-  over production 
by the carriers of STAT4
P450S
 (II.2 and II.3) (Figure 3.11 A). Moreover, STAT4 is 
important for IL-21 producing TFH formation and this subset is essential for B cells 
function and plasma cell formation (Schmitt, Bustamante, and Bourdery 2013). II.3 
exhibited an increased number of CXCR5 cTFH, and both II.3 and II.2 exhibit 
increased expression of IL-21 in CD4+ T cells ex-vivo. Despite this enhanced TFH 
activity, the B cell phenotype of II.3 revealed reduced B memory (CD19/CD27) with 
normal transitional B cells (Figure 3.1 A). By contrast, the B cell phenotype of II.2 
was normal for memory and transitional cells (Figure 3.6 C). In other words, despite 
the expanded TFH assessed by CXCR5 and ex vivo production of IL-21, there was no 
expansion of memory B cells in II.3. On the other hand, as noted above, before 
initiation of IVIG replacement, II.3 had high total IgA and IgG, which was mainly 
made up of IgG1 and IgG3, while IgG2 was reduced. He mounted a suboptimal 
specific antibody to tetanus toxoid. By contrast, II.2 had a normal immunoglobulin 
profile with normal subclass and specific antibody responses.  
 
Assessment of plasma cells exvivo in II.2 revealed a slight increase compared with 
controls (CD19
high
 CD38+ CD27
high
) (Figure 3.11. B).This has prompted us to 
examine B cell responses to activation in vitro. B cells from both II.2 and II.3. 
PBMCs from both II.2 and II.3(STAT4
P450
 ) as well as other controls, were stimulated 
for four days with CpG and IL-21 alone, or in the presence of either IFN- or anti 
IFN-. This was done to assess the ability of B cell to form plasma cells to investigate 
the possibility that IFN- might be inhibitory for plasma cell formation in the 
presence of this novel mutation. Cells from controls as well as both II.2 and II.3 
showed a normal ability to form plasma cells (Figure 3.11 C). In fact, overall addition 
of IFN-γ did not impair plasma cell formation in all samples especially in the 
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condition containing CpG (Figure 3.11C-D). Thus, the presence of IFN- in vitro 
experiment had a positive effect on plasma cell formation. Assessment of in vitro 
class switching revealed enhanced IgG1 and IgG3 formation in B cells from II.3 
(Figure 3.11E-F). Moreover, II.3 had ex-vivo propensity toward IgG1 and IgG3 
deviation and this was replicated in the n-vitro system (Figure 3.11E-F).  
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Figure ‎3-11 STAT4 P450S and B cell phenotype 
A. Flow cytometric analysis of ex-vivo intracellular IFN- by B cells from the 
available family members after 4 hours stimulation with PMA and ionomycin and 
brefeldin-A .B. Circulating plasma cells (gated as CD27
 high
 and CD38 
high
) in II.2 and 
normal controls (n=2).. C. Flow cytometry analysis of induction of plasma cell after 
stimulation of PBMCs with a stimulus that is either CPG(1uM) +IL-21(10ng/ml ) or 
CD40L(1 µg)+IL-21(10ng/ml ) with either (IFN), IFN- ( 100U/ml) or (anti) anti-
IFN- (I µg /ml) for four days. PBMCs were washed, stained for 7AAD, CD3, CD14 
(negative gate), then gated on CD19, CD27. PBMCs obtained from available family 
members (n=3) and normal controls (n=2). D. Summary of the frequency (%) of 
induced plasma cell as proportion of the memory B cells E. Induction of subclass 
switching in II.3 and normal controls (n=2) after stimulating PBMCs with CD40L (1 
µg /ml) and IL-21(10ng/ml) for four days. PBMCs were then washed, surfaced 
stained for CD19, CD27&CD38 and then fixed, permabilised and then stained for 
IgG total and subclass. Gates were set using gating on a freshly thawed and stained 
tonsil sample. F. Summary of the frequency (%) of different IgG subclass out of 
induced plasma cell (II.3), and normal controls (n=2).*,p<0.05 
 
3.10  Chapter summary and discussion 
 
We discovered a novel and private germ line STAT4
P450S
 in a discovery project 
utilizing second generation sequencing (whole exome sequencing) in a proband (II.3) 
recruited to the Australian and New Zealand Antibody Deficiency Allele (ANZADA) 
project. We have shown that the same mutation was found in another otherwise 
healthy sibling (II.2) and one of her offspring.  
 
STATs are made of very similar domains and mutations affecting different domains 
have been described to impede or enhance development of specific effector T cells. 
STAT4
P450S
 is a novel mutation affecting DNA binding domain of STAT4. Mutations 
in the DNA binding domain have recently been discovered in association with a gain 
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of function in general. STAT1 gain of function due to mutations in the DNA binding 
domain has been seen in patients with different clinical phenotypes ranging from 
CMC (Takezaki et al. 2012; Yamazaki et al. 2014), HLH (Faitelson et al. 2014) 
,invasive dimorphic yeast infection (Sampaio et al. 2013) and IPEX like clinical 
phenotype (Uzel et al. 2013). All of these germline mutations of the DNA binding 
domain gain of function were associated with increased activation and 
phosphorylation of STAT1 in response to cytokine stimulation and subsequent 
increased transactivation of its target genes (Frans et al. 2014; Takezaki et al. 2012; 
Yamazaki et al. 2014; Sampaio et al. 2013). Recently, germline mutations in the 
DNA binding domain of STAT3 have also been reported in patients with solid organ 
autoimmunity and early onset lymphoproliferation (Milner et al. 2015). These 
mutations were also associated with high STAT3 activation and phosphorylation in 
response to activating cytokines (Milner et al. 2015). Therefore, based on association 
of most DBD mutations with a gain of function phenotype, we have assumed that this 
mutation of STAT4 is a gain of function (GoF). Up to our knowledge there are no 
reported cases of STAT4 GoF mutations. However, polymorphism possibly being a 
gain of function was reported to be associated with increased risk of autoimmunity 
and inflammatory conditions (Pang et al. 2007; Remmers et al. 2007; Martinez et al. 
2008; Sigurdsson et al. 2008; Zervou et al. 2008). 
 
STAT4 deficiency is associated with lack of Th1 development in mice. Furthermore, 
it is known that IL-12-STAT4 system is crucial in up regulation of T-bet, master 
regulation of formation and maintenance of Th1. Therefore , IL12, STAT4, T-bet 
system is very important for adoption and maintenance of Th1 phenotype in the 
CD4+ and CD8+ T cells (Figure 3.5 A-B). Mice deficient in either IL-12, STAT4 or 
T-bet have defective Th1 formation which can be assessed by measuring Th1 
signature cytokine and that is IFN- (Kaplan, Sun, et al. 1996; Cho et al. 1996; 
Nishikomori et al. 2002; Szabo et al. 2002; Szabo et al. 2000; Ylikoski et al. 2005; 
Hsieh, Macatonia, Tripp, Wolf, Ogarra, et al. 1993; Magram et al. 1996).Our results 
have shown excessive Th1 deviation assessed by presence of abundance of ex-vivo 
IFN- in the CD4+ and CD8+ T cells compartment in II.3 (proband)(Figure 3.2 A-D) 
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as well as in II.2 though slightly to a lesser extent(Figure 3.6 E). These finding of 
exceptional Th1 phenotype were replicated by the in-vitro culture system in which 
naïve (unpolarised cells) were separated and polarized to become Th1 versus other 
lineages. Cells were cultured under Th1 polarizing ((CD2/3/28) +IL-12), and this 
combination supports the expression and activation of STAT4 protein in the cells. 
This has resulted in detection of almost twice the amount of the IFN- (Figure 3.2 H 
upper row) compared to the amount detected in cells came from a normal control. 
Moreover, the Th1 formation even in the carrier of STAT4
P450S
 was accentuated and 
was also cytokine dependent (Figure 3.2 H lower row). This was more evident after 
examining cells harbouring STAT4
P450S
 in a system that has lacked either STAT4 
expression or activation as in the conditions of Th2 polarization (CD2/3/28 +IL-4), 
Figure 3.6 E upper row) or neutral conditions as in (Th0(CD2/3/28 +IL2), Figure 3.6 
E lower row) of STAT4. Therefore, so far we have established that STAT4
P450S
 is 
associated with deviated Th1 phenotype in the T cell compartment in human in line 
with literatures from animal models.   
 
STAT4
P450S
 is a novel mutation involving the highly conserved DNA binding domain 
in STAT4. STAT4 is activated after stimulation with IFN-α or IL-12. Phosphorylated 
STATs in general bind to their elements in the nucleus via the DNA binding domain 
(Xu, Sun, and Hoey 1996; Meyer et al. 2003; Horvath, Wen, and Darnell 1995) and 
be protected from dephosphorylation (Mertens et al. 2006; Meyer et al. 2003). The 
longer they bind to these elements the longer the effect of trans-activating specific 
genes. The level of STAT4 in lymphocytes is low in resting state (Bacon, Petricoin, et 
al. 1995) and any stimulation with either IFN-α or IL-12 did not lead to any 
stimulation of STAT4 (Figure 3.5 C). However, after stimulating cells with agents 
such as PHA or TCR and co stimulation using (CD2/3/28) (Bacon, Petricoin, et al. 
1995) , assessment of STAT4 can be done. In polarized Th1 conditions, cells carrying 
STAT4
P450S
 have demonstrated a prolonged and sustained phosphorylation compared 
to other controls (Figure 3.7 A). Moreover, we attempted to replicate the same 
finding using transfected HEK293T cell line with mutant allele versus wild allele. 
The mutant allele has demonstrated a prolonged phosphorylation of STAT4 assessed 
Pathological actions of STAT4, MTOR and STAT3 in human T cell 
differentiation 
  
126 
 
by flow-cytometry and western blot compared to the wild type after stimulation 
(Figure 3.7 B-D). In addition, STAT4 binds to the IRF1 element in the nucleus upon 
its activation and phosphorylation. Therefore, examination of the nuclear localization 
and the IRF1 transactivation can be used as readout to assess the gain of function of 
STAT4
P450S
. The direct immunofluorescence of transfected HEK293T cells with wild 
type versus mutant type post stimulation with IFN- α has revealed a nuclear 
localization in the mutant but not in the wild allele transfected cells (Figure 3.7 E). 
Moreover, examination of the IRF1 signal in cells transfected with either mutant or 
wild allele of STAT4 has shown clearly a prolonged transcription of IRF1 (Figure 3.8 
A-D). 
 
All of the above finding supported the initial assumption that STAT4
P450S
 is a gain of 
function mutation. To our knowledge there is no reported gain of function mutation in 
human mutation affecting DNA binding domain or any other domain in STAT4. 
STAT4
P450S  
 is a cytokine dependent and was associated with prolonged 
phosphorylation (Meyer et al. 2003). STAT4
P450S
 upon stimulation resulted in an 
enhanced transcriptional activation of its target genes shown by the luciferase 
reporter. In the reported literatures of Th1 deficiency in mice through defects in the 
STAT4 signalling pathway, Th1 deficiency was associated with deviated Th2 
formation(Kaplan, Sun, et al. 1996; Usui et al. 2003) (Wood et al. 2005). In human, 
however, there was no enhanced Th2 formation in patients with different defects in 
the IL-12 IFN- pathway (Wood et al. 2005). Similarly, our data demonstrated that 
expanded Th1 due to STAT4 did not affect frequency of Th2 CD4+T cells. This 
might suggest that in human STAT4 does not cross regulate STAT6 or other Th2 
related genes directly or indirectly in contrast to the STAT1-STAT3 cross regulation 
(Takezaki et al. 2012; Yamazaki et al. 2014; Liu et al. 2011). However, this 
possibility would need to be examined in details.  
 
Persistent STAT4 leads to T- bet up regulation, both of which are needed for Th1 
formation in the CD4+ T and CD8+ T compartments (Figure 3.5 A-F) (Yamamoto et 
al. 1994; Zhong, Wen, and Darnell 1994; Kaplan, Sun, et al. 1996). 
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The described STAT4 mutation here presented with significant Th1 deviation and T-
bet up regulation (Figure 3.9 B).The same finding was substantiated using cells from 
the affected sibling with the same mutation. The presence of high T-bet is associated 
with Th1 response (IFN-) associated with IgG1 predominant immune response 
(Stoicov et al. 2009).  
  
Finally, STAT4 has been recently linked to the formation of TFH cells. We observed 
enhanced IL-21 expression in cTFH cells within the proband, II.3, and indeed in his 
STAT4
P450S
 sibling, II.2, consistent with enhanced Il-21 expression as a result of 
STAT4 gain of function (Figure 3.10). This was also replicated in the in-vitro system 
of inducing TFH using IL-12 as a stimulus (Figure 3.10-E-H). Our findings provides 
the first in vivo evidence for the importance of STAT4 for human Th1 (IFN-), T-bet 
up regulation and TFH formation.  
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Figure ‎3-12 Proposed model of action of STAT4 P450S 
A. Wild allele of STAT4 is stimulated with either IFN-α or IL-12 which leads to 
phosphorylation of STAT4. Phosphorylated STAT4 forms dimer, is recruited to the 
nucleus to bind to its transcription region (IRF1). In cells bearing wild allele of 
STAT4 , pSTAT4 is dephosphorylated and leave the nucleus.  B. However, in the cells 
bearing STAT4
P450S
  , pSTAT4 is bound to the nucleus for a longer time and therefore 
exert a prolonged transactivation of its target genes(IRF1). Moreover, its binding to 
the nucleus protect against dephosphorylation. 
 
 
CHAPTER 4 : MTOR 
T2448M
 IS A NOVEL GAIN OF 
FUNCTION ALLELE 
 
4.1 Introduction 
 
On comparison of CD4 +and CD8+ T cells from II.2 and II.3 for the extent of Th1 
deviation (assessed by IFN-γ) and T-bet levels in CD3+ T cells, we identified a trend 
towards Th1 deviation which was less marked in II.2 compared to II.3 despite the fact 
that both were carriers of the STAT4
P450S
 GoF mutation. Therefore, this raised the 
possibility that the exceptional Th1 phenotype in II.3 compared to II.2 might not be 
all due to STAT4
P450S
.  
 
Moreover, we have shown that II.3 has marked effector CD8+ T cell phenotype with 
expansion of Temra subset. We therefore considered the possibility that the extreme 
effector Th1 phenotype observed in II.3 is the result of a modifier mutation. 
 
4.2 Exceptional effector Th1 CD8+ and CD4+ T cells phenotype is a result of STAT4 
GoF and a modifier mutation 
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As shown earlier in the previous chapter, the CD8+ T cell compartment in II.3 
exhibits prominent expansion of the Temra subset compared to normal adult controls 
(Figure 3.1 C-D) in addition to the remarkable Th1 phenotype (Figure 3.2). 
Examining the rest of the available family member for these two signatures revealed 
that there are members who expressed a similar phenotype though slightly to a lesser 
extent of Th1 deviation in CD4 +T cell and CD8+ T cell as well as expansion of the 
Temra subset in CD8+ T cells (Figure 4.1 A-D, in blue). Therefore, there are other 
members in the family whom exhibited these two main findings of Th1 deviation 
(IFN- γ) and expansion of terminally differentiated CD8+ T cell. 
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Figure ‎4-1 Exceptional Th1 CD8+ and CD4+ T cell phenotype is a result of STAT4 GoF 
and a modifier mutation 
A. Summary of % of intracellular IFN- producing CD4+ and CD8+ T cells 
obtained by flow cytometry after 4 hours stimulation with PMA and ionomycin 
and brefeldin-A in controls(n=16, unfilled circles ), II.3(red filled circle, 
heterozygous STAT4
P450S
) II.2 (green filled circle) and I.I, II.4, III.3 and III.4 
(blue filled circles, heterozygous  STAT4
P450S
). B. Electropherogram of STAT4  
in the available family members depicting the heterozygous  STAT4
P450S 
(1
st
 row 
from top, star), intracellular IL-17 versus IFN-  expression in CD4+ and CD8+ 
T cells (middle row) obtained by flow cytometry after 4 hours stimulation with 
PMA and ionomycin and brefeldin-A in different family members. CD8+ 
subsets analysed according to CD45RA and CCR7 expression in the available 
family members (lower row). Available family members, (starred, II.2, II.3 and 
III.2, heterozygous STAT4
P450S
), (un starred I.1, II.4, III.3 and III.4, wild type 
STAT4). .C .Summary of % of different circulating CD8 T subsets naive 
(CD45RA+CCR7+), Tcm (CD45RA-CCR7+), Tem (CD45RA-CCR7-) and 
Temra(CD45RA+CCR7-). D summary % of Tcm (significance was calculated 
using Man-Whitney test) obtained by flow cytometry in controls (black 
unfilled, n=5) and available family members (red filled II.3, heterozygous  
STAT4
P450S
), (green filled II.2), (blue filled, I.1, II.4, III.3 and III.4, 
heterozygous STAT4
P450S
). 
 
4.3 CD8+ T cell subsets and effect of mTOR CD8 subsets 
 
CD8+ T cells can be divided into four different subsets according to their surface 
markers (CD45RA and CCR7) CCR7 (Hamann et al. 1997; Sallusto et al. 1999; 
Tomiyama et al. 2004). These subsets are functionally different and exhibit different 
cytokine profiles (Hamann et al. 1997; Sallusto et al. 1999). CD45RA+CCR7+ naïve 
T cells have negligible cytotoxic ability or IFN- γ production. On the other hand, 
CCR7- subsets, both CD45RA+ and CD45RA-, are effector memory cells that are 
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both cytotoxic and IFN- γ producers. CD45RA- CCR7+ T cells have no immediate 
effector or cytotoxic activity, but these cells are easily induced in a recall response. In 
young subjects, most CD8+ T cells are naïve. With aging, memory effector CD8+ T 
cells predominate in the circulation and Tcm CD8+ T cells predominate in lymphoid 
tissue(Koch et al. 2008).  
 
Recent evidence indicated that blocking mTOR does not only inhibit immune system 
activation but has also paradoxical action that fine tunes CD8+T cell immunity. 
mTOR signalling through the mTORC1 complex influences memory versus effector 
differentiation of naïve CD8+ T cells (Araki et al. 2009). Blocking mTOR with 
rapamycin promotes formation of memory CD8+ T cells (Tcm) (Araki et al. 2009), 
(Rao et al. 2010) and (Ramos et al. 2009). These effects appear to be CD8+ T cell-
intrinsic, since RNA interference of mTOR solely in CD8+ T cells replicates the 
effect of incubating PBMCs with rapamycin (Araki et al. 2009). Furthermore, the use 
of mutant CD8+ T cells, rendered specifically insensitive to rapamycin failed to 
replicate the phenotype of expanded memory CD8 T cells when cells were treated 
with rapamycin (Araki et al. 2009).  
 
4.4 Segregation of CD8+ T cell phenotype and the variant of MTOR 
 
We reanalysed the whole exome sequence from II.3 for candidate modifiers. We 
identified a novel heterozygous missense mutation in (Figure 4.2 A-B) in MTOR 
(MTOR
T2446M
). The mutation encoding MTOR
T2446M 
is unique and predicted to be 
damaging by in silico analysis. This amino acid substitution is located in the negative 
regulatory domain of MTOR. Sanger sequencing confirmed the mutation in II.3 and 
other family members (I.1, II.4, III.3 and III.4) (Figure 4.2 C-D). Of note, the finding 
that the family members exhibiting expansion of effector Th1(IFN-γ) and Temra 
CD8+ T cell subset (Figure 4.1 A-D, in blue ) are the same members carrying this 
novel variant of MTOR (MTOR
T2446M
).Thus, the mutation segregates with this cellular 
phenotype.  Of considerable interest, II.3 is the only member of the kindred to carry 
mutations in both STAT4 and MTOR (Figure 4.2 D).  
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Figure ‎4-1 Segregation of TEMRA expansion phenotype and MTORT2446M 
A. Filter Score obtained for novel missense mutation (MTOR) score circled. B. 
Protein structure including T2446 in the negative regulatory domain (upper row). 
Alignment of NRD of different species (lower row). C. Electropherogram depicting 
the heterozygous 2446T>M mutation in the patient (II.3). D. Family tree. 
Heterozygous STAT4 
P450S
 in black and heterozygous MTOR 
T2446M
 in yellow. 
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4.5 MTOR T2446M is a not a loss of function mutation 
 
Inhibition (Brunn et al. 1997) or deletion (Sekulic et al. 2000b) of the highly 
conserved negative regulatory domain (NRD) leads to constitutive activity of mTOR. 
The NRD has 3 phosphorylation sites, T2446, S2448 and S2481. Serine 2448 is 
phosphorylated by protein kinase B (PKB) after stimulation by insulin (Sekulic et al. 
2000a). On the other hand, the phosphorylation of Ser2448 is attenuated with amino 
acid deprivation. In contrast, nutrient deprivation activates AMP activated protein 
kinase (AMPK), which results in phosphorylation of Thr2446. This is thought to 
reduce mTOR activity, reflected in diminution of P70S kinase activity (Cheng et al. 
2004). Interestingly, P70S kinase itself has the ability also to phosphorylate both 
T2446 and S2448. (Holz and Blenis 2005). There is some evidence to suggest that 
phosphorylation of T2446 and S2448 might be a mechanism of mutual cross-
regulation, which integrates availability of nutrition and growth factors (Cheng et al. 
2004) . 
 
 Moreover, as described above (Chapter 3.5 and 3.7), rapamycin leads to expansion of 
Tcm (opposite to the phenotype observed in Figure 4.1 C-D) and reduction in effector 
CD8+ T cells Tem in the circulation and secondary lymphoid organs, and inhibits 
formation of tissue memory CD8+ T cells. On the other hand, active mTOR is needed 
for formation of effector subsets of CD8+ T cells (Araki et al. 2009; Rao et al. 2010; 
Rao, Li, and Shrikant 2010) through up regulation of T-bet , master regulator of 
effector CD8+T cells. The T-bet up regulation and effector phenotype is impaired in 
the presence rapamycin that favour up regulation of eomesodermin, master regulator 
for central memory phenotype. We have demonstrated previously more deviated 
effector CD8 +T cell phenotype and Th1 (IFN-) (Figure 4.1).  
 
Taken together, the biochemical importance of T2446 and the negative regulatory 
domain and the known action of mTOR on CD8+ T cell differentiation toward 
effector CD8+ T cell differentiation, this lend plausibility to the postulate that 
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T2446M in MTOR is a functional mutation toward effector Th1 phenotype and most 
likely to be a gain of function mutation. 
 
Therefore, we proceeded to examine the functional consequences of the MTOR
T2446M
 
mutation. We first tested the opposite possibility to our assumptions, that MTOR 
T2446M
 confers a reduction in mTOR function rather than a gain of function. First, we 
examined the effect of addition of rapamycin to CD8+ T cells from healthy donors. T 
cells were stimulated with CD2/3/28 and rapamycin was added in the presence or 
absence of IL-12 for 3 days. We observed an increase in percentage of cells adopting 
Tcm phenotype (CCR7+CD45RA-) and a significant reduction in the number of cells 
adopting the effector phenotype (Tem and Temra) (Figure 4.3A-C). 
 
Next, we performed the same experiments using cells isolated from II.2 (STAT4
P450S
 
and wild type MTOR). If the MTOR
T2446M 
mutation is a loss of function (LoF) then we 
might expect to recapitulate the phenotype observed in II.3 of expanded extreme 
Temra over other subsets. Furthermore, treatment of rapamycin did not lead to 
increase in the total number of CD8+ T cells. (Figure 4.3A-C).  
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Figure ‎4-2 Active mTOR is important for the formation and maintenance of Temra and 
Tem CD8Tcells 
A. Flow cytometry analysis of surface markers of CD 8 and its subsets in 
controls(n=2) and II.2 in freshly thawed PBMCs (Nill) , after 3 days culture with 
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rapamycin (100ng/ml) with IL-12(2ng/ml) (+Rapa+12) or Rapamycin alone 
(+Rapa)B. Summary plots of the percentage of total and different subsets of CD8 in 
the three different conditions (controls in grey and II.2 in green). C. Ratio of Temra 
over Tcm obtained for each of the controls and II.2 in the three different conditions 
(p<0.05, Friedman test).  
 
Similarly, treatment of CD4+ T cells with rapamycin led to more cells adopting naïve 
and Tcm surface phenotype rather than effector phenotype (Figure 4.4 A-C). Taken 
together, these findings suggested that if the MTOR
T2446M
 mutation is functional and it 
is likely to confer a gain of function (by reducing activity of the negative regulatory 
domain) rather than being a loss of function. 
 
 
Pathological actions of STAT4, MTOR and STAT3 in human T cell 
differentiation 
  
139 
 
 
 
Figure ‎4-3 Active mTOR is important for the formation and maintenance of Temra and 
Tem CD4Tcells 
A Flow cytometry analysis of surface markers of CD4+ T subsets in controls and II.2 
as in freshly thawed PBMCs(Nill) , after 3 days culture with rapamycin (100ng/ml) 
with IL-12(2ng/ml) (+Rapa+12) or Rapamycin alone (+Rapa)B. Percentage of 
different subsets of CD4+ T cells in the three different conditions in controls (n=2) 
and II.2. C. Ratio of Tem over Tcm obtained for each of the controls and II.2 in the 
three different conditions. (p<0.05, Friedman test).  
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IL-7 is necessary for proliferation and homeostasis of naïve CD8+ T cells (Tan et al. 
2001) as well as homeostasis of resting memory T cells (Schluns et al. 2000; Goldrath 
et al. 2002). IL-7Rα (CD127) is thought to promote CD8+ T cell survival as IL-7R 
expressing naïve and Tcm express the highest percentage of BCL-2 as anti-apoptotic 
marker (Araki et al. 2009), and cells deficient in IL-7R are more prone to apoptosis  
in mice (Schluns et al. 2000). Both naïve and Tcm memory CD8+ T cells express 
higher levels of CD127 than effector subsets (Tem and Temra) or recently activated 
CD8+ T cells (Schluns et al. 2000).  
 
Active mTOR signalling leads to down regulation of CD127, which is thought to 
promote formation of effector CD8+ T cells, and IFN- and granzyme- B production. 
As stated earlier that rapamycin (blocking mTOR) enhances transition of Tem CD8+ 
T cells into Tcm CD8+T cells (Araki et al. 2009) but as well it lead to persistent 
expression of CD127 (Rao et al. 2010). Therefore, we proceeded to examine the 
effect of the MTOR
T2446M
 on the level of CD127 surface expression on different 
CD8+T cells and other effector phenotype such as level of expression of granzyme-B 
in normal versus our proband (II.3). 
 
We examined IL-7 receptor α (CD127) expression in CD8+ T cells from a healthy 
control. In keeping with published findings, we found that Tcm and naïve CD8+ T 
cells express higher levels of IL-7R α (CD127) and minimal granzyme- B. By 
contrast, Tem and Temra have low expression of CD127 and are enriched for IFN- 
and granzyme-B production (Figure 4.5 A and C). We performed the same 
comprehensive phenotyping of CD8+ T cells from (II.3). This revealed a relative 
increase in IFN- and granzyme- B expression in the Temra subset with low CD127 
expression (which constitutes the major CD8+ T cell subset in II.3) (Figure 4.5 B and 
D). We examined the ratio of Temra to Tcm CD8+ T(Araki et al. 2009) cells from 
other family members. This revealed a trend toward increased effector CD8+ T cells 
relative to Tcm in the members carrying the MTOR 
T2446M
 mutation (Figure 4.5 E) 
with enrichment for IFN-γ and granzyme-B(GzmB) production (Figure 4.5 F). The 
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above findings are consistent with the postulate that MTOR 
T2446M
 mutation is a gain 
of function leading to effector Th1 phenotype in CD4+ T but also in CD8T+ cells. 
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Figure ‎4-4 Effector CD8+ T cell phenotype due to MTORT2446M 
A-B. Representative flow cytometry analysis of level of IL-7Rα, CD127 expression 
by different CD8+T subsets and their production of IFN- in a control (A) and in II.3 
(B). C-D. Representative flow cytometry analysis of level of granzyme-B expression 
by different CD8+ T cell subsets in a control (C) and in II.3 (D). H. Summary of ratio 
of percentage of Temra over Tem controls (n=5) and MTOR
T2446M 
(n=3). The 
difference was p<0.05 using wilcoxon test for independent samples. I. Summary of 
percentage of granzyme-B positive CD8+ T cells from normal controls (unfilled 
black circles), II.2 (filled green), II.4 (filled blue) and II.3 (filled red).  
 
4.6 MTORT2446M is a gain of function mutation 
 
So far, the shown functional cellular data supported our initial postulate that 
MTOR
T2446M
 confers gain of function. In order to support this postulate further, we 
proceeded to biochemical evaluation of the mTOR pathway. S6 kinase is a direct 
substrate of mTOR. Cellular activation via the mTOR pathway results in 
phosphorylation of 70 S6 Kinase (pS6K) and subsequent S6 phosphorylation (pS6) 
(Brown et al. 1995). The activation of mTOR can be achieved either through the use 
of PMA (Oubrahim et al. 2013) or TCR engagement (Hamilton et al. 2014). 
Therefore, PBMCs from family members and controls were either left unstimulated 
or stimulated with PMA, and were then lysed and analysed by western blot for the 
level of pS6K. Three individuals with a MTOR
T2446M
 genotype showed higher 
baseline phospho-S6K1 compared to normal controls, supportive of a gain-of-
function or constitutively active allele (Figure 4.6 A-B). Activated S6K catalyses 
phosphorylation of S6. We therefore also examined pS6 by flow cytometry in 
controls and three of four family members identified with MTOR
M2446T
 and similarly 
demonstrated enhanced pS6 at baseline as well as after stimulation. This effect was 
reversed by co-culture with rapamycin (Figure 4.6 C). These findings are consistent 
with the MTOR
M2446T 
mutation conferring gain of function on mTOR. This is most 
likely the result of loss of function of the negative regulatory domain of MTOR. This 
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is in keeping with previous data that deletion(Sekulic et al. 2000a) or blocking (Brunn 
et al. 1997)of this domain give rise to active mTOR .The consequence of this 
mutation is effector Th1 phenotype deviation especially with a deviation toward 
Temra (Figure 4.6D). 
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Figure ‎4-5 MTORM2446T is a gain of function mutation 
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A. Western blots of pS6K. PBMCS were either not stimulated or stimulated with 
PMA (50nM) for 30 minutes, lysed or the lysate was then run on Tris glycine minigel 
from 3 normal controls and II.4, III.3, III.4.  B. Summary of the normalised pS6 
against GAPDH (housekeeping protein) in the unstimulated conditions and the PMA 
stimulation. P<.05, using Wilcoxon test for independent samples. C. Histogram of 
level of pS6 (ser235/236) in activated T cells at 0, 10 and 20 minutes after being 
unstimulated (red unfilled histogram), stimulated with CD3 (unfilled blue) or with 
CD3 and rapamycin (unfilled orange). D. Summary of the ratio of Temra over Tcm or 
effector (Temra and Tem) over Tcm CD8+ T cells from in different donors. Normal 
controls (n=5 unfilled black circle), II.4, III.3, III.4 (filled blue), II.2 (filled green) 
and II.3 (filled red). 
 
4.7 Interaction between MTOR and STAT4 
 
4.7.1  Introduction 
 
Activation of naïve CD8+ T cells by IL-12 acting via STAT4 (signal 3) is thought to 
be crucial for normal CD8+ T cell differentiation. IL-12 induces the effector 
phenotype of CD8+ T cells, including IFN-, perforin, granzyme-B as well as 
cytolytic activity of CD8+T cells(Ramos et al. 2009)and enhances up-regulation of T-
bet, which in turn regulates formation of Tem over Tcm with high expression of T-bet 
in Tem compared to Tcm(Ramos et al. 2009).  
 
As we have just shown in previous sections (figure 4.3-4.6), there is considerable 
evidence that mTOR regulates effector cell differentiation of CD8+ T cells (Araki et 
al. 2009; Rao, Li, and Shrikant 2010; Rao et al. 2010). Active mTOR supports T-bet 
up regulation, IFN-  and granzyme-B production (Rao, Li, and Shrikant 2010; Rao et 
al. 2010).  
In fact, we find mTOR is a plausible positive modifier for STAT4 due to many 
reasons. Activation of STAT4 by IL-12 enhances mTOR activation, when compared 
with antigenic stimulation alone (Rao et al. 2010). Conversely, mTOR signalling 
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system is necessary to maintain active STAT4 signalling. In addition based on 
previous literatures, both IL-12 and mTOR are crucial for the expansion of effector T 
cells especially in the CD8+ compartment, through up regulation of T-bet and down 
regulation of eomesodermin.  
 
Taken together the facts that, there is a biochemical importance of T2446 , the known 
action of mTOR on CD8+ T cell differentiation and the importance of both IL-
12STAT4 and active mTOR toward effector CD8+ T cell differentiation, lend 
plausibility to the postulate that MTOR 
T2446M
  is positive a modifier of STAT4
P450S
 
both of which acting toward exaggerated Th1 responses, and this what we aimed to 
investigate next.  
 
4.7.2  STAT4 and MTOR cooperate toward maximal effector CD8+ T cell and CD4+ T 
cell differentiation giving rise to high T-bet signature 
 
To investigate the effect of STAT4 activation by IL-12 on activation of mTOR, we 
first cultured naïve CD4+T cell isolated from a normal donor with CD2/3/28 and IL-2 
for 4 days with or without IL-12. TCR and co stimulation (CD2/3/28) has caused 
activation of mTOR assessed by pS6. The addition of addition of IL-12 to this 
experimental system has caused optimal activation of mTOR (pS6) (Figure 4.7A). 
Therefore, the activation of STAT4 was needed to induce maximal activation of 
mTOR. In addition, in the same system, stimulation of the cells with TCR and co 
stimulation (CD2/3/28) has up regulated the level of T-bet. However, IL-12 resulted 
in maximal T-bet up-regulation (Figure 4.7B).  
 
In other words, activation of TCR and co stimulation (CD2/3/28) has activated 
mTOR and up regulated T-bet but maximal activation of both, mTOR and up 
regulation of T-bet is IL-12 and STAT4 dependent. These experiments support 
previous observations that IL-12 acting via STAT4 activates mTOR and up regulates 
T-bet (Rao et al. 2010; Li et al. 2011). 
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Next, to show that active mTOR is required to up regulate T-bet and maintain active 
STAT4, we treated PBMCs from a normal control with CD2/3/28 and IL-12 with and 
without rapamycin. TCR and co stimulation (CD2/3/28) in the presence of IL-12 
resulted in maximal up regulation of T-bet, and this was sensitive to rapamycin 
(Figure 4.7C). Moreover, phosphorylation of STAT4 also appears to be mTOR 
sensitive, as rapamycin reduced the extent of STAT4 phosphorylation observed in 
II.3 to the same level seen in normal controls (Figure 4.7 D). These experiments 
support the observation that active mTOR is required for optimal STAT4 activation 
and T-bet up regulation. The experiments shown here points toward that both active 
STAT4 and active mTOR are needed for maximal T- bet expression.    
 
Approximately 20% of all human CD4+ T cells express T-bet. Approximately 60% of 
all human CD8+ T cells express T-bet, with Temra and Tem exhibiting the highest 
levels of expression (Joshi et al. 2007). The proportion of T-bet positive cells is 
highest in the effector memory compartment (Knox et al. 2014). Therefore, the level 
of T-bet expression can be taken as readout for the extent of Th1 deviation in CD4+ 
and CD8+ T cells. 
 
We evaluated T-bet (TBX21) expression in the proband (II.3) and available family 
members. Un-manipulated PBMCs taken from the proband (II.3) were uniformly T-
bet positive (Fig. 3.9B). The proportion of T-bet+ cells were increased in II.2 
STAT4
P450S
 single mutant CD3+ T cells, but not to the same level observed in the II.3.  
II.4, MTOR
T2446M
, single mutant CD3+ T cells analysed immediately ex vivo also 
exhibited increased T-bet expression which was even higher than we observed in II.2 
(Figure 4.7 E). Taken together, these findings are consistent with constitutively active 
allele of MTOR
T2446M
 mutation that enhances T-bet expression. However, since T-bet 
requires activated STAT4 for Th1 differentiation, these effects remain subclinical 
unless combined with another abnormality, in this case, cytokine dependent 
overactive STAT4
P450S
 both together leading to high T-bet expression and so effector 
CD4+ and CD8+ T cell differentiation. All of this would explain the pathological 
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elevation of T-bet even at the level of mucosa when assessed on gut biopsy (Figure 
4.7 F).  
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Figure ‎4-6 STAT4P450S MTORT2446M cross regulate each other toward extreme Th1 
deviation  
A.  Overlay histogram of the level of pS6 (mTOR) in naïve CD4+T cells stimulated for 
4 days with CD2/3/28 (grey shadowed histogram), CD2/3/28 with IL-2 (80ng/ml, blue 
unfilled) or CD2/3/28 +IL-2+IL-12 (20ng/ml, red unfilled). B. Overlay histogram of the 
level of T-bet in naïve CD4+T cells stimulated for 4 days with CD2/3/28 (grey filled 
histogram), TCR with IL-2 (80ng/ml ,blue unfilled) or CD2/3/28 +IL-2+IL-12 (20ng/ml 
,red unfilled). C. Overlay histogram of the level of T-bet in CD3+T cells in freshly 
thawed PBMCs (grey filled histogram), stimulated for 4 days with (CD2/3/28), IL-
12(20ng/ml) without (red unfilled) or with rapamycin (100ng/m, blue unfilled). D. 
Overlay histogram of the level of pSTAT4 in FACS sorted naïve CD4+ T cell 
stimulated for 3 days with TCR(CD2/3/28) and IL-12(20ng/ml) with and without 
rapamycin(100ng/m ) in a control (grey filled histogram) and in II.3(red unfilled). E. 
Summary of the percentage of CD3+T-bet +analysed by flow cytometry in controls 
(n=6, filled grey), II.3 (red filled), II.2 (green filled) and II.4 (filled blue). F. Level of T-
bet mRNA of tissue expression detected by RT-PCR on a biopsy obtained from the 
oesophagus. II.3 (red filled circle), controls (n=2 grey filled circles). G. Proposed model 
of interaction between STAT4 and mTOR toward extreme Th1 deviation.Stimulation of 
STAT4, leads to phosphorylation of STAT4 which is essential for T-bet upregulation 
and  adoption of Th1 phenotype. Moreover, phosphorylated STAT4 activate MTOR 
complex especially mTORC1 . Active mTOR  in turn activates STAT4 further. It also 
causes upregulation of T-bet in T cell that dictate the adoption of IFN-g Th1 producing 
phenotype. In cells bearing STAT4
P450S
  and MTOR
T2446M
 , the T-bet upregulation is 
accentuated giving rise to exceptional Th1 CD4+ and CD8 effector memory phenotype. 
4.7.3  CHAPTER SUMMARY AND DISCUSSION 
 
Active STAT4 and mTOR together drive T cell differentiation toward exaggerated 
Th1 deviation marked by IFN-γ production and T-bet up regulation. The proband 
(II.3) is the only one among his family to carry both STAT4
P450S
 and MTOR
T2446M
. We 
have shown that STAT4
P450S
 is a gain of function mutation in the DBD causing 
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prolonged binding to the nucleus and therefore prolonger transcription of Th1 related 
genes.  
 
MTOR
T2446M
 is a mutation in the highly conserved negative regulatory domain, the 
dysfunction of which was associated with constitutive mTOR as assessed by level of 
pS6. So far there is no reported human germ line mutation in mTOR though there are 
reports (Angulo et al. 2013; Lucas et al. 2014) of PI3KCD mutations that were shown 
to cause downstream activation of mTOR. The clinical and cellular feature in this 
cohort is similar to our proband and carrier of MTOR
T2446M
 in terms of expansion of 
CD8+ T cell effector subsets (Temra) and IFN-γ production.  
 
Trm CD8+ T cells are a newly described subset that resides in non-lymphoid 
parenchyma. Trm appear to be more closely related to effector T cells, and have been 
implicated in inflammatory pathology such as in allergic contact dermatitis, psoriasis 
and crohn’s disease. In contrast to the positive effect of blocking mTOR on CD8+ 
Tcell central memory abundance in SLO, rapamycin appears to inhibit Trm 
recruitment and formation.   
 
T-bet up regulation occurs shortly after TCR ligation to some extent and is 
augmented and prolonged with activation of STAT4 through IL-12 (Szabo et al. 
2000; Yang, Ochando, et al. 2007). Cells deficient in STAT4 failed to induce T-bet in 
mice (White et al. 2001). IL-12 STAT4 system is known for its positive effect on 
mTOR activation leading to effector T cell differentiation and T-bet up regulation. 
The unique combination of STAT4 and MTOR gain of function mutations in the 
proband (II.3) can plausibly explain the extreme T-bet up regulation by all peripheral 
as well as tissue lymphocytes. The presence of high T-bet is associated with Th1 
response (IFN-γ) associated with IgG1 predominant immune response (Stoicov et al. 
2009) and some of the inflammatory diseases such as in the gastrointestinal tract 
(Kolumam et al. 2005). Up- regulation of T- bet is a main mechanism through which 
effector Th1 inflammatory response predominate in patients with crohn’s disease 
(Matsuoka et al. 2004) gastritis and gastric cancer (Stoicov et al. 2009)as well as 
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acute graft versus host disease. Therefore, animals with deficiency in T- bet had less 
gut and liver GVHD (Fu et al. 2015). Moreover, patients with chronic GVHD 
(D'Asaro et al. 2006) had high representation of  effector Temra CD8+ T cell. Higher 
T-bet was also responsible for inflammatory gut due to helicobacter felis leading to 
gastric cancer (Stoicov et al. 2009). On the other hand damping this high T-bet Th1 
effector signature through administration of rapamycin treated dendritic cells was 
associated with prolonged cardiac allograft survival (Chiang et al. 2004). All the 
presented evidences support the possibility that extreme Th1 deviation and high T-bet 
expression might be responsible for the inflammatory phenotype exhibited by our 
patient's mucosal tissues. 
 
CHAPTER 5 : DEPENDENCY OF IL-10 PRODUCTION 
BY HUMAN EFFECTOR CD4+ T TH2 CELL SUBSETS 
ON STAT3 
 
5.1 Introduction 
 
Autosomal dominant Hyper IgE syndrome (AD-HIES) is an immunodeficiency 
disease due to impaired function of STAT3 and subsequent failure in the formation of 
Th17 (Minegishi et al. 2007; Ma et al. 2008). However, one of the main criteria to 
diagnose AD-HIES is a prominent Th2-type phenotype, shared by other similar 
diseases mainly atopic eczema (Eyerich and Novak 2013), including high eosinophil 
count, high IgE levels and rashes (Schimke et al. 2010).  While susceptibility to 
infection in this syndrome has been explained by the discovery that STAT3 mutation 
compromises formation of TH17 cells, the explanation for high IgE in this disease 
remains unclear. 
 
IL-10 is a potent regulatory cytokines against excessive Th1 and or Th2 effector 
immune response. This was made clear in animal models where reports have 
supported a role for STAT3 to induce IL-10 production in the context of chronic and 
excessive Th2 immunopathology (Altin, Goodnow, and Cook 2012). This STAT3 
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dependent production was by Th2 CD4+ T cells that remained Foxp-3 negative 
despite their new role as regulatory T cell. 
 
It remains a possibility that there is a similar Th2 subset exists in human and the 
formation of this inducible subset is STAT3 dependent. Therefore we aimed to 
investigate requirement of STAT3 for normal IL-10 production by CD4+T cells and 
especially by Th2 CD4+ T cell making use of cells from patient with abnormal 
STAT3 signalling versus normal controls. 
 
5.2 IL-10 positive human CD4+ T cells are rare and not STAT3 dependent 
 
First, we compared the proportion of IL-10 producing CD4+ T cells isolated from 
normal controls and patients with AD-HIES. IL-10 producing CD4+ T cells are rare, 
accounting for less than 1% of CD4+ T cells in healthy donors (Figure 5.1 A-B). 
There was no difference between the frequency of these cells in normal controls and 
patients with AD-HIES.  Moreover, in line with previous observations, we observed a 
higher proportion of IL-10+ cells in the memory compartment (CD4+ CD45RA-) 
compared to naïve (CD4+ CD45RA+) (Figure 5.1 C). These data suggest that 
baseline production of IL-10 from memory CD4+ T cells is not STAT3-dependent.  
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Figure ‎5-1 Ex vivo IL-10 positive human T cells are rare, not STAT3 dependent and 
mainly produced by memory CD4+T cells 
A. Representative flow cytometry analysis of intracellular IL-10 expression by CD4+ T 
cells (CD3+CD4+) cells in a normal control(Con) and patient with ADHIES after 4 
hours stimulation with PMA+ ionomycin and brefeldin-A. B. Summary % of IL-10 
production by CD4+ T cells. ADHIES (red filled circle) and controls, n=5 (grey filled 
circles). C. Summary % of IL-10 production by RA+(CD45RA+) naïve and RA-
(CD45RA-) memory CD4+ T cells in controls ( n=5). Mann - Whitney test P <0.05. 
 
5.3 IL-10 can be induced in CD4+ T cells in a STAT3-dependent way 
 
Although we did not detect any significant difference in the proportion of ex vivo IL-
10-positive CD4+ T cells between the two groups (Figure 5.1A-B), we proceeded to 
investigate the possibility that STAT3 might contribute to induction of IL-10 after 
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activation. PBMCs from a normal control and a patient with AD-HIES were 
stimulated with IL-21 in the presence of CD2/3/28 for 2 days. The ability to 
phosphorylate STAT3 in response to IL-21 is retained in patients with AD-HIES, as 
the syndrome usually results from missense mutations that result in amino acid 
substitutions in the DNA binding domain (Figure 5.2 A-B) or the SH2 domain. There 
was a significant induction of IL-10 in controls, which was not seen in the AD-HIES 
cells (Figure 5.2 C-D). 
 
 
 
Figure ‎5-2  IL-21 can induce STAT3 dependent IL-10 production from human CD4+ T 
cells 
A. Representative histogram of the level of pSTAT3 in a control and a patient with 
AD-HIES before and 20 minutes after stimulation of IL-21(100ng/ml), (unstimulated, 
grey filled. Stimulated, red unfilled). B. Summary of mean fluorescence intensity 
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(MFI) of pSTAT3 in CD4+ T cells, either left unstimulated or after 20 minutes 
stimulation with either IL-6 (200ng/ml) or IL21(100ng/ml) in normal controls(n=3). 
C. Representative flow cytometry of flow cytometry analysis of intracellular IL-10 
induced expression by CD4 +T cells (CD3+CD4+) in a normal control and patient 
with ADHIES after stimulating PBMCs with CD2/3/28 with IL 21 (100ng/ml) for 2 
days. D. Summary % of induced IL-10 production by CD4+T cells after 2 days 
stimulation of the PBMCs with CD2/3/28 and IL-21(100ng/ml), in normal controls 
(n= 6) and AD-HIES (n=2). Mann-Whitney: P<0.05.  
 
5.4 STAT3-dependent IL-10 induction is best seen in memory T cells (CD45RA 
negative) 
 
As demonstrated here and elsewhere, naïve CD4+ T cells produce very little IL-
10(Figure 5.1 A)  (Yssel et al. 1992). We analysed CD4+ T cells according to 
expression of CD45RA. Memory CD4+ T cells (CD45RA-) responded to STAT3 
stimulation with greater IL-10 production than their naïve counterparts. By contrast, 
IL-10 induction was impaired in memory CD4+ T cells from ADHIES. Thus, STAT3 
is required for the augmented component of IL-10 production which is best seen in 
memory CD4+ T cells. It remains possible that the diminished responsiveness of 
naïve cells reflects differences in cytokine receptor expression; nevertheless, 
induction of Il-10 appears to be STAT3-dependent (Figure 5.3 A-C). 
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Figure ‎5-3 Memory human CD4+ T cells can induce IL-10 production in a 
STAT3 dependent way 
A. Representative dot plot of IL-10 production in FACS sorted memory CD4+ T cells 
(CD4 +CD45RA-) after 2 days stimulation with CD2/3/28 and IL-21 (100ng/ml) in a 
normal control (con) and a patient with AD-HIES. B. Representative dot plot of IL-10 
production in FACS sorted naive CD4+T cells (CD4 +CD45RA+) after 2 days 
stimulation with CD2/3/28 and IL-21 (100ng/ml) in a normal control and a patient 
with AD-HIES. C. Summary % of IL-10 production by FACS sorted CD4+ T cells 
(naïve vs. memory) after 2 days stimulation with CD2/3/28 and IL-21 in normal 
controls(black unfilled circles= 2) and AD-HIES (red filled circles, n=2). Mann-
Whitney: P<0.05. 
 
5.5 IL-10 is not readily expressed by recently induced Th1 or Th2 cells 
 
 As noted above, murine studies had identified that IL-10 can be detected in cells 
cultured under either Th1 or Th2 inducing conditions. We purified naïve CD4+ T 
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cells and stimulated them with different conditions to induce either Th1 or Th2 cells, 
and then analysed them for expression of IL-10. We found that the frequency of Il-
10+ cells is extremely low in recently induced Th1 and Th2. Moreover, we found no 
difference in the frequency of these rare IL-10+ cells in Th1 or Th2 cells (Figure 5.4 
A-B).   
 
In mice, STAT3-dependent cytokines were shown to be good inducers of IL-10 
production by Th2 cells (Altin, Goodnow, and Cook 2012). We therefore investigated 
this further in human cells. We induced Th0, Th1 and Th2 differentiation from FACS 
sorted naïve T cells in vitro . Cells cultured under Th2 conditions became uniformly 
GATA3 positive compared to Th1 and Th0 (Figure 5.4 C). Cells generated under 
each of the three culture conditions were then stimulated with IL-21. We observed 
sustained STAT3 phosphorylation in each effector cell type in response to this 
stimulus compared to cells out of culture with no additional IL-21 (Figure 5.5 A).  
 
 
 
Figure ‎5-4 IL-10 is not readily produced by recently induced Th1 or Th2 
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A. Representative dot plot of IL-10 production in FACS sorted naive CD4+ T cells 
(CD4 +CD45Ro-) after 4 days stimulation in either Th1( CD2/3/28 + IL-12(20ng/ml)) 
or Th2 (CD2/3/28 +IL-4( 20 µg /ml) conditions. B. Summary % of IL-10 production by 
induced Th1 (n=3) versus Th2 in normal controls (n=2). C. Histogram of GATA-3 level 
in induced Th2 versus those Th1 or Th0 (CD2/3/28+IL-2(80ng/ml)). 
 
5.6 IL-10 can be induced in Th2 after further re stimulation in a STAT3 dependent 
way 
 
Cells cultured under each of the polarizing conditions exhibited sustained pSTAT3 
response when incubated with IL-21 for 2 days (Figure 5.5 A), which suggests that 
STAT3 is active in each subset. Previous reports have shown that activation of either 
STAT4 or STAT3 in Th1 deviated T cells has the ability to induce IL-10 production. 
Our data does not support these findings (Figure 5.5 B) and (Figure 5.6A). This might 
be due to difference in the duration of Th1 induction or the strength of the stimulus as 
it has been shown that strong STAT4 stimulations needed for IL-10 production by 
TH1. 
 
Figure ‎5-5 IL-10 is not readily induced inTh1 even after activation of STAT3 or STAT4 
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A. Histogram of p-STAT3 level in newly induced Th1, Th0 and Th2 before and after 
further re-culture with IL-21(100ng/ml) for 2 days. B. Representative dot plot of IL-10 
production in FACS sorted naive CD4+ T cells (CD4 +CD45Ro-) after 4 days 
stimulation in either Th1( CD2/3/28 + IL-12) alone or supplemented with 2 days of IL-
6 (200ng/ml) or IL-12 (20 ng/ml). 
 
Next, we investigated the outcome of STAT3 signalling in other effector subsets. 
First, recently induced Th2, Th1 and Th0 cells were further cultured with IL-2, IL-6 
or IL-21 for two days, then harvested and examined for IL-10 production. In 
comparison with Th1 cells, Th2 cells (Figure 5.6A-C) exhibited greater augmentation 
of IL-10 production in response to these cytokines. IL-2, IL-6 and IL-21 signal 
through STAT3, but not exclusively, and therefore, in order to prove that STAT3 is 
required for the observed response; we have made use of cells with impaired STAT3 
signalling from patients with AD-HIES. These cells showed a reduced response 
compared to normal controls (Figure 5.7A-C).  
 
Figure ‎5-6  IL-10 can be induced in Th2 subsets after STAT3 re-stimulation 
Representative dot plot of IL-10 production in FACS sorted naive CD4+ T cells (CD4 
+CD45Ro-) after 4 days stimulation in either A. Th1( CD2/3/28 + IL-12, 20 ng/ml) or 
Pathological actions of STAT4, MTOR and STAT3 in human T cell 
differentiation 
  
162 
 
B. Th0 ( CD2/3/28 + IL-2, 80ng/ml)  or in C. Th2( CD2/3/28 + IL-4(20 µg /ml). All 
either before or after 2 days stimulation of these subsets with IL-2 (80ng/ml), IL-6 
(200ng/ml) or IL-21(100ng/ml) in a normal control. 
 
 
Figure ‎5-7 IL-10 can be induced in Th2 subsets in a STAT3 dependent way 
Representative dot plot of IL-10 production in FACS sorted naive CD4+ T cells (CD4 
+CD45Ro-) after 4 days stimulation in stimulation in either A. Th1( CD2/3/28 + IL-12, 
20 ng/ml) or B. Th0 ( CD2/3/28 + IL-2, 80ng/ml)  or in C. Th2( CD2/3/28 + IL-4, 20 
µg /ml). All either before or after 2 days stimulation of these subsets with IL-2 
(80ng/ml), IL-6 (200ng/ml) or IL-21(100ng/ml) in a patient with AD-HIES. 
 
5.7 Discussion and Summary 
 
We demonstrated here that there is a basal IL-10 production by CD4+ T cells that is 
STAT3 independent and an inducible component of the IL-10 by Th2 cells, which is 
STAT3-dependent. 
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AD-HIES patients exhibit some features of chronic Th2-mediated immunopathology, 
such as rashes, high eosinophil count and very high IgE level. It has been already 
shown that defective STAT3 signalling in these patients compromises the formation 
of telorogenic antigenic presenting cells in response to IL-10 (Saito et al. 2011) 
leading to formation and production inflammatory cytokines. 
 
IL-10 is widely known as an immunomodulatory cytokine that counteracts excessive 
immunopathology associated with uncontrolled Th1 (Gazzinelli et al. 1996; Li, 
Corraliza, and Langhorne 1999) (Kuhn et al. 1993; Berg et al. 1996; Sato et al. 2006; 
Engelhardt et al. 2013; Engelhardt and Grimbacher 2014) (Glocker et al. 2010; 
Kotlarz et al. 2012; Glocker et al. 2009; Lee et al. 2014) or Th2 induction (Altin, 
Goodnow, and Cook 2012; Ankathatti Munegowda et al. 2012) (Delprete et al. 1993; 
Altin, Goodnow, and Cook 2012). IL-10 acts indirectly through antigen presenting 
cells as well as directly by inhibiting proliferation and cytokine production by T cells.  
 
Moreover, IL-10 production by murine Th1 requires high concentrations of IL-12 and 
strong TCR stimulation, and depends on STAT4 and ERK signalling (Saraiva et al. 
2009). Therefore, it would be expected that individuals with high STAT4 signalling 
would have higher frequency of IL-10 CD4+T cells. However, the ex-vivo frequency 
of IL-10 producing cells in the proband and sibling carrying STAT4
P450S
 gain of 
function was not high. Furthermore, stimulating naïve CD4+T cells under Th1 
inducing condition did not yield higher frequency of IL-10 compared to those of Th2, 
both of which conditions had almost negligible amount of basal IL-10 production. 
Therefore, in human STAT4 does not appear to support IL-10 production. 
 
The high level of IgE and other manifestation of chronic Th2 immunopathology have 
not been explained. In animal model it has been shown that chronic Th2 stimulation 
is associated with induction of IL-10 regulatory Th2 subset. This IL-10 producing 
Th2 subset despite the fact that they remain Foxp3 negative, they exert regulatory 
function to counteract the excessive Th2 phenotype. 
Pathological actions of STAT4, MTOR and STAT3 in human T cell 
differentiation 
  
164 
 
 
The data presented here have demonstrated that the STAT3 stimulation in human as 
well support the formation of this inducible subset from Th2 polarised cell. 
Therefore, it plausible that, deficiency in this inducible Treg phenotype in Th2 CD4+ 
T cells is one of the reasons toward the chronic Th1 immunopathology seen in the 
AD-HIES. 
 
 
CHAPTER 6 : STAT3 REGULATE CYTOTOXICITY IN 
CD57+ CD4+ T CELLS 
 
6.1 Introduction 
 
Follicular helper CD4+ T cells (TFH) are specialized T cells accumulate in the follicles 
of secondary lymphoid organs by virtue of CXCR5 expression and CCR7 down 
regulation. TFH also express high level of PD-1 (Ansel et al., 1999; Förster et al., 1996; 
Hardtke et al., 2005) (Breitfeld et al., 2000; C. H. Kim et al., 2001; Schaerli et al., 
2000). In humans, but not mice, a significant subset of human TFH cells express CD57 
(Bentebibel et al., 2011; C. H. Kim et al., 2001). CD57 expression (encoded by 
B3GAT1) is sometimes considered a hallmark of senescence (Brenchley et al., 2003) 
and germinal centre CD57+ CD4+ T cells exhibit limited capacity to make IL-2, 
another characteristic of observed in replicative senescence (Velardi et al., 1986).There 
is mixed evidence with regard to the relative propensity of the CD57+ and CD57- 
subsets to provide help to B cells in the tonsil (J. R. Kim et al., 2005; Rasheed et al., 
2006), and to date there is no other evidence that this subset is functionally distinct 
from CD57- TFH cells. Circulating counterpart of TFH cells (cTFH) CD4+ T cells in 
the blood are also though to am lower level express CXCR5+, PD-1+ and some of this 
subset are also CD57 +. They are expanded in various autoimmune diseases, including 
SLE, juvenile dermatomyositis and rheumatoid arthritis (Craft, 2012; Morita et al., 
2011; Simpson et al., 2010). 
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Although originally CD57 was restricted to identify NK cells, now it is well established 
that it is expressed by CD8+ T cell as well and to a lesser extent by CD4+ T cells. 
CD57+ CD4+T cell subset is expanded in the context of chronic immune 
activation(Fleischer 1984) such as in infections with EBV or HIV  (Palmer et al. 2005) 
, some autoimmune diseases such as rheumatoid arthritis (Maeda et al. 2002; Appay 
2004) and IgG4 related disease (Mattoo et al. 2016). IL-2-dependent expression of 
CD57 is observed on a subset of NK cells, which are characterised by attenuated 
responsiveness to cytokines (Lopez-Vergès et al., 2010). Within the CD8+ T cell and 
NK cell compartments, CD57 expression also correlates with cytotoxic potential 
(Chattopadhyay et al., 2009; Lopez-Vergès et al., 2010). In addition, it was shown that 
CD4 + T cell capable of being cytotoxic and this ability is under the control of CRTAM 
(Takeuchi et al. 2016).  
 
AD-HIES due to heterozygous missense mutations in STAT3 results in a cell intrinsic 
reduction in memory CD4+  T cells, a reduction in CXCR5+ cells as a proportion of 
CD4+ T cells, (Freeman and Holland, 2010; Holland et al., 2007; Ma et al., 2012; 
Mazerolles et al., 2013; Minegishi et al., 2007; Siegel et al., 2011) (de Beaucoudrey et 
al., 2008; Ma et al., 2008; Milner et al., 2008). On the other hand a new syndrome of 
immunodeficiency as well as autoimmunity and lymphoproliferation has been 
described in association with STAT3 gain of function (Milner et al. 2015). 
 
The relationship of dissection of senescence versus exhaustion is not clear for CD4+ 
T cell and if there is any role for STAT3 in regulating this process is not clear. For 
this aspect, we revisited the questions of CD57 being a surrogate marker for TFH, 
possible cytotoxic function of CD57 CD4+ T cells in human by examining both TFH 
cells from secondary lymphoid tissue (tonsil) and comparing it to circulating TFH 
(cTFH). Moreover, we were also interested to find out the role of STAT3 in their 
generation and function of these circulating and cytotoxic CD57+ CD4+ T cells. 
Therefore, we made use of the LoF and GoF STAT3 to clarify this.  
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6.2 CD57 expression correlates with PD-1 in tonsil but not blood 
 
We examined the distribution of follicular T cells in tonsils. Normally, CD57+ CD4+ T 
cells represent a small proportion of GC TFH cells enriched in the light zone of GCs 
(Figure 6.1A). By direct immunofluorescence, CD57 expression coincides with PD-1 
expression (Figure 6.1B). Concordance of CD57 and high levels of PD-1 expression 
was confirmed by flow cytometric analysis of single cell suspensions. In fact, co-
staining of these two markers has revealed four populations among CD4+ T cells in the 
tonsil and almost all CD57+ cells express high levels of PD-1 (Figure 6.1C). PD-1
high
 
CD57+ CD4+ T cells were mainly present in the secondary lymphoid organs compared 
to peripheral blood when examining paired tonsils and blood samples from the same 
donor (Figure. 6.1D). Moreover, expression of CD57 is biased towards CXCR5+ T 
cells (TFH) in the tonsil compared to blood.  In fact in the blood, most CXCR5+ T cells 
(cTFH) are PD-1
low
, but CD57 expression identifies cells expressing higher levels of 
PD-1(Figure 6.1E).  After gating on PD-1
hi
 cells in tonsils, approximately 90% of 
CD4+ T cells co-express CXCR5 irrespective of whether they are CD57+ or CD57- 
(Figure 6.1F-G). Moreover, the level of CXCR5 expression is similar on PD-1
hi
 cells 
irrespective of CD57 expression(Haynes et al., 2007) (Crotty, 2011; Ma et al., 2009).  
CD57 and PD-1 are not expressed by the naïve CD4+ T cells (CD45RA+ 
compartment) (Figure 6.1F).  
 
We have shown that tonsil CD4+ T cells are classified according to PD-1 and CD57 
expression into four distinct memory populations. CD57 identify PD-1 high CXCR5 
high TFH cells in the tonsil. In comparison, in the blood, CD57 identifies those rare 
subsets with the highest PD-1 level and CXCR5+ T cells (cTFH) but it is also 
expressed in the CXCR5- T cells memory population. 
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Figure ‎6-1 Distribution of CD57+ CD4+ T cells in blood and tonsil 
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A-B. Immunohistological and confocal analysis of CD57+ T cells in sections of tonsil, 
stained for CD57, CD3 and IgD (A) and IgD, PD-1 and CD57 (B). High power analysis 
of individual cells is shown at the left. C. Representative flow cytometry analysis of T 
cell subsets of four CD4+ T cell tonsil subsets determined by PD-1 and CD57 
expression in tonsil. D. Summary of flow cytometric analysis of single cell suspensions 
from PBMCs (n=2) and from tonsil (n=6), indicating the proportion of cells within the 
indicated subsets. E. Analysis of CXCR5 and PD-1 expression in a paired sample gated 
on total CD4+ T cells and then on CD57 status. F. Analysis of CXCR5 and CD45RA 
expression by the four tonsil subsets obtained from the co-staining of PD-1 and CD57. 
G. Overlay histogram of the level of CXCR5 expression by the four subsets as defined 
in C. Summary of mean fluorescence level of CXCR5 expression in the four defined 
subset as in C.  
 
6.3 CD57+ CD4+ T cells exhibit attenuated cytokine production 
 
Now, having shown that CD57 identifies TFH cells (PD-1
hi
 cells and CXCR5+ T cells) 
in the tonsil but identify cells with PD-1
hi
 among cTFH and non cTFH, we were 
interested to examine the functional ability of these different subsets (according to PD-
1 and CD57) by examining the cytokine expression. Initially examining paired blood 
and tonsillar samples from the same donor, has revealed a significant bias towards IL-
17, IL10, and IL-21 production in tonsil (Figure 6.2A). In other words, there is a 
relative increase in production of STAT3-dependent cytokines within tonsil. We also 
examined cytokine expression in different four tonsil subsets according to CD57 and 
PD-1 expression. PD-1
hi
 are relatively enriched for IL-4 (Figure 6.2B-C). Interestingly, 
while IL-4 predominates in CD57+ cells relative to other cytokines, IL-10 and IL-21 
predominate in the CD57- PD-1
hi
 subset (Figure 6.2B-C). Although PD-1
hi
 CD4+ T 
cells are rare in peripheral blood, a relatively high proportion of them produce IL-21 
and IL-10 (Figure 6.2D). Indeed, expressed as a proportion of the total subset, the bias 
towards IL-21 production by PD-1
high
 cells is even greater in blood than tonsil. 
Interestingly, cytokine production is attenuated in the CD57+ subset. Relative to PD-1
hi
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CD57- cells, far fewer tonsil cells in the CD57+ PD-1
hi
 double positive fraction express 
either IL-10 or IL-21.  
 
TFH populations can also be sub classified according to chemokine receptor 
expression, which is sometimes taken as a surrogate for cytokine production and 
capacity to provide help to B cells. Consistent with the intracellular cytokine analysis, 
few CD57+ cells express CXCR3, and almost none express CCR6 (Figure 6.2E). 
Expression of these chemokine receptors is more abundant on tonsil CD4+ T cells with 
lower levels of PD-1 expression (Figure 6.2E-F). Overall, PD-1
hi
 cells exhibit a similar 
cytokine phenotype in blood and tonsil, and CD57 identifies a subset with attenuated 
cytokine production and chemokine receptor expression. 
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Figure ‎6-2 Cytokine production by cell according to PD-1 and CD57 expression 
A. Summary plot of the relative abundance of intracellular cytokine as indicated in 
paired blood and tonsils (n=7 for IFN-, IL-17, IL-4, IL-10 and n=4 for IL-21 
assessment). B. Representative plot of intracellular cytokine detection in FACS sorted 
four tonsil subsets according to the CD57 and PD-1 expression as in (figure 5.1 C). C. 
Summary plot % of CD4 + T cells positive for indicated intracellular cytokine in the 
four subsets in the four FACS sorted tonsil subsets (n=2) as in (figure 5.1 C) .D. 
Summary plot of the relative abundance of intracellular IL-10 (n=4) and IL-21 (n=5) 
production by the four subsets according to PD-1 and CD57 expression as in (figure 5.1 
C) in paired blood and tonsil.  Each symbol represents the result from an individual. E. 
Representative flow cytometry analysis of expression of CXCR3 and CCR6 in different 
subsets of CD4+ T cells defined in(figure 6.1 C) and the summary data for similar 
analysis (F), n=5.  
 
6.4 STAT3 responsiveness is impaired in PD-1high CD4+ T cells  
 
Having established that STAT3-dependent cytokines are enriched within tonsil, and 
that two of these (IL-10 and IL-21) are abundantly expressed within PD-1
hi
 CD4+ T 
cells in blood and tonsil, we proceeded to examine responsiveness to STAT3-
dependent cytokine stimuli within the CD4+ T cells compartment. We sorted tonsil 
CD4+ T cells into four populations according to PD-1 and CD57 expression, and 
examined STAT3 phosphorylation, expression of IL-4 and IL-10, and induction of IL-
10 in response to IL-6 or IL-21. We observed an inverse relation between PD-1 
expression and pSTAT3 induction in response to IL-21, with virtually no expression in 
PD-1
high
 CD57+ cells containing pSTAT3 (Figure 6.3 A).The pSTAT3 response to 
various cytokines within Tregs is shown for comparison. We observed a reduction in 
pSTAT1 signalling in response to IFN-γ in PD-1hi cells, suggesting that this state of 
unresponsiveness is not restricted to STAT3 signalling cytokines. STAT3 signalling is 
not globally compromised, however, as pSTAT3 was detected after stimulation with 
IL-6.  
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Next we examined the same populations of cells for expression of IL-4 and IL-10 
analysed immediately ex vivo, or after stimulation in vitro  (Figure 6.3 B). As noted 
earlier, IL-10 production as a proportion of CD4+ T cells was greatest in PD-1
hi
 CD57- 
T cells, and was attenuated in the CD57+ subset. Activation of FACS sorted CD4+ T 
subsets with anti-CD2/3/28 and either IL-6 or IL-21 resulted in induction of IL-10 by 
PD-1
med
 cells. We saw no cytokine induction in CD57+ PD-1
hi
 cells (Figure 6.3 B).  
 
Next, we examined the same purified CD4+ T cell populations for proliferation and 
cytokine production in response to stimulation with anti-CD2/3/28 in the absence of 
exogenous cytokines (Fig. 6.3C). CD57- CD4+ T cell population exhibited a similar 
response to stimulation irrespective of PD-1 expression. By contrast, CD57+ cells 
exhibited a marked defect in proliferation. Fewer cells entered cycle, and those that did 
progressed through fewer cell divisions than CD57- CD4+ T cells. Examination of 
cytokine production confirmed the relative unresponsiveness of CD57+ cells. 
Interestingly, we observed IL-21 induction in the absence of any polarizing stimulus, 
and this was more marked in PD-1
low
 cells (Figure 6.3 C).  
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Figure ‎6-3 Responsiveness of CD57+ CD4+ T cells 
A. Overlay histogram of phosphorylation of STAT3 and STAT1 after stimulation of 
each PD-1 and CD57, CD4+ T cell subset with either IL-6(200ng/ml), IL-21(100ng/ml) 
or IFN-(10 U/ml). Responses in Treg (CD4+CD25+CD127-) are shown for 
comparison. Unstimulated (filled grey) and stimulated (unfilled red). B. Flow 
cytometry analysis of ex-vivo and induced intracellular IL-10 and IL-4 expression after 
stimulation of purified subsets with either IL6 (200ng/ml) or IL-21(100ng/ml) for 2 
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days. C. Flow cytometry analysis of proliferation and induction of intracellular 
expression of IL-21 or IFN-γ by purified cells from each of the indicated subsets.     
 
6.5 CD57+ CD4+ PD-1high T cells are not T follicular regulatory cells 
 
Since CD57+ cells irrespective of PD-1 expression, appear to be less able to make 
cytokines or proliferate, we wondered whether this subset might harbour T follicular 
regulatory cells (TFR). This does not appear to be the case, since CD25+ CD127
lo
 cells 
are predominantly CD57- (Figure. 6.4 A-B). Conversely, CD57+ cells are 
predominantly located in the CD25- CD127- compartment. In addition, the small 
population of CD25+ CD127- cells in tonsil those are CD57 +, are FOXP3- in the 
tonsil and in the blood (Figure. 6.4 C). Gating on TFH by PD-1 and CXCR5, 
approximately 24% of CD25+ cells express CD57, while 40% of the much larger 
CD25- fraction are CD57+(Figure. 6.4 D-E).  Consistent with data shown above, 
analysis of conventional Tregs and conventional memory T cells shows that IL-10 
production is confined to the CD57- population (Figure. 6.4 E-G). 
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Figure ‎6-4 CD57+ CD4+ T cells are not enriched with TFR cells 
A. Flow cytometry analysis of CD4+ tonsillar T cells that are either CD25+ CD127- or 
CD25- CD127- cells for expression of CD57 and PD-1. B. Summary plot of A (n=4). 
C. Flow cytometry analysis of FOXP3 and CD57 expression in CD127- that are either 
CD25+ or CD25- cells obtained from either blood or tonsil. D. Flow cytometry analysis 
of TFH cells (gated on CXCR5 and PD-1)  for proportion of CD25 and CD57 and  E. 
Summary plot proportion of CD57+ in either CD25+ or CD25- cells (n=4)TFH cells 
(CXCR5+ PD-1 
hi
 ) in the tonsil. F. Analysis  by flow cytometry  for CD57 and 
intracellular expression of IL-10 cells after gating on indicated TFR phenotype 
CXCR5+PD-1 
lo 
  according to CD25 and CD127 expression . G. Summary plot 
proportion of F (n-4). 
 
6.6 CD4+ CD57 TFH cells exhibit a cytotoxicity gene expression signature 
 
So far we shown that regardless of CD57 status, PD-1
high
 CD4+ T cells have reduced 
cytokine production and proliferation capacity. Therefore, failing to demonstrate any 
difference in these two aspects between CD57+ and CD57 – CD4+ T cells.  We then 
investigated possible functional differences between CD4T cells that are either CD57+ 
or CD57- cells by examining their gene expression signature. We purified PD-1
high
 
CD4+ T cells from tonsils according to expression of CD57. For comparison, we 
purified PD-1
lo
 cells (CD45RA-) from the same tonsils, and analysed them for gene 
expression using RNASeq. Overall, we observed considerable similarity between 
expression patterns in CD57+ and CD57- PD-1
hi
 CD4+ T cells, nevertheless, we 
identified some important differences (Figure 6.5 A) Consistent with cellular 
phenotyping, we observed a relative bias towards IL-17 and IFN- within CD57- cells. 
By contrast, we noted increased expression of EOMES, WNK2 and PRDM8 in the 
CD57+ subset (Figure 6.5 B). Analysis of gene expression in each PD-1
hi
 population 
relative to PD-1
lo
 cells identified a number of additional possible signals. Genes 
exhibiting greater expression in CD57+ cells included GZMA, CRTAM, and IL21, while 
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LAG3, TNFRSF11A, CD248 were expressed at lower levels in the CD57+ subset 
(Figure 6.5 C). 
 
 
 
Figure ‎6-5 Analysis of global gene expression 
PD-1hi CD57+, PD-1hi CD57- and PD-1lo CD57- cells were purified and then 
analysed for gene expression by RNASeq. A. Comparison of each subset. Results show 
three biological replicates in each group. B. Analysis of relative expression in PD-1hi 
CD57+, PD-1hi CD57- cells. Genes of interest are highlighted (red).C. Comparison of 
PD-1hi CD57+ with PD-1lo and PD-1hi CD57- with PD-1 lo reference data. 
 
CRTAM (MHC class-I restricted T cell associated molecule) has been reported recently 
as a master regulator of CD4+ cytotoxic T cells in mice (Takeuchi et al., 2016). We 
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proceeded to analyse CD57+ and CD57- cells a for intracellular CRTAM protein 
expression. In tonsil, only a small proportion of CD57+ cells co-express CRTAM, but 
very few CRTAM+ cells are present in the CD57- population (Figure 6.6 A). Thus, the 
proportion of CRTAM+ cells in the CD57+ population is about twice that in CD57- 
cells in the tonsil (Figure 6.6 B). Similar analysis of circulating CD57+ cells revealed a 
more substantial bias to CRTAM expression (Figure 6.6 A-B). As noted above, the 
CD57+ population in blood is small, nevertheless, approximately 30% of these cells 
express CRTAM protein. As a result, the proportion of CD57+ cells that are CRTAM+ 
cells is approximately 8-fold greater than in CD57- cells.  
 
CRTAM is identified as a master regulator of cytotoxic CD4+ T cells, we also 
examined CD57+ and CD57- cells for additional cytotoxicity related proteins. 
Consistent with gene expression, we observed a small proportion of granzyme-A cells 
within the CD57+ compartment in tonsil, and a more substantial proportion on 
circulating CD57+ cells (Figure 6.6 C-D). On analysis of all four tonsil subsets 
(defined by PD-1 and CD57-), we observed most granzyme positive cells are located 
within the CD57+ PD-1
hi
 population (Figure 6.6 D). Similarly, in blood, almost all 
granzyme-A cells are CD57+. 
 
We tested whether expression of CRTAM and granzyme, together with the cytotoxicity 
transcriptional signature, translates into a granzyme-perforin mediated functional 
cytotoxicity phenotype. We purified CD57+ and CD57- PD-1
hi
 CD4+ T cells and co-
cultured these with B cell targets. After 1 hour, pre-labelled target cells were analysed 
for intracellular perforin. We observed a small but consistent increase in cytotoxicity 
mediated by CD57+ cells (Figure 6.6 E). 
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Figure ‎6-6 Cytotoxicity phenotype in CD57+ CD4+ T cells 
A.  Flow cytometry analysis of intracellular CRTAM expression in tonsil and blood 
CD4+ T cells. Tonsils gated on PD-1hi CD57- or PD-1hi CD57+; PBMCs gated on 
CD57+ or CD57-. B. Summary plot of relative CRTAM expression in each subset 
gated in (A) in blood (n=8) and tonsil (n=6). C. Flow cytometry analysis of 
intracellular granzyme-A expression in tonsil and blood. Tonsils gated on PD-1hi 
CD57- or PD-1hi CD57+; PBMCs gated on CD57+ or CD57-. D. Summary of relative 
granzyme positive cells in PBMC (n=2) and tonsil (n=3) according to PD-1 CD57 
subsets. E. Flow cytometric analysis of cytotoxicity of target cells co-cultured with 
CD57+ or CD57- CD4+ T cells, with summary plot of similar experiments (right panel, 
n=2). 
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6.7 STAT3 regulates CD4+ T cell cytotoxicity independently of exhaustion 
 
Finally, we were interested to investigate possible pathways that regulate abundance of 
CD57+ CD4+ T cells both within the CXCR5+ follicular compartment, and in the 
periphery. Our previous results had demonstrated that in humans, STAT3 
haploinsufficiency (loss-of-function, LoF), observed in patients with autosomal 
dominant hyper IgE syndrome, results in a reduction in CXCR5+ CD4+ T cells in 
blood(Ma et al., 2012) (Figure 6.7 A-B). More comprehensive analysis of blood from 
these patients reveals that despite the deficiency in cTFH, there is an increase in PD-1
hi
 
CD4+ T cells (Figure 6.7A). Indeed, when PD-1
 high
 cells are expressed as a proportion 
of each parent population, STAT3 deficiency results in a relative increase of PD-1
hi
 
cells in both CXCR5+ and CXCR5- populations in the peripheral blood (Figure 6.7 C-
D). The proportion of CD57+ cells is increased in the peripheral blood, and as in 
normal tonsil, this increase is predominantly within the PD-1
high
   population, but unlike 
in tonsil, in STAT3 LoF these cells are mostly both CXCR5+ and CXCR5- populations 
(Figure 6.7 A).  
 
We also examined blood from rare individuals with STAT3 gain-of-function (GoF) 
mutations, which confers a phenotype of antibody deficiency and autoimmunity 
(Flanagan et al., 2014; Haapaniemi et al., 2015; Milner et al., 2015). Thus, as with 
STAT3 LoF, lymphocytes from these patients are expected to be under chronic 
antigenic stimulation (either self- or foreign antigen). In CD4+ T cells STAT3 GoF 
patients, we observed an expansion of cTFH cells (Figure 6.7A-B). Relative to normal 
blood samples, this is associated with an increase in the proportion of PD-1
hi
 cells, but 
not as marked as observed with STAT3 LoF (Figure 6.7C-D). By contrast, there was no 
expansion of CD57+ cells (Figure 6.7 A). Furthermore, the distribution of CD57 was 
similar to that observed in normal blood, with similar low CD57 expression in both PD-
1
hi
 and PD-1
lo
 CD4+ T cells. The surface phenotype suggested that STAT3 LoF results 
CXCR5- cells adopting a phenotype similar to that observed in CXCR5+ cells (in 
tonsil) compared to normal individuals (Figure 6.7 C-D),more of exhausted phenotype 
marked by PD-1
 high
  and CD57+  regardless of the CXCR5 status.  Consistent with this 
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observation, analysis for CRTAM and granzyme expression is similar in tonsil and 
STAT3 LoF PBMC. By contrast, STAT3 GoF results in a substantial increase in 
CRTAM and granzyme-A expression similar to seen in normal controls (Figure 6.7 F-
G). Taken together, these findings reveal that the CD57+ exhaustion phenotype and 
cytotoxicity phenotypes can be dissociated, and that normal STAT3 promotes 
cytotoxicity without exhaustion.  
 
 
Figure ‎6-7 STAT3 influence on CD4+ T cell cytotoxicity 
A. Flow cytometry analysis of abundance of CD57+ cells in CXCR5+ and CXCR5- 
compartments in blood from patients with STAT3 loss-of-function (LoF), gain-of-
function (GoF) mutations, or from PBMC of normal donors, or tonsil. B. Summary plot 
of TCH cells (CXCR5+ CD45RA-) cells from STAT3 GoF(n=3), STAT3 LoF (n=9)or 
normal donors. C-D. Summary plot of abundance of PD-1hi cells (as a percentage of 
total CD4+ T cells) in CXCR5- (C) and CXCR5+ (D) compartments in PBMCs from 
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STAT3 GoF(n=3), LoF(n=4), healthy donors(n=7) or tonsil(n=5). E. Summary plot of 
abundance of CD57+ cells in CCR7+ compartments in PBMCs from STAT3 GoF(n=3), 
LoF(n=2), healthy donors(n=7) or tonsil(n=5). F-G. Representative flow cytometry 
analysis of intracellular CRTAM expression in PBMCs from STAT3 GoF and STAT3 
LoF patient, with summary plot of similar analyses (G) STAT3 GoF(n=1) and STAT3 
LoF patient(n=2), healthy donors(n=7) or tonsil(n=6 ).    
 
6.8 Discussion 
 
We have presented evidence that CD57 expression identifies cells with cytotoxic 
potential, and a subset of these cells demonstrates overt cytotoxic activity. This 
function is flagged by expression of CRTAM, recently identified in mouse CD4+ T 
cells, as a master regulator of the CD4+ cytotoxic T cell subset (Takeuchi et al., 2016). 
Our findings are therefore consistent with CRTAM performing a similar function in 
human CD4+ T cells. We show that CD57 identifies cells with cytotoxic potential in 
both blood and tonsil, although this association is accentuated in circulating cells. Our 
findings indicate that while CD57 identifies the subset of CD4+ T cells that are either 
have exhausted phenotype or cytotoxic function; this distinction can be dissociated 
according to the intensity of STAT3 signalling. 
 
Using blood and tonsil samples from the same donors, we show that there is an overall 
deviation towards increased PD-1 expression in tonsil relative to blood in each well-
defined T cell subset analysed. This means there is also a much greater abundance of 
PD-1
 high
 cells in tonsil than blood. Furthermore, T cell function varies with PD-1 
expression. We show that cytokine production varies qualitatively according to PD-1 
expression, although the level of PD-1 expression does not correlate well with 
proliferative potential. Thus, there is no conclusive evidence that PD-1 by itself reads 
out exhaustion. Nevertheless, a subset of tonsillar CD4+ PD-1 high T cells express 
CD57, and these cells acquire an exhausted phenotype of diminished proliferative 
potential, and reduced chemokine receptor expression, and cytokine production. It has 
been known for some time that this subset produces less IL-4  than their CD57- 
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counterparts (Bowen et al., 1991; Butch et al., 1993). CD57+ cells simultaneously 
adopt the potential for cytotoxicity. In tonsil, where CD57 only occurs on PD-1 high 
cells, the cytotoxic potential is also attenuated relative to CD57+ counterparts in blood, 
where PD-1
hi
 cells are rare.  
 
Senescence and exhaustion within the CD4+ T cell compartment remain incompletely 
understood. There is much more information about these two phenotypes in the CD8+ 
T cell compartment, and here, exhausted cells express a range of inhibitory molecules, 
including PD-1, TIM3, CD244, and CTLA4, and generally exhibit a relative defect in 
IL-2 production(Crawford et al., 2014). In chronic viral infection, exhausted T cells are 
characterised by increased expression of IL-10, and chronic murine viral infection is 
associated with enhanced IL-21 production by CD4+ T cells (Elsaesser et al., 2009). 
Indeed, chronic infection has been reported to promote adoption of the TFH phenotype 
(Fahey et al., 2011). Since mice do not express CD57, these studies have not 
determined whether exhaustion or indeed the TFH phenotype that arises in states of 
chronic antigenic stimulation might be associated with cytotoxicity in a subset of these 
cells. Within the human NK cell compartment, CD57 expression is associated with 
lytic activity, but with decreased responsiveness to cytokines (PMID20733159), and is 
marked by induction of Eomes (Lopez-Vergès et al., 2010). 
 
We demonstrate that there is not only a bias towards more PD-1 expression in tonsil 
(for any given subset), but also a bias towards production of STAT3-depependent 
cytokines. It is of interest, and somewhat paradoxical that we also show that the 
cytotoxic potential of CD57+ CD4+ T cells is enhanced by STAT3 signalling, with 
increased expression of CRTAM and granzyme-A, whereas impaired STAT3 signalling 
is associated with increased abundance of CD57+ CD4+ T cells, but not an increase in 
cytotoxicity. As TFH cells acquire the PD-1
 high
 CD57+ phenotype they also become 
refractory to STAT3 signalling. The bias towards STAT3-dependent cytokines within 
tonsil implies that there are other CD4+ T cell subsets that respond well, and this 
appears to be the case based on isolation and stimulation of cells according to PD-1 
expression. Indeed, STAT3 appears to be important for TFH to form in the first place, 
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as CXCR5+ cells are less abundant in patient with STAT3 LoF, and as we show here, 
more abundant in patients with STAT3 GoF. Nevertheless, within the TFH population, 
STAT3 refractoriness occurs, and this is marked by CD57 expression, high level PD-1, 
and coincides with adoption of potential for cytotoxicity. Consistent with evidence 
from NK cells and mouse models of chronic viral infection, PD-1 high phenotype is 
associated with maximal IL-10 and IL-21 production, but once these cells express 
CD57 they become refractory to signalling, and cytokine production. 
 
Previous investigations have suggested that CD57+ and CD57- cells are similar with 
regard to B cell help (J. R. Kim et al., 2005; Rasheed et al., 2006). Furthermore, both 
CD57+ and CD57- cells express comparable levels of BCL-6 (not shown). Consistent 
with this similarity in B cell help, the difference between CD57+ and CD57- cells, at 
least by transcription, is very small yet significant, with up regulation of EOMES and 
CRTAM.  CRTAM had previously been identified in CD8+ T cells and NK cells, but a 
small fraction (2-5%) of mouse CD4+ T cells are CRTAM+, and also express Eomes 
and granzyme-B. Transgenic expression of CRTAM indicates that it is the master 
regulator of this CD4+ T cell fate. Although CD57+ cells in blood are not universally 
PD-1
hi
, they do exhibit the same cytotoxic phenotype. Indeed, we observed a higher 
proportion of cells expressing of markers of cytotoxicity, granzyme and CRTAM, in 
blood. On the other hand, CD57+ CD4+ T cells are much more abundant in tonsil than 
blood. Thus, in blood there appears to be a constraint on CD57+ cell formation, which 
is not present in tonsil. Conversely, CD57+ cells in blood appear to adopt the cytotoxic 
potential more readily than their tonsillar counterparts.  
 
STAT3 appears to be central to regulation of these phenotypes. As noted, STAT3 
regulates adoption of the CXCR5+ phenotype(Ma et al., 2012). In addition, evidence 
presented here indicates that STAT3 promotes adoption of CRTAM and granzyme 
expression. By contrast, loss of STAT3 signalling, either genetically specified or 
acquired within follicles, correlates with PD-1 and CD57 expression, but not 
accentuation of the cytotoxic phenotype. Indeed, while CD57 expression marks cells 
with a cytotoxic potential, the abundance of CD57+ CD4+ T cells does not predict the 
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proportion that adopt the cytotoxic phenotype. In both tonsils (TFH cells), and analysis 
of circulating T cells from patients with STAT3 LoF , PD-1+ CD57+ cells are abundant, 
but the CRTAM phenotype is relatively uncommon in these cells. By contrast, STAT3 
GoF appears to promote the cytotoxic phenotype without expansion of the CD57 
population in which these cytotoxic T cells arise.  
 
From our analysis we infer that the follicular compartment guards against cytotoxicity, 
while at the same time, cells adopt a phenotype of exhaustion more readily than their 
circulating counterparts. 
 
One possible scenario is that the balance between exhaustion with or without 
cytotoxicity hinges on the relative abundance of IL-2 and STAT3-mediated cytokine 
signals. IL-2 has been shown to promote cytotoxicity amongst NK cells, that can then 
adopt a more cytotoxic phenotype, and simultaneously become CD57 positive  (Lopez-
Vergès et al., 2010). In STAT3 deficiency, IL-2 effects predominate and promotes 
acquisition of CD57 irrespective of whether they are CXCR5+ or negative. Indeed, in 
STAT3 deficiency, this CD57 phenotype dominates in both compartments of CXCR5+ 
and CXCR5- . On the other hand, normal to high STAT3 signalling appears to promote 
cytotoxic phenotype, independently of CD57 adoption. In STAT3 GoF, IL-2 signal is 
not altered.  
 
What has emerged from our analysis is that irrespective of whether CD57 identifies 
exhausted or senescent T cells, their cytotoxic phenotype can be dissociated from this 
surface phenotype by the strength of STAT3 signalling. This observation could have 
several consequences. First, our observation suggests a cell of origin for human 
cytotoxic CD4+ T cells. This might also explain the ontogenic counterpart of large 
granular lymphocytes in leukaemia, which are often CD57+ and develop in states of 
chronic antigen stimulation (Lamy). Second, the decision between help and 
cytotoxicity appears to be part of a continuum, and while there are conditions that 
operate within the GC that appear to result in a bias away from cytotoxicity, relative to 
CXCR5+ cells that are found in the blood, there remains a small and measurable 
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cytotoxic subset within the TFH compartment. This might explain the paradoxical 
coincidence of antibody deficiency and autoimmunity which is observed with some 
forms of primary immune deficiency. Mutations that result in enhanced TFH formation 
might in some GCs also result in expansion of the cytotoxic subset. Indeed, this 
paradoxical association is observed in patients with STAT3 GoF mutations.  
 
Finally, our observations might have therapeutic potential. There is already 
overwhelming evidence that interruption of ligation of PD-1 can enhance anti-tumour 
responses, and alter the natural history of several types of cancer (Brahmer et al., 2012; 
Topalian et al., 2012). At present, it remains unclear whether this action is attributable 
to CD4+ T cells. In the light of our findings, monitoring CRTAM expression within 
CD57+ cells, PD-1+ compartment might be a useful strategy for assessing cancer 
immunotherapy. Beyond this, our observations raise the possibility that at least some of 
this effect might be the result of induction of cytotoxicity within CD4+ T cells. If this 
were the case, the action would be predicted to be even greater with concurrent use of 
treatments that enhanced STAT3 signalling. 
 
CHAPTER 7 OVERALL SUMMARY AND DISCUSSION 
 
The signals involved in shaping the faith of these subsets and their terminal 
differentiation include strength and duration of the TCR signalling, presence of 
specific costimulatory or co-inhibitory molecules as well as the presence of specific 
cytokines that mediate their signalling through a specific STAT molecules shape the 
faith of the T cell lymphocytes in assuming one pathway or another. Similarly CD8 T 
cells differentiate into different subset; naïve, Tcm, Tem and Temra , and this 
differentiation process is influenced by similar factors including strength and duration 
of TCR signalling, cytokines and their STAT molecules as well as mTOR.    Most of 
the available information are based on animal studies. 
 
The information gained from animal model is invaluable to understand paradoxical 
association of immunodeficiency that might also present as autoimmunity and 
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inflammation. However, the presence of rare human with specific mutations is crucial 
to confirm or refute the importance of a proposed pathway or mechanism that is also 
shared by other common autoimmune or inflammatory diseases in human. We aimed 
to elucidate mechanism of such diseases using two approaches. 
 
First, a discovery project in which we identified a proband who presented with both 
inflammation and recurrent infections, including bronchiectasis by the age of 4 years 
old associated with hypergammaglobulinaemia. Whole exome sequencing revealed 
novel mutations in STAT4 and MTOR.  
Analysis of the whole exome sequencing, cellular phenotype and the functional 
analysis has shown that STAT4
P450S
 is a novel and cytokine dependent mutation in the 
DNA binding domain (Takezaki et al. 2012; Yamazaki et al. 2014). Most of the 
reported DBD mutation in STATs molecules were gain of function(Faitelson et al. 
2014) , (Sampaio et al. 2013) and (Uzel et al. 2013) and (Frans et al. 2014; Takezaki 
et al. 2012; Yamazaki et al. 2014; Sampaio et al. 2013). Similarly, STAT4
P450S
 is a 
gain of function with prolonged phosphorylation (Figure 3.7 A-D) and binding to the 
nucleus (Figure 3.7 E). The prolonged binding was associated with prolonged 
transcription of IRF1 (Figure 3.8 A-D) explaining the excessive formation of IFN-γ, 
T-bet up regulation and Th1 formation (Figure 3.9 B). We also observed enhanced 
IL-21 expression in cTFH cells, as a result of STAT4 gain of function (Figure 3.10). 
This was also replicated in the in-vitro system of inducing TFH using IL-12 as a 
stimulus (Figure 3.10-E-H). Our findings provided the first in vivo evidence for the 
importance of STAT4 for human Th1 (IFN-), T-bet up regulation and TFH 
formation.  
 
We have also discovered a novel MTOR
T2446S
 mutation in the highly conserved 
negative regulatory domain. The dysfunction of which was associated with 
constitutive active mTOR as assessed by level of pS6. So far there is no reported 
human germ line mutation in mTOR though there are reports of PI3KCD mutations 
(Angulo et al. 2013; Lucas et al. 2014) that were shown to cause downstream 
activation of mTOR. The clinical and cellular feature in this cohort is similar to our 
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proband and carrier of MTOR
T2446M
 in terms of expansion of CD8+ T cell effector 
subsets (Temra) and IFN-γ production. The MTORT2446S mutation as well is a gain of 
function that is causing activation of mTOR at the basal level. It is known that mTOR 
is important in CD4 and CD8 effector T cell formation. Moreover, mTOR cross talk 
with STAT4 giving rise to effector CD8 expansion. This cross talk of MTOR
T2446S
 
and STAT4
P450S
 can explain the extreme deviated effector T cells of Th1 phenotype 
(IFN-g) and T-bet expression even at the mucosal surface seen in the patient.  
 
The second approach we adopted to elucidate mechanism of the paradoxical 
association is through examination of T cell differentiation in patients with known 
defects such as in STAT3.  STAT3 LoF mutation result in autosomal dominant hyper 
IgE syndrome (AD-HIES) in which these patients present with unexplained atopic 
manifestations and extreme elevation of IgE. On the other hand, STAT3 GoF 
mutations have been reported in which antibody deficiency occurs concurrently with 
organ-specific autoimmunity. 
 
STAT3 loss of function (LoF) mutations is now well-characterised syndrome that 
results in Th17 deficiency in human. The pathophysiology of the high level of IgE in 
HIES, however, remains enigmatic. The level of IgE does not become high until 
patients reach 1 year of age(Kamei and Honig 1988). Interleukin- 4 (IL-4) response 
as a main Th2 cytokine is a well know inducer of class switching to IgE (Romagnani 
1994; Avery et al. 2008). IL-10 is not readily expressed by recently formed Th1 or 
Th2 cells. IL-10 produced by CD4+ Th2 cells has also been shown to control 
excessive Th2 and IL-4 immunopathology in animal models. Formation of this 
regulatory subset was shown to be enhanced by STAT3-dependent cytokines. We 
have demonstrated here that there is a basal IL-10 production by CD4+ T cells that is 
STAT3 independent. There is also an inducible component of the IL-10 by Th2 cells, 
which is STAT3-dependent in human, similar to the mice data. We propose here, the 
deficiency in this inducible Treg phenotype in Th2 CD4+ T cells is one of the reasons 
toward the chronic Th1 immunopathology seen in the AD-HIES. 
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TFH cells express markers such as PD-1(exhaustion marker) with or without CD57 
(cytotoxic marker) among other markers. Formation and function of TFH and cTFH 
are comprised in patients with AD-HIES (STAT3 LoF) defined by the classical marker 
of CXCR5. However, it is not clear if there is a clear cytotoxic or exhaustion 
distinction between the two subsets based on expression of CD57 by TFH and cTFH. 
Moreover, there is no data to implicate STAT3 in the formation of these two subsets.  
We have presented evidence that CD57 expression identifies cells with cytotoxic 
potential, and a subset of these cells demonstrates overt cytotoxic activity and this 
cytotoxicity is STAT3 dependent. Indeed, STAT3 appears to be important for TFH to 
form in the first place, as CXCR5+ cells are less abundant in patient with STAT3 LoF, 
and as we show here, more abundant in patients with STAT3 GoF. Nevertheless, 
within the TFH population, STAT3 refractoriness occurs, and this is marked by CD57 
expression, high level of PD-1, that coincides with adoption of potential for 
cytotoxicity.  
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